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Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is an established treatment in 
various hematologic malignancies, non-malignant hematologic diseases, immune disorders 
and metabolic disorders in both adult and pediatric patients. Allo-HSCT has the potential 
to replace the affected stem/progenitor cells, resulting in a properly functioning immune-
hematologic system. In certain metabolic diseases, donor hematopoiesis will restore delivery 
of leukocyte-derived enzymes.
Pharmacotherapy is an essential part of the allo-HSCT procedure. When a patient receives an 
allo-HSCT, first the patient is prepared for the transplantation in the so-called conditioning 
phase. In this phase the patient receives immunosuppressive drugs with the goal to cause 
suppression of the host immune system to allow donor cell engraftment and prevent rejection 
of the transplant. Furthermore, the patients receives myelosuppressive drugs to create “space” 
in the bone marrow of the patient for donor hematopoietic stem/progenitor cells and if 
applicable, maximum reduction of malignant cells. Figure 1.1 gives an overview of the HSCT 
procedure and the risks involved. 
Following conditioning, the patient reaches aplasia and the donor stem cell graft is administered. 
In the post-HSCT phase the goal is engraftment of donor cells and restoring the immune system 
and hematopoiesis. During aplasia and the early post-transplant period patients are highly 
susceptible to infectious complications. Therefore, patients are cared for in isolation rooms 
and receive antibacterial, antiviral and antifungal prophylaxis.
Next to infections, graft-versus-host disease (GvHD) is another major risk after allo-HSCT which 
affects 15-25% of pediatric HSCT recipients, despite routine administration of pharmacological 
prophylaxis.1,2 The immune cells of the graft react with host tissue cells especially in the skin, 
Figure 1.1 Overview of the allo-HSCT procedure and risks involved. Allo-HSCT: Allogeneic 





gastro-intestinal tract and liver.3 Systemic treatment with high-dose glucocorticoids is currently 
the gold standard as first line treatment. Unfortunately, approximately half of the patients 
respond to this therapy.4
In recent years, improvements in different parts of the transplantation procedure have indeed 
made an allo-HSCT a curative treatment for an increasing number of diseases. Improvements 
in HLA-typing, and with that donor matching, treatment of infectious complications and 
optimization of conditioning regimens have improved the safety of allo-HSCT. Despite these 
improvements infections, conditioning regimen related toxicity and aGvHD are still major 
causes of severe side effects and transplant related mortality.5 
Optimization of current drug therapies holds the potential to improve the outcome and safety 
of allo-HSCT. The goal of this thesis is to optimize busulfan- and treosulfan-based conditioning 
regimens and acute GvHD treatment with glucocorticoids by applying pharmacokinetic and 
pharmacogenetic profiling. Studies are performed in adults and pediatric patients. It is known 
that drug disposition and the pharmacodynamic effect can vary between these two populations, 
due to differences in body composition, metabolic capacity and maturation of enzyme function.6 
Therefore, findings in adults cannot be directly extrapolated to pediatric patients.
In the first part of this thesis the focus is on individualization of busulfan- and treosulfan-
based conditioning. In chapter 2 an overview is given of the current strategies to optimize 
busulfan and treosulfan therapies in pediatric allo-HSCT. Evidence has been provided that 
busulfan exposure is related to both HSCT efficacy and toxicity.7,8 Therefore, therapeutic 
drug monitoring is applied to target busulfan exposure in the individual patient. However, 
a significant interpatient variability in pharmacokinetics of busulfan remains, which might 
be explained by pharmacogenetic variation between patients.9–11 In chapter 3 the role 
of single nucleotide polymorphisms in genes encoding for glutathione-S-transferases on 
busulfan clearance is investigated in adults patients undergoing an allo-HSCT. In chapter 4, a 
comprehensive pharmacogenetic analysis of busulfan PK in adult patients is performed; the 
DMET (drug metabolism and transport) array is applied to identify genetic markers involved 
in drug metabolism and transport. Based on the results in adults in chapter 4, subsequently 
a selection of genetic markers is analyzed in pediatric patients, this is presented in chapter 5. 
Chapter 6 and 7 focus on treosulfan-based conditioning in pediatric patients. Treosulfan is an 
alkylating agent and it has a similar structure to busulfan. It is currently more often applied in 
allo-HSCT due to its beneficial toxicity profile in comparison with busulfan.12 The experience with 
treosulfan prior to allo-HSCT is limited and only a few studies were performed to investigate 
treosulfan pharmacokinetics in pediatric patients. Clinical outcome of HSCT using busulfan is 
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associated with the exposure of the drug. Therefore, we presume that clinical outcome after 
HSCT applying a treosulfan-based regimen might be dependent on exposure as well. In order 
to study the dose-effect relation of treosulfan in HSCT, both a method of bioanalysis and a 
population pharmacokinetic model for treosulfan are essential. In chapter 6 the development 
of a reversed phase high pressure liquid chromatography (RP-HPLC) bioanalytical method to 
detect treosulfan in serum is described. Furthermore, a population pharmacokinetic model 
and limited sampling strategy were developed. Chapter 7 demonstrates a pilot study in 
which pharmacokinetic parameters of treosulfan in 21 pediatric patients were related to 
patient characteristics, such as age, disease, etc. Next to this, early clinical outcome is studied 
in relation to treosulfan exposure in this pilot study. Chapter 8 focuses on the involvement of 
genetic markers in glucocorticoid responsiveness. In a retrospective cohort of pediatric patients 
with acute GvHD, the relation between genetic markers and glucocorticoid responsiveness is 
studied. In this analysis the genetic markers are investigated in both donor and recipient DNA, 
since both sources of immune cells are involved in the process of aGvHD. Chapter 9 describes 
a case of pharmacogenetic testing in an allo-HSCT patient. The case highlights the importance 
of proper quality control in pharmacogenetic analysis and the challenge of pharmacogenetic 
testing in patients that received an allo-HSCT and have a mixed hematopoietic system. The 
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stem cell transplantation: the role of 
pharmacogenetics and pharmacokinetics









Busulfan- and treosulfan-based conditionings are the cornerstone of pediatric allogeneic 
hematopoietic stem cell transplantation (HSCT). Although both drugs are alkylating agents, 
their mechanisms of action, pharmacokinetics (PK) and toxicity profiles are different. Experience 
with busulfan in pediatric HSCT is broad and the knowledge on the pharmacodynamics (PD), 
PK and, to a lesser extent, pharmacogenetics (PG) has resulted in a more effective therapy. 
Treosulfan has only recently been introduced in pediatric HSCT and is considered a promising 
new therapy because of its beneficial toxicity profile. However, knowledge of the PK and PG of 
treosulfan is limited. In this review, we describe the pharmacology of both agents and discuss 
factors causing variability in PK in relation to therapeutic outcome in HSCT.
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IntroductIon
Allogeneic HSCT (allo-HSCT) is a potential curative treatment for a range of hematological 
malignancies and non-malignant diseases in pediatric patients. The main reasons for treatment 
failure are relapse and treatment-related mortality (TRM). TRM can occur in up to 5–20% of 
patients,1–3 mostly caused by infections, graft-versus-host disease (GvHD) or toxic organ damage, 
which is dependent on the underlying disease, donor matching, graft source, supportive care 
and conditioning regimen administered before the HSCT. A conditioning regimen usually 
comprises a combination of immunosuppressive and myeloablative drugs with the goal to 
cause suppression of the host immune system to prevent rejection, create ‘space’ in the bone 
marrow of the recipient to allow donor cell engraftment, and, if applicable, eliminate the 
underlying malignancy. The alkylating agents busulfan (1,4-butanediol-dimethylsulfonate, 
Busilvex®) and treosulfan (L-threitol 1,4-bismethanesulphonate, Ovastat®) are commonly applied 
in different conditioning regimens before HSCT. Both drugs have different profiles in relation 
to the toxicity and mechanism of action in HSCT. In this review, we describe the PD, PK and PG 
profiles of both drugs. The experience with busulfan-based conditioning in pediatric patients 
is extensive compared with that of treosulfan. In recent years, a large series of PK, PD and PG 
studies has reported on the optimization of busulfan treatment. We provide an overview of 
the most important findings and of future perspectives on how to further optimize busulfan 
dosing. Dose-optimization studies for treosulfan are scarce and lessons might be learned from 
previous studies in busulfan.
Mechanism of action of busulfan
Busulfan is a bifunctional alkylating agent of the alkylsulfonate type, comprising two instable 
methanesulfonate groups (Figure 2.1). Busulfan is hydrolyzed in aqueous environments and 
releases the methanesulfonate groups, leading to a reactive carbonium ion that alkylates 
DNA. Busulfan is only slightly soluble in water, although an intravenous formulation became 
available in 2000. It was first applied in the palliative treatment of chronic myeloid leukemia 
(CML) for its myelosuppressive properties and antitumor effects.4 Furthermore, busulfan 
is mainly cytotoxic for proliferating tissues and depletes non-cycling primitive stem cells. 
Although busulfan is a strong myelosuppressive drug, it is only weakly immunosuppressive; 




Mechanism of action of treosulfan
Treosulfan has a strong myeloablative potential and is considered less toxic than busulfan and, 
therefore, an interesting alternative for busulfan in conditioning before HSCT. The first clinical 
application of treosulfan in pediatric patients prior to HSCT was in 2002.6 Treosulfan is a prodrug 
and a water-soluble alkylating agent. It is non-enzymatically, pH-dependently converted by 
intramolecular nucleophilic substitution into a monoepoxide ((2S,3S)-1,2-epoxy-3,4 butanediol 
4-methanesulphonate) and a diepoxide (L-diepoxybutane) (Figure 2.1).7 Conversion occurs 
at a pH > 6.0 and the conversion to the monoepoxide is necessary for DNA alkylation, DNA 
crosslinking occurs via the diepoxide only.8 Treosulfan gives a rapid and sustained myeloablation, 
which is comparable to that of busulfan. This was demonstrated by a fast reduction in colony-
forming unit granulocyte macrophages in mice; aplasia was reached on day 1 and was 
maintained after completion of treatment.9 Furthermore, the immunosuppressive profile of 
treosulfan was demonstrated by a strong and durable splenic B and T cell depletion and low pro-
inflammatory cytokines release. In vitro and in vivo data suggest a stronger immunosuppressive 
and cytotoxic effect against leukemic cells compared with busulfan.9,10
reported on the optimization of busulfan treatment. We provide
an overview of the most important findings and of future perspec-
tives on how to further optimize busulfan dosing. Dose-optimi-
zation studies for treosulfan are scarce and lessons might be
learned from previous studies in busulfan.
Mechanism of action of busulfan
Busulfan is a bifunctional alkylating agent of the alkylsulfonate
type, comprising two instable methanesulfonate groups (Fig. 1).
Busulfan is hydrolyzed in aqueous environments and releases the
methanesulfonate groups, leading to a reactive carbonium ion
that alkylates DNA. Busulfan is only slightly soluble in water,
although an intravenous formulation became available in 2000.
It was first applied in the palliative treatment of chronic myeloid
leukemia (CML) for its myelosuppressive properties and antitumor
effects [4]. Furthermore, busulfan is mainly cytotoxic for prolifer-
ating tissues and depletes noncycling primitive stem cells. Al-
though busulfan is a strong myelosuppressive drug, it is only
weakly immunosuppressive; at a dose causing 50% decrease in
myelopoiesis, only a mild decrease in lymphocyte numbers is
observed [5].
Mechanism of action of treosulfan
Treosulfan has a strong myeloablative potential and is considered
less toxic than busulfan and, therefore, an interesting alternative
for busulfan in conditioning before HSCT. The first clinical
application of treosulfan in pediatric patients prior to HSCT was
in 2002 [6]. Treosulfan is a prodrug and a water-soluble alkylating
agent. It is nonenzymatically, pH-dependently converted by in-
tramolecular nucleophilic substitution into a monoepoxide
[(2S,3S)-1,2-epoxy-3,4 butanediol 4-methanesulphonate] and a
diepoxide (L-diepoxybutane) [7] (Fig. 1). Conversion occurs at a
pH >6.0 and the conversion to the monoepoxide is necessary for
DNA alkylation because DNA crosslinking occurs via the diepoxide
only [8]. Treosulfan gives a rapid and sustained myeloablation,
which is comparable to that of busulfan. This was demonstrated by
a fast reduction in colony-forming unit granulocyte macrophages
in mice; aplasia was reached on day 1 and was maintained after
completion of treatment [9]. Furthermore, the immunosuppres-
sive profile of treosulfan was demonstrated by a strong and durable
splenic B and T cell depletion and low pro-inflammatory cytokines
release. In vitro and in vivo data suggest a stronger immunosup-
pressive and cytotoxic effect against leukemic cells compared with
busulfan [9,10].
Busulfan and treosulfan in malignant disease
In malignant disease, myeloablative conditioning (MAC) is usually
used, aimed at myeloablation and maximum reduction of leuke-
mic cells. High-dose busulfan or total-body irradiations are the
cornerstones of MAC. Initially, busulfan was mainly combined
with cyclophosphamide, which is an effective therapy, but is
accompanied by severe toxicities. Recently, several attempts have
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FIGURE 1
Activation of busulfan and treosulfan. (A) Busulfan is hydrolyzed and releases one methanesulfonate group. Through the reaction with a thiol group (NH2-R), an
instable carbonium ion is formed. When releasing the second methanesulfonate group, tetrahydrofuran is formed. (B) Treosulfan is nonenzymatically, pH-



















Figure 2.1 Activation of busulfan and treosulfan. a) Busulfan is hydrolysed and releases one 
methanesulfonate group. Through the reaction with a thiol group (NH2-R) an instable carbonium 
ion is formed. When eleasing the s co d methanesulphonate group, tetrahydrofuran (THF)
is formed. b) Treosulfan is non-enzymatically, pH-dependently converted by intramolecular 
nucleophilic substitution into a monoepoxide ((2S,3S)-1,2-epoxy-3,4 butanediol 4-methane-
sulpho nate) and a diepoxide (L-diepoxybutane).
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busulfan and treosulfan in malignant disease
In malignant disease, myeloablative conditioning (MAC) is usually used, aimed at myeloablation 
and maximum reduction of leukemic cells. High-dose busulfan or total-body irradiations are the 
cornerstones of MAC. Initially, busulfan was mainly combined with cyclophosphamide, which 
is an effective therapy, but is accompanied by severe toxicities. Recently, several attempts have 
been made to maintain the efficacy of a MAC, but reduce the toxicity; for example, by targeting 
busulfan exposure and the replacement of cyclophosphamide with fludarabine. 
In malignant disease, treosulfan-based conditioning was only recently introduced. It is 
usually used in patients who are not eligible for the standard preparative regimen because 
of pre-existent morbidity and in cases of second HSCT after initial traditional myeloablative 
conditioning. Casper et al.11 initially investigated treosulfan in malignant disease in adult 
patients, but studies on treosulfan in malignant disease in pediatric patients are limited. A 
large retrospective study on behalf of the European Society for Blood and Marrow Transplant 
(EBMT) Pediatric Diseases Working Party on the effectiveness and safety of treosulfan-based 
conditioning was performed in pediatric patients with high risk or advanced hematologic 
malignancies.12 The treosulfan-based conditioning demonstrated efficacy rates similar to rates 
found in busulfan-based studies and the toxicity profile was comparable to that of reduced 
intensity conditioning (RIC). Although treosulfan seems to be a promising candidate in 
HSCT for malignant disease, there is no direct comparison of busulfan- and treosulfan-based 
conditioning. Therefore, a prospective study directly investigating both agents in malignant 
diseases in pediatric patients is warranted. 
An overview of all recent studies (2008–2013) using busulfan- and treosulfan-based conditioning 
in allo-HSCT in pediatric patients is provided in Tables 2.1 and 2.2, respectively. This period was 
selected as an update of the review by Glowka et al. on treosulfan.13
busulfan and treosulfan in non-malignant disease
An increasing number of non-malignant disorders in pediatric patients are suitable for allo-
HSCT. These patients often have severe comorbidities or are very young. In these types of 
disease, the main goal of HSCT is to establish normal donor hematopoiesis and to reverse or 
halt disease progression. The level of donor engraftment that is needed for cure is dependent 
on the disease and the extent of engraftment of a certain lineage of hematopoietic cells. The 
main risk of allo-HSCT in non-hematologic disease is graft rejection and toxicities related to the 
HSCT, such as acute GvHD (aGvHD), infections and organ toxicity. Busulfan-cyclophosphamide 
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of the conditioning, RIC was developed to minimize the toxic effects before HSCT. A busulfan-
based conditioning with an intermediate dose of 8 mg/kg in total was applied in RIC and 
treosulfan was introduced as an alkylating agent.12 In non-malignant disease, busulfan and 
treosulfan are applied in the same group of patients, in line with current Working Party Inborn 
Errors/EBMT guidelines. Most experience with treosulfan-based conditioning is gained in 
primary immune deficiencies (PID) and β-thalassemia. In a large study of 70 pediatric patients 
with a PID, treosulfan was combined with fludarabine or cyclophosphamide. In these children, 
a generally mild toxicity profile was observed combined with an overall survival (OS) of 
more than 80%.14 The largest study of treosulfan in pediatric patients and young adults with 
β-thalassemia demonstrated a 5-year OS of 93%, a β-thalassemia-free survival of 84% and no 
cases of hepatic sinusoidal obstruction syndrome (SOS).15 The authors suggest that treosulfan-
based conditioning is as effective as busulfan-cyclophosphamide-based conditioning and is 
probably accompanied with less toxicity. However, the long-term effects of treosulfan-based 
conditioning are not known yet. 
Again, there is no study available directly comparing treosulfan- and busulfan-based condi-
tioning in pediatric patients with non-malignant disease. Two studies compared treosulfan, 
combined with fludarabine and thiotepa, with a retrospective cohort of busulfan (Bu/Cy) in 
patients with high-risk β-thalassemia.16,17 In the first study, TRM and OS were more beneficial in 
the treosulfan-treated group; OS was 87% in the treosulfan group versus 64% in the busulfan 
group. The main toxicity was SOS, and the incidence was significantly higher in the Bu/Cy group 
(66%) compared with the treosulfan-treated group (22%). However, the second study found 
a higher TRM in the treosulfan group (21%), compared with the busulfan-treated group (0%) 
and 11% of the treosulfan-treated patients died because of severe SOS. Remarkably, in both 
studies, especially in the treosulfan group, the incidence of SOS was unusually high.
Therefore, treosulfan is a potentially effective agent with a relatively mild toxicity profile. 
However, there is a need for a prospective study directly comparing busulfan- and treosulfan-
based conditioning in non-malignant diseases. Furthermore, data on the long-term effects of 
treosulfan in pediatric patients are warranted.
toxicity of busulfan
Early toxicity
The main early toxicities of busulfan are liver toxicity, pulmonary toxicity, hemorrhagic 
cystitis, seizures, skin toxicity, diarrhea and mucositis.18,19 Busulfan-based regimens are 
Chapter 2
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known to cause liver toxicity, ranging from elevated liver enzymes to SOS. Together with 
GvHD and infections, SOS is one of the most common early complications after HSCT, 
occurring in 5–40% of pediatric patients with potentially fatal outcomes.20,21 The syndrome is 
characterized by hepatomegaly, elevated serum bilirubin levels and fluid retention resulting 
in weight gain. The variability of incidence of SOS can be influenced by the conditioning 
regimen, patient characteristics, age, underlying disease and existing liver damage.22 High 
busulfan exposure and busulfan combined with cyclophosphamide is related to an increased 
risk of SOS.23–25 Sufficient time between busulfan and cyclophosphamide administration 
to allow recovery of glutathione (GSH) depletion or replacement of cyclophosphamide by 
fludarabine could reduce SOS incidence.26 Furthermore, orally administered busulfan is 
associated with a higher rates of SOS, because of high variability in exposure and possibly 
the first-pass effect after oral administration leading to high busulfan concentrations in the 
small hepatic venules, resulting in damage.27
The incidence of seizures in pediatric patients receiving busulfan has been reported to be 
between 2% and 10%.28,29 It is common practice to administer seizure prophylaxes during 
busulfan-based conditioning and a variety of antiepileptic drugs has been applied with success 
in clinical practice.
Late toxicity
Many pediatric allo-HSCT recipients develop long-term complications. Given their improved 
life expectancy as a result of HSCT, long-term effects are of major concern. In contrast to total-
body irradiation, busulfan itself does not cause growth retardation. Growth retardation after 
busulfan-based conditioning is probably caused by factors such as prior cranial irradiation, 
underlying disease or long-term use of high doses of glucocorticoids for chronic GvHD.30,31 
Gonadal dysfunction is a prominent adverse effect after busulfan-based conditioning, 
especially in young girls, where up to 70% of patients have ovarian failure following busulfan-
based HSCT.32,33 Furthermore, both hypothyroidism and hyperparathyroidism frequently 
occur after Bu/Cy-based conditioning for HSCT.33 Busulfan causes permanent alopecia in 
up to 50% of the patients and is related to busulfan exposure.34 
toxicity of treosulfan
The main toxicities of treosulfan are mucositis, skin toxicity, diarrhea and hepatic toxicity.12,14,35 
Mucositis and hepatic toxicity are generally mild compared with busulfan-based conditioning.36 
Only rarely does hepatic toxicity develop into SOS and occurrence of SOS is dependent on 
29
Busulfan and treosulfan: how to further individualize conditioning in pediatric HSCT
2
pre-HSCT comorbidities and the combination of treosulfan with other alkylating agents (e.g. 
cyclophosphamide or melphalan).12,14 In a recent report, 513 children received treosulfan-based 
conditioning for their allo-HSCT. The overall SOS incidence was 5%. However, the incidence 
was higher in patients younger than 6 months (12%).35 In other reports, nappy rash and skin 
toxicities were reported regularly in infants.37 It is suggested that nappy rashes are probably 
caused by secondary excretion of the active metabolite l-epoxybutane in the urine.38 Slatter et 
al.14 reported seizures in treosulfan treated infants after cessation of treosulfan; however, other 
studies did not report any seizures in such children when patients had pre-HSCT central nervous 
system (CNS) injury. In general, the use of anticonvulsant prophylaxes before treosulfan is not 
recommended. However, prophylaxes might be useful in infants.
Given that treosulfan treatment has only recently been introduced for HSCT, only limited data 
on the long-term effects of treosulfan treatment are available. To date, no long-term toxicities 
have been reported. Therefore, common long-term toxicities in busulfan-treated patients, 
such as gonadotoxicity, are to be evaluated in pediatric patients undergoing treosulfan-based 
conditioning.
PK oF busulFAn
Busulfan PK is best described as a one-compartment model. When busulfan is administered 
orally, absorption is a determinant of high inter- and intrapatient variability in exposure. Cmax 
generally occurs within 1.5–2.5 h and bioavailability is approximately 70–90%, but highly 
variable.39 Different factors can cause reduced and variable bioavailability in pediatric patients; 
the administration of numerous tablets can cause nausea and vomiting and different methods 
of administration are applied. Crushed tablets are suspended in water, mixed with food or 
encapsulated to promote swallowing, and tablets can be administered directly or through a 
gastric tube. Furthermore, a higher gastric pH, differences in transit time and, potentially, a 
higher first-pass clearance in children can affect bioavailability.40 A higher intestinal clearance 
in children is probably caused by upregulation of glutathione-S-transferase (GST) activity 
in younger children (0–4 years) compared with older children.41 Intrapatient variability in 
exposure was reduced after introduction of the intravenous formulation and is generally 
<15%.42 Interpatient variability with an oral formulation can be up to 50% and, when using 
the intravenous formulation, approximately 20–30% interpatient variability is observed.42,43
Busulfan clearance is age dependent; clearance in pediatric patients is enhanced compared 
with adults and can be two to four times higher.40 In Table 2.3, different PK models are 
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provided. Busulfan is metabolized by conjugation with glutathione, resulting in formation of 
a glutathione conjugate. This reaction is catalyzed by GSTA1, GSTM1 and GSTP1, and occurs in 
the liver and intestine. GSTA1 is the predominant GST enzyme involved in busulfan metabolism; 
GSTM1 and GSTP1 have 46% and 18% of the activity of GSTA1 in busulfan metabolism, 
respectively.44 The glutathione-conjugate dissociates into γ-glutamyldehydroalanylglycine and 
tetrahydrothiophene (THT). THT is oxidized into sulfolane and subsequently into 3-hydroxy 
sulfolane (Figure 2.2).45,46 It is suggested that cytochrome P450 enzymes are involved in the 
oxidation of THT and sulfolane.47 Furthermore, it is suggested that transporters are involved in 
active transport of the glutathione conjugate out of the cell (Figure 2.2).48,49
Figure 2.2 Metabolism of busulfan and potential involvement of enzymes and transporters. 
Busulfan conjugation with glutathione (GSH) is catalyzed by glutathione-S-transferases (GST). 
The conjugate dissociates into γ-glutamyldehydroalanylglycine and tetrahydrothiophene (THT). 
THT is oxidized into sulfolane and subsequently into 3-hydroxy sulfolane. GSTs are involved in the 
conjugation of busulfan with GSH. It is suggested cytochrome P450 enzymes (CYPs) are involved 
in the oxidation of THT and sulfolane and transporters are involved in active transport of the 
glutathione conjugate out of the cell. ABC: ATP-binding cassette transporters.
intravenous administration [54]. However, other groups did not
find an association of GSTA1 with busulfan clearance, or only in
patients receiving busulfan orally [23,55,56]. There are also con-
flicting results on the effect of the GSTM1 genotype in relation to
busulfan PK; one study demonstrated a lower busulfan clearance in
patients with the GSTM1-null genotype [23], which is conflicting
with the findings of Srivastava et al. [57], who demonstrated a
higher clearance and risk of SOS in GSTM1-null patients. The
authors suggest that toxicity is caused by the metabolite rather
than by busulfan itself. Several factors could account for these
conflicting results, including the route of administration, the age
range of patients and the way clearance is expressed. If clearance is
not adjusted for body size, the interpatient variability in clearance
is larger and the effect of body size dominates the probably smaller
effect of the genetic variants.
Apart from GSTs, the involvement of other enzymes and trans-
porters has been suggested [47,48]. Polymorphisms in transporters
and other enzymes in relation to busulfan PK have been studied;
Krivoy et al. [58] found a combined association of the GSTM1 and
ATP-binding cassette, sub-family B (MDR/TAP), member 1
(ABCB1) genotype and oral busulfan clearance in adults and
another study demonstrated the involvement of CYP2C9 and
CYP2B6 in busulfan metabolism [47]. Furthermore, in a recent
study, 40 genetic polymorphisms, including several genes encod-
ing drug transporters and CYP enzymes, in relation to HSCT
outcome were studied [59]. Only one polymorphism in GSTA2
was related to OS and TRM. In most of the PG studies on busulfan
PK, a small set of polymorphisms was investigated that were likely
to be involved in busulfan metabolism, according to the candidate
gene approach. To further investigate the PG contribution to
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FIGURE 2
Metabolism of busulfan and potential involvement of enzymes and transporters. Busulfan conjugation with glutathione (GSH) is catalyzed by glutathione-S-
transferases (GST). The conjugate dissociates into g-glutamyldehydroalanylglycine and tetrahydrothiophene (THT). THT is oxidized into sulfolane and
subsequently into 3-hydroxy sulfolane. GSTs are involved in the conjugation of busulf n with GSH. It is suggest d that cytochrome P450 e zymes (CYPs) are























Factors influencing busulfan PK
Children have an increased busulfan clearance compared with adults, which is partially caused 
by an increased liver size to body weight (BW) ratio.50 Therefore, clearance should be expressed 
by body surface area or allometrically scaled BW to account for this age-related variability 
in hepatic function.47,51 These measures do not account for all the differences in busulfan 
clearance between adults and pediatric patients. It is demonstrated that younger children 
(2–4 year) have an elevated ratio THT+ (the metabolite of busulfan) to busulfan, because of 
enhanced conjugation of busulfan compared with older children and adults. No elevated 
GSH levels were measured and it was suggested that children have an increased metabolism 
due to higher expression or activity of GST rather than through more available GSH.52 These 
processes have been incorporated in population PK models (Table 2.3). Furthermore, Savic et 
al.53 developed a population PK model for busulfan in infants (<12 kg). In the model, BW was 
allometrically scaled as a measure of physiological growth. Age was also incorporated into the 
model to account for maturation of enzyme function during the first 2 years of life. In infants, 
clearance increased 1.7-fold between 6 weeks and 2 years of life. Overall, maturation in the 
GST expression or activity during the first 2 years of age is likely to have an important role and 
GST activity reaches a maximum by the age of 2 years.
Several investigators studied the effect of polymorphisms in the genes encoding GSTs involved 
in busulfan metabolism. The first study in pediatric patients demonstrated that children who 
were heterozygous or homozygous for the GSTA1*B haplotype (regardless of age) exhibited a 
30% decrease in busulfan clearance after intravenous administration.54 However, other groups 
did not find an association of GSTA1 genotype with busulfan clearance, or only in patients 
receiving busulfan orally.23,55,56 There are also conflicting results on the effect of the GSTM1 
genotype in relation to busulfan PK; one study demonstrated a lower busulfan clearance in 
patients with the GSTM1-null genotype,23 which is conflicting with the findings of Srivastava et 
al.57, who demonstrated a higher clearance and risk of SOS in GSTM1-null patients. The authors 
suggest that toxicity is caused by the metabolite rather than by busulfan itself. Several factors 
could account for these conflicting results, including the route of administration, the age range 
of patients and the way clearance is expressed. If clearance is not adjusted for body size, the 
interpatient variability in clearance is larger and the effect of body size dominates the probably 
smaller effect of the genetic variants.
Apart from GSTs, the involvement of other enzymes and transporters has been suggested.48,49 
Polymorphisms in transporters and other enzymes in relation to busulfan PK have been studied; 
Krivoy et al.58 found a combined association of the GSTM1 and ATP-binding cassette, sub-family B 
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(MDR/TAP), member 1 (ABCB1) genotype and oral busulfan clearance in adults and another study 
demonstrated the involvement of CYP2C9 and CYP2B6 in busulfan metabolism.48 Furthermore, in a 
recent study, 40 genetic polymorphisms, including several genes encoding drug transporters and 
CYP enzymes, in relation to HSCT outcome were studied.59 Only one polymorphism in GSTA2 was 
related to OS and TRM. In most of the PG studies on busulfan PK, a small set of polymorphisms was 
investigated that were likely to be involved in busulfan metabolism, according to the candidate 
gene approach. To further investigate the PG contribution to interpatient variability in busulfan 
PK, a shift from the candidate gene approach to a more broad PG analysis should be made. 
In several studies, clearances between different disease groups were compared. It is suggested 
that patients with β-thalassemia have an increased and highly variable busulfan clearance 
caused by an iron overload inducing GST activation and pre-HSCT liver injury.60 Pediatric patients 
with inherited diseases were associated with a low and highly variable busulfan clearance.61 
This could have been caused by the young age of the patients (mean age < 1 year) and co-
medication. Hence, the role of underlying disease on busulfan PK is not clear, given that different 
studies demonstrate conflicting results.
Of the regularly administered co-medication, theoretically phenytoin, itraconazole, acetami-
nophen and metronidazole are associated with altered busulfan clearance.62–64 Itraconazole is a 
strong inhibitor and phenytoin a strong inducer of cytochrome P450 enzymes, but its effect on 
busulfan metabolism is not clear. Phenytoin is often replaced with a different anticonvulsant, 
such as levetiracetam or clonazepam. The effect of itraconazole on busulfan exposure in 
clinical practice is not always evident; in one study, no influence of itraconazole on busulfan 
exposure was observed.65 The effect of metronidazole on busulfan PK is probably caused by GSH 
depletion by the metronidazole reactive metabolites.64 However, clinical evidence is missing, and 
metronidazole is rarely combined with busulfan. Hence, several interacting drugs for busulfan 
have been identified, although their effects in clinical practice are limited.
Analytical methods
To relate a PK profile of a drug to outcome and to guide dosing based on exposure, it is 
essential to have a proper bioanalytical method. Any method applied should be accurate 
and precise over the whole concentration range; the lower limit of quantification (LOQ) and 
concentration range should be adequate for busulfan determination in clinical practice and 
the method should be selective. Furthermore, relative short run times and sample preparations 
are important, because of the short course of busulfan. An overview of bioanalytical methods 
for determination of busulfan, cited in recent literature on busulfan, is given in Table 2.4. When 
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busulfan is administered daily, it is completely eliminated and, therefore, the LOQ of a method 
should be as low as possible, but at least 40 µg/L. In HPLC-UV and GC-MS analytical assays, 
derivatization of busulfan is conducted to make the compound detectable. This procedure is 
selective; only derivatized compounds are detected.66,67 However, it can be a time consuming 
step; for example, in GC-MS, derivatization steps can take up to 2 hours. Another essential part is 
the required volume of patient material (plasma or serum), especially in young children. A limited 
sampling model is a helpful method to reduce the required total blood volume and, with that, 
patient burden. In modern LC-MSMS methods, 50–100 µl of serum or plasma can be sufficient. 
Older methods require up to 1000 µl. Overall, LC–MSMS methods are the preferred methods 
because of the smaller volumes required, shorter run times and simple sample preparation. 
However, disadvantages of these methods include the complexity and high costs of equipment.
PK and clinical outcome
For oral busulfan, several investigators demonstrated a relation between busulfan exposure 
and clinical outcome. In adults, high exposure was related to toxicity, especially SOS, and lower 
exposure was related to rejection of the transplant.68
However, in children, this relation was not that evident, which is likely to be the result of a 
lower overall exposure in pediatric patients because of an enhanced clearance, resulting in 
less toxicity and lower SOS incidence. Furthermore, soon after the relation between exposure 
and clinical outcome was established, therapeutic drug monitoring (TDM) was introduced to 
table 2.4 Overview of bioanalytical methods for determination of busulfan, cited in recent 
literature on busulfan












Kellog LC-MSMS 123–2463 µg/L 50 µL plasma 3 min NA 2 hour for
10 samples
101
Mürdter LS-MS 10–2000 µg/L 200 µL plasma 10 min NA Unknown 88
Quernin GC-MS 20–2000 µg/L 1000 µL plasma 14 min 2 hour Unknown 102  
Lai GC-MS 40–4000 µL/L 1000 µL blood 12 min 1 hour 24h for 40 samples
3 h manual labour
66
Bleyzac HPLC-UV 100–2000 µg/L 200 µL plasma 10 min Direct 32 minutes 
per samples
103
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optimize exposure, thereby reducing interpatient variability.69 However, there are several studies 
demonstrating an association between exposure and clinical outcome in pediatric patients. 
Ljungman et al.70 investigated the busulfan concentration at steady state (Css) in a cohort of 
adults and pediatric patients and demonstrated that a Css>721 ng/mL was associated with 
increased TRM and OS. Furthermore, in two pediatric cohorts, Css>600 ng/mL was associated 
with a higher probability of engraftment.71,72 Unfortunately, these studies provided no target 
for busulfan exposure. Finding the optimal target for busulfan is hampered by the application 
of different measures of exposure: Css in ng/mL, area under curve (AUC) in µM*min or mg*h/L. 
Furthermore, these measures can be expressed per dose or cumulative over a 4-day course. In 
addition, busulfan can be administered one, two or four times daily, which results in different 
exposure levels per dose. Therefore, we advocate that busulfan exposure is expressed as a 
cumulative exposure over a 4-day course to make exposures more easily comparable. 
Bartelink et al.73 attempted to find the optimal busulfan AUC in pediatric patients receiving 
Bu/Cy-based conditioning. Exposure proved related to event free survival (EFS), graft failure 
and relapse, and the authors advocated targeting busulfan to a narrow therapeutic range of 
74–82 mg*h/L. Many studies applied an AUC target of 900–1350 µM*min/dose, which is 
equivalent to a total AUC of 57.6–86.4 mg h/L which is a broad target compared with that 
defined by Bartelink et al.73
Using TDM, the total exposure can be optimally guided toward a narrow range. In a recent 
study, the cumulative exposure over a four day course was not related to clinical outcome and 
90% of the patients were within the target range.74 However, in this study, a Css after the first 
dose below 600 ng/ml was associated with increased OS and EFS and decreased non-relapse 
mortality. According to the authors, a higher first dose Css causes increased depletion of GSH, 
resulting in decreased metabolism of cyclophosphamide and increased toxicity.
Overall, busulfan exposure is related to clinical outcome and tight control of exposure could 
improve HSCT outcome after busulfan-based conditioning. Furthermore, the target exposure 
of busulfan depends on the regimen it is applied in. Optimal targets have mainly been 
investigated in Bu/Cy regimens. The optimal range for busulfan exposure in more recent applied 
combinations, such as busulfan and fludarabine, is more difficult to define, because of the up-
front targeting of busulfan. In a recent study on busulfan–fludarabine-based conditioning in 
pediatric patients, the target AUC for busulfan was 80–95 mg h/L. This conditioning regimen 
proved to have a favorable toxicity profile compared with Bu/Cy (Mel) conditioning and 
was equally effective.75 Moreover, more individualized target exposures should be defined, 




Treosulfan is non-enzymatically converted into its active metabolites; a mono- and diepoxide.7 
The two metabolites are excreted in the urine and no enzyme or transporter is known to be 
involved in treosulfan metabolism. There are several studies investigating the PK of treosulfan 
in patients, most of which were performed in adults. In almost all the studies, a linear relation 
between dose and exposure of treosulfan was found. Yet, the exposures demonstrated in the 
different studies are not in accordance with each other. The PK of treosulfan was first analyzed 
in adult patients with solid tumors.76,77 Patients received 8 or 10 g/m2, which is a typical dose 
in solid tumors,76 or 20–56 g/m2 with stem cell support.77 The half-life of treosulfan was 1.8 
hour76 and 2.0 hour77 and urinary excretion of the parent compound was approximately 25%. 
Half-life and AUC were somewhat increased in patients receiving the highest dose of 56 g/m2, 
possibly because of acidotic changes in plasma leading to the decreased formation of active 
metabolites. Both studies demonstrated a linear relation between dose and exposure. After 
10 g/m2, a mean AUC0–24 h of 977 ± 182 µg/ml*h was observed and a dose of 20 g/m
2 resulted in a 
mean AUC of 2325 µg/ml*h. In a third study in adult patients receiving 12 or 14 g/m2 of treosulfan 
before SCT, a mean treosulfan exposure of 898 ± 104 µg/ml*h and 1104 ± 173 µg/ml*h, 
respectively, was observed.78 Renal excretion of treosulfan was approximately 39%, a half-life that 
was comparable to earlier studies. However, exposures after 12 and 14 g/m2 were comparable 
to the earlier observed AUC after a dose of 10 g/m2. In another study with HSCT recipients, 
pediatric patients were also included. The mean AUC levels were higher than in the studies 
with solely adult patients, although the AUC levels after two different doses were similar: 1365 
± 293 µg/ml*h and 1309 ± 262 µg/ml*h, for 12 g/m2 and 14 g/m2, respectively.79 Therefore, 
the authors suggested that increased doses would be unlikely to lead to increased efficacy. 
PK studies of treosulfan in pediatric populations are limited. Glowka et al.80 described the PK 
of a set of seven pediatric patients. In this study, three different dosages were administered: 
10 g/m2 (n = 1), 12 g/m2 (n = 5) and 14 g/m2 (n = 1) daily. Treosulfan PK was best described by 
a two-compartment disposition model with first-order elimination. Interpatient variability in 
patients receiving 12 g/m2 was large, with a coefficient of variation of 70%. The exposure in the 
single patient receiving 14 g/m2 was relatively high (1960 µg/ml*h) when considering a linear 
relation between dose and exposure. This high AUC could result from metabolic acidosis as 
a result of methanesulfonic acid formation resulting in a reduction of treosulfan conversion 
into the active derivatives. 
There are some conflicting results between the different PK studies in adults and pediatric 
patients and, therefore, larger pediatric cohorts should be investigated. At this point, dose 
optimization-based PK of treosulfan is of interest, especially in pediatric patients.
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Analytical methods
The PK data regarding treosulfan are scarce, which could be because of the limited availability 
of an analytical method for determination of treosulfan. Although treosulfan is a prodrug, most 
bioanalytical methods are aimed at analyzing treosulfan itself. Treosulfan is non-enzymatically 
converted into its active metabolites. Therefore, it is suggested that the concentration of 
treosulfan itself is a good representation of the alkylating activity.76 Most analytical methods are 
based on reversed phase-HPLC methods (rp-HPLC) with refractometric detection.77,81 To make 
treosulfan (and its metabolites) detectable via UV detection, treosulfan can be derivatized.82 
UV-detection is a more selective and sensitive detection method, although derivatization 
can be time consuming. The conversion of treosulfan is pH dependent; therefore, in most 
studies, blood samples were acidified directly after collection by adding citric acid. This could 
be considered a complicated logistics step that might hamper sample collection in clinical 
practice. 
PK and clinical outcome
Data of treosulfan exposure in relation to clinical outcome are scarce. Moreover, most of the 
studies on treosulfan PK have only limited patient numbers and insufficient power to assess 
an association with clinical outcome, although attempts have been made to relate clinical 
outcome to treosulfan dose. Scheulen et al.77 performed a dose escalation study to assess the 
maximum tolerated dose. Doses higher than 47 g/m2 were associated with severe toxicities. 
Normally in treosulfan-based conditioning, treosulfan doses up to 42 g/m2 are divided over 3 
days. It is unknown whether toxicities are comparable when the cumulative dose is administered 
as one dose or when it is divided over multiple days.
In a small adult patient population (n = 18) with malignant disease, the PK and clinical outcome 
of two different doses of treosulfan (36 and 42 g/m2, cumulative dose) were studied. There were 
no differences in clinical outcome (engraftment, non-relapse mortality and OS) between the 
two doses.78 Different doses of treosulfan in pediatric patients undergoing HSCT because of 
malignant diseases (myeloid and lymphoid, n = 51) have been studied.12 In this study, the higher 
dose of treosulfan (total 42 g/m2) was more beneficial in relation to donor engraftment and 
hematopoietic chimerism. Nevertheless, there was no significant difference in DFS in patients 
receiving different doses of treosulfan. 
The cumulative dose of 42 g/m2 is a common dose regimen for treosulfan-based conditioning; 
toxicity is mild and engraftment might be enhanced at this dosing level. However, the outcome 
of HSCT is based on many factors and the most appropriate dose remains to be elucidated. 
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Whether exposure is a better marker for treosulfan efficacy and safety than the cumulative 
dose, as observed in busulfan, needs to be further investigated. Furthermore, in clinical practice, 
children under 1 year of age frequently receive a reduced dose of 30–36 g/m2. However, there 
is currently no evidence supporting this practice.
dose oPtIMIzAtIon oF busulFAn
therapeutic drug monitoring
Therapeutic drug monitoring (TDM) is of clinical value for drugs with a narrow therapeutic index, 
a clear relation between exposure and clinical outcome, substantial interpatient variability 
and small intrapatient variability, repeated administration, absence of alternative laboratory 
parameter and an appropriate analytical method.83
Busulfan meets all the criteria for applying TDM, except for intrapatient variability in oral 
busulfan, which is relatively large. Lindley et al. applied a test dose to predict busulfan exposure 
after oral administration and, in only 46% of the patients, the apparent oral clearance predicted 
the appropriate dose to achieve the target AUC.84 After intravenous administration, the 
intrapatient variability was significantly reduced and, in a higher percentage of the patients, 
the target exposure was reached when TDM was applied.85 Therefore, TDM-guided dosing is 
more useful in an intravenous regimen of busulfan. Furthermore, because of the short treatment 
course with a maximum of 4 days, it is necessary to have sufficient expertise and a proper 
logistic process in place for TDM-guided dosing of busulfan.
Especially in pediatric patients, it is essential to limit the burden of TDM caused by serial blood 
sampling. Therefore, the application of a limited sampling model can help to achieve this goal.
Based on two to four plasma-level measurements, the exposure to busulfan can be adequately 
estimated. Many published limited sampling models are based on a regression algorithm. 
Regression algorithms are capable of predicting the busulfan exposure accurately and precisely 
using concentrations measurements in three samples.86 However, the disadvantage of these 
algorithms is the necessity of sampling at the exact time points included in the algorithm. 
Small deviations in the sampling time point can results in significant deviations in predicted 
AUC. In addition, Bayesian PK procedures have been used to determine busulfan exposure. 
These procedures provide more flexibility in sampling times and, with that, higher accuracy 
in exposure estimation.67
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dosing nomograms and population PK modelling
A population PK model (pop-PK model) can be constructed to describe the PK profile of a drug 
in the population, incorporating patient characteristics that contribute to the interpatient 
variability. From these PK models, dosing nomograms can be extracted, ultimately leading to 
target exposure in individual patients without requiring TDM or at least rapid achievement of 
target AUC. Nguyen et al. developed a five-step nomogram for intravenous busulfan with different 
doses based on body weight of the patient (<9 kg, 1.0 mg/ kg; 9–16 kg, 1.2 mg/kg; 16–23 kg, 
1.1 mg/kg; 23–34 kg, 0.95 mg/ kg; and >34 kg, 0.8 mg/kg).87 This nomogram is the official dosing 
recommendation of the European Medical Agency (EMA), although studies have demonstrated 
that, with this dosing nomogram, a large portion of the patients do not reach the target AUC and 
TDM remains necessary to individualize the dose.88 Recent models apply allometric scaling of the 
PK parameters clearance and volume of distribution. For clearance, the scaling component can be 
either fixed at 0.75 or the exponent can be varied based on the age or weight of the individual. 
The latter approach results in a higher exponent in infants and neonates, which accounts for a 
faster increase in clearance with growth and maturation. Not only body size, but also an increase 
in GST activity causes this phenomenon.53,89 Dosing simulations based on the recently developed 
pop-PK models (Table 2.3) demonstrate that a large proportion of patients theoretically reach 
the target exposure. However, the proposed regimens have not been validated prospectively in 
independent cohorts. Furthermore, approximately 25% of the interpatient variability remains 
unexplained, suggesting that TDM is still a necessity to further optimize busulfan dosing.
dose oPtIMIzAtIon oF treosulFAn
In a phase I dose escalation study in adults, it was demonstrated that a dose of 47 g/m2 is 
the maximum tolerated dose of treosulfan.77 Furthermore, in a few studies, different doses of 
treosulfan in patients undergoing HSCT were applied, and relations with clinical outcome were 
assessed. However, most of these studies were limited by sample size78 or highly variable patient 
characteristics12 and no definite conclusion about the optimal dose can be made based on them.
It is essential to further study the PK and PD profile of treosulfan in pediatric patients. It seems 
more rational to choose the treosulfan dose based on the underlying disease and condition of 
the patient. In malignant diseases and, for example, β-thalassemia, a myeloablative regimen 
is required to give a maximum reduction of the malignancy and autologous hematopoiesis 
and to allow adequate donor engraftment. Treosulfan was first applied in allo-HSCT as a 
reduced intensity regimen. However, aplasia induced by treosulfan is rapid and sustained, and 
engraftment after high doses of treosulfan is prompt, resulting in early achievement of full donor 
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chimerism.90 To date, it is not clear which dose of treosulfan is more likely to be a RIC or MAC, 
and which other factors are involved. For example, other drugs in the conditioning regimen 
and age of the patient and, with that, the level of treosulfan exposure could contribute to the 
myeloablative potency and toxicity profile of treosulfan.
concludIng reMArKs
Busulfan and treosulfan are both effective in conditioning before HSCT in pediatric patients. The 
experience with busulfan is broader than with treosulfan, and many studies have demonstrated 
that TDM-based dosing is pivotal to achieve optimal busulfan exposure and, thus, clinical 
outcome. Furthermore, improved understanding of maturation processes in children, the 
development of pop-PK models and PG studies has revealed factors accounting for interpatient 
variability in busulfan exposure. The role of PG markers in the efficacy of busulfan should be 
further elucidated by broader PG analyses and in larger cohorts. Additionally, the effect of 
genetic markers could be incorporated in pop-PK models and could explain a portion of the 
remaining interpatient variability. 
Knowledge of the treosulfan PK profile in pediatric patients is limited and PK-PD studies are 
necessary to optimize the dose. The first steps to increase this knowledge have been made. 
It is essential to have a proper bioanalytical method and population PK methods should be 
developed. At this point, PG analysis on treosulfan metabolism is probably not relevant because 
no metabolic enzymes or transporters appear to be involved in treosulfan PK.
The two agents were not prospectively compared in children with either malignant or non-
malignant disease. Therefore, trials comparing both agents in well-defined patient groups are 
warranted. The development of a new study in pediatric patients with acute lymphoblastic 
leukemia in which treosulfan and busulfan are randomized versus total-body irradiation based 
conditioning is important. In this study, primary outcome will be mainly focused on relapse risk.
In addition, the usefulness of TDM and PG to achieve optimal clinical outcome is mainly based 
on short-term outcome parameters, such as relapse, engraftment and GvHD, whereas, for both 
alkylating agents, long-term outcome parameters (such as longterm survival and late toxicities) 
are also important. In the long run, given the potential long-term toxicity of chemotherapeutic 
agents, one would like to define the lowest dose level at which these drugs are effective in 
the various disease situations, thus limiting adverse effects as much as possible. In conclusion, 
better understanding of the PK and PG of busulfan and treosulfan has the potential to further 
improve the outcome of pediatric allo-HSCT.
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Busulfan is used in conditioning regimens before allogeneic hematopoietic stem cell 
transplantation (allo-HSCT). High busulfan exposure is associated with toxicity, whereas low 
busulfan exposure leads to higher rates of therapy failure. The pharmacokinetics of busulfan 
show large interpatient variability, hypothesized to be caused by variability in busulfan 
metabolism. In this report, the effect of genetic polymorphisms in three glutathione-S-
transferase genes involved in busulfan metabolism GSTA1 (-69C/T), GSTM1 (deletion–mutation) 
and GSTP1 (rs1695) on the pharmacokinetics of busulfan in Caucasian adult patients was 
investigated. In all, 66 adult patients received busulfan as part of their conditioning regimen. 
After the first infusion, two serum samples were collected and measured using a HPLC assay. 
A one-compartment population model was used to estimate individual pharmacokinetic 
parameters. The genetic variants of the three glutathione S-transferase (GST) genes were 
determined by pyrosequencing and PCR. A reduction of 14% in busulfan clearance was seen 
for the GSTA1*B allele and an increase in busulfan exposure was found. No relationship was 
found between polymorphisms in GSTM1 and GSTP1 and busulfan pharmacokinetics. This study 
shows that an increasing number of copies of GSTA1*B allele results in a significant decrease 
of busulfan clearance.
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IntroductIon
Busulfan is frequently used in high-dose conditioning regimens before allogeneic hematopoietic 
stem cell transplantation (allo-HSCT) in malignant and non-malignant diseases. Busulfan has 
a narrow therapeutic index; high busulfan exposure is associated with toxicity, such as veno-
occlusive disease (VOD) and mucositis, whereas low busulfan exposure leads to higher rates 
of graft failure and rejection.1,2
Initially, busulfan was available as an oral formulation only, which resulted in high variability in 
exposure, probably as a result of inter- and intraindividual variation in bioavailability. However, 
the introduction of an intravenous formulation did not completely eliminate the variability in 
pharmacokinetics.3 Therefore, treatment with busulfan in clinical practice is often individualized 
by therapeutic drug monitoring.
It is presumed that the variability in busulfan exposure could be assigned to busulfan 
metabolism. Conjugation with glutathione is the primary route of metabolism of busulfan, 
catalyzed by isoenzymes of the glutathione S-transferase (GST) protein superfamily. GSTA1 is 
the predominant GST isoenzyme involved; GSTM1 and GSTP1 have 46 and 18% of the activity 
of GSTA1 in busulfan metabolism, respectively.4 Therefore, it is hypothesized that single 
nucleotide polymorphisms (SNPs) in the genes encoding for the isoenzymes of GST could 
influence busulfan clearance and that interindividual variability might be explained by SNPs 
in these genes.
Expression of GSTA1 is variable due to four SNPs in linkage disequilibrium in the promoter region 
of the gene; -631T or G, -567T, -69C, -52G, designated as hGSTA1*A; and -631G, -567G, -69T, 
-52A, designated as hGSTA1*B.5 GSTM1 is highly polymorphic; a deletion mutation resulted in no 
expression of the gene,6 which is the case in 50% of the Caucasian population.7 The SNP 313A/G 
in GSTP1 leading to amino acid replacement in the active binding site of GSTP1, decreases the 
catalytic activity of the enzyme.8,9 We hypothesize that SNPs in the genes encoding for the three 
GST isoenzymes influence the pharmacokinetics of busulfan. Furthermore, this effect may be 
dependent on race or age of the patients. We reported earlier on a study in which the effect of 
polymorphisms in the GSTs on busulfan pharmacokinetics in children was investigated.10 No 
overall effect was found, however, a small effect was found in the older children suggesting 
an age effect on the expression of the GSTs. For this reason, we investigated the association 
between polymorphisms in genes encoding for the GSTs GSTA1, GSTM1 and GSTP1 and busulfan 




Patient and disease characteristic
Patients receiving allo-HSCT between 2004 and 2008 in the Leiden University Medical Center 
were included using the following selection criteria: age between 18 and 70 years, Caucasian 
ethnicity, receiving busulfan as conditioning before their allo-HSCT with measured busulfan 
blood samples. Diagnoses that required HSCT were malignant; acute myeloid leukemia, 
chronic myeloid leukemia, chronic lymphocytic leukemia, chronic myelomonocytic leukemia, 
non-Hodgkin’s lymphoma or multiple myeloma or non-malignant; aplastic anemia or sickle 
cell anemia.
conditioning regimes and transplantation details
Patients received either myeloablative conditioning or non-myeloablative conditioning. The 
myeloablative conditioning consisted of intravenous busulfan 0.8 mg/kg four times daily from 
day -9 to -6,intravenous alemtuzumab 15 mg once daily on days -6 and -5 and intravenous 
cyclophosphamide 60 mg/kg once daily on days -4 and -3. The non-myeloablative conditioning 
consisted of intravenous busulfan 0.8 mg/kg four times daily on days -6 and -5, oral fludarabine 
50 mg/m2 once daily from day -10 to -5 and anti-thymocyte globulin from day -4 to -1. Patients 
with chronic myelomonocytic leukemia received the same non-myeloablative conditioning plus 
2 days of cyclophosphamide 750 mg/m2 once daily on days -4 and -3. The graft was incubated 
with 20 mg of alemtuzumab just before infusion in all patients. Busulfan dosing was based 
on actual body weight. All patients received 92 mg phenytoin three times daily for seizure 
prophylaxis, starting 1 day before busulfan administration.
blood sampling
Busulfan was administered intravenously in a 2 h infusion, starting in the morning at 0900 
hours. Serum drug level measurements were carried out at 2.5 and 4.0 h after the start of the 
first infusion on the first day of treatment as part of routine patient care. Blood samples were 
stored at -20°C before processing, when processing took place on the same day, the samples 
were stored at 4°C.
A validated limited sampling model was used in order to minimize the number of blood 
samples necessary to calculate the busulfan clearance and area under curve (AUC).11 Busulfan 
was analyzed in serum by a validated HPLC involving precolumn derivatization, liquid/liquid 
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extraction, and UV detection according to Chow et al.12 The assay was linear between 0.03 
and 8 mg/L. The limit of quantification was 30 mg/L. Precision at 0.2 and 1.5 mg/L was 3.5 and 
0.8%, respectively. The pharmacokinetic model used was developed in MW/Pharm version 3.6 
(Mediware, Groningen, The Netherlands).13 A one-compartment population model with linear 
elimination as formulated, based on a busulfan model developed for children by this group 
first in NONMEM11 and after that in MW Pharm.14 Using the KinPop module of MW Pharm, in 
which an iterative two- stage Bayesian procedure based on busulfan serum concentration 
values of 34 adult patients was carried out, the new means, medians and standard deviations 
of the pharmacokinetic parameters were calculated. During the iterative two-stage Bayesian 
procedure, pharmacokinetic parameters were set to be distributed normally. The mean final 
pharmacokinetic parameters of the population pharmacokinetic model used are clearance: 
13.3 L/h, volume of distribution: 50.8 L and busulfan half-life: 2.65 h. The calculated mean 
population pharmacokinetic parameters, clearance and half-life, were individualized according 
to the maximum a posteriori Bayesian fitting method.15 AUC was calculated by dividing the 
administered dose by clearance. No dose adjustments were made on the basis of the individual 
calculated AUC.
dnA extraction and Gst analysis
Residual blood samples taken for routine patient care were used for genotyping. All blood 
samples were anonymized according to the instructions stated in the Codes for Proper Use and 
Proper Conduct (http://www.federa.org). A crude DNA extract, prepared by lysing WBCs in SDS 
and proteinase k containing buffer, was used for PCR. The GSTA1 haplotype was determined 
by investigating the SNP at -69C/T. The following genetic variants for GSTP1 (313A/G, rs1695) 
and GSTM1 (deletion–mutation) were determined.6 The SNPs in the GSTA1 and GSTP1 genes 
were separately genotyped by pyrosequencing10 (Isogen, Maarssen, The Netherlands) and 
presence of the GSTM1 was determined by PCR amplification (215 bp) together with an internal 
control (albumin gene (350 bp). PCR products were analyzed on 2% agarose gels, as previously 
described by Zwaveling et al.10
clinical outcomes
Next to pharmacokinetic parameters, the association of GST SNPs and HSCT clinical outcome 
was assessed. VOD was diagnosed according to the Seattle criteria: the occurrence of at 
least two of the following symptoms; painful hepatomegaly, unexplained weight gain of ≥ 
2% from baseline and hyperbilirubinaemia; bilirubin 34 mmol/L or greater, present before 
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day 21 after HSCT and after exclusion of other possible causes.16 The diagnoses and severity 
of acute graft-versus-host disease (aGvHD) was defined according to Glucksberg et al.17 
Rejection of the graft was defined as absence of donor cells. Engrafment was defined as stable 
donor chimerism.
statistical analysis
All pharmacokinetic parameters are shown as mean ± s.d. Associations with busulfan 
pharmacokinetic parameters (clearance and AUC) and polymorphisms were tested with analysis 
of variance for GSTA1 and GSTP1 or Student’s t-test for GSTM1. The effect of the number of 
copies of the T-allele in GSTA1 genotype was tested by linear regression analysis. The effect of 
the polymorphism on the defined clinical outcome was explored by χ2-test. P-values < 0.05 
were considered significant. All statistical analyses were carried out in PASW statistics, version 
17.0.01 (SPSS Inc., Chicago, IL, USA).
results
description of the cohort
A total of 66 patients that received busulfan in the period between 2004 and 2008 were included. 
Baseline patient characteristics are shown in Table 3.1. The average age of the patients was 
52.1 years and 59% were male. Most of the patients (n = 64) received busulfan in the non-
myeloablative regimen. Patients included in this study received an average dose of 59.3 mg 
busulfan, which resulted in a mean busulfan clearance of 0.18 ± 0.05 L/h/kg and a mean AUC 
of 1153 ± 331 mmol*min/L.
Gst polymorphisms
The overall success rate of genotyping the GSTA1, GSTM1 and GSTP1 polymorphisms was 97, 
98 and 88%, respectively. An overview of genotype frequencies for all three SNPs is given in 
Table 3.2. Missing GSTP1 genotypes were due to lack of patient material (n = 8) and assay 
genotyping failure (n = 2 for GSTA1 and n = 1 for GSTM1). However, all variants showed Hardy–
Weinberg equilibrium and were comparable with distributions of the genotypes found in 
other studies.10,18,19
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effect of Gst on busulfan pharmacokinetic parameters
After the first dose of 0.8 mg/kg, a higher clearance was observed in the GSTA1*A/*A genotype 
group (0.21 ± 0.055 L/h/kg) compared with GSTA1*B heterozygous patients (0.18 ± 0.041 L/h/
kg) and GSTA1*B homozygous patients (0.15 ± 0.039 L/h/kg; Table 3.3). Analyzing using linear 
table 3.1 Baseline characteristics of HSCT patients
Characteristic Mean (range)
Age in years 52.1 (25–70)
Weight 74 (51–108)
Body surface area 1.89 (1.51–2.36)
Body mass index 24 (19–34)
Sex (%(N))
Male 56 (37) 





Matched family 46 (30)
Mismatched family 1 (1)








Flu Busulfan ATG 94 (62)
Flu Busulfan ATG CY 3 (2)
Busulfan AL CY 3 (2)
*Presented underlying diseases in the category malignant diseases are , acute myeloid leukemia (n = 14), 
chronic myeloid leukemia (n = 3), chronic lymphocytic leukemia (n = 6), non-Hodgkin lymphoma (n = 12), 
multiple myeloma (n = 21), chronic myelomonocytic leukaemia (n = 2) and non-malignant diseases aplastic 
anaemia (n = 7) and sickle-cell anemia (n = 1).
**Dosing schemes refer to Flu busulfan ATG: busulfan 0.8 mg/kg four times daily on days -6 and -5, oral Flu 
50 mg/m2 once daily from day -10 to -5 and ATG from day -4 to -1. Flu busulfan ATG CY: busulfan 0.8 mg/kg 
four times daily on days -6 and -5, oral Flu 50 mg/m2 once daily from day -10 to -5, ATG from day -4 to -1 and 
CY 750 mg/m2 once daily on days -4 and -3. Busulfan AL CY: busulfan 0.8 mg/kg four times daily from day -9 
to -6, AL 15 mg once daily on days -6 and -5 and CY 60 mg/kg once daily on days -4 and -3.
ATG: anti-thymocyte globusulfanlin, AL: alemtuzumab, Flu: fludarabine, CY: cyclophosphamide.
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regression a reduction of 14% in busulfan clearance was found per GSTA1*B allele. The GSTA1 
polymorphism could explain 18% of the variability in clearance. An inverse effect was observed 
for the AUC, as shown in Figure 3.1, AUC increases with 18% in GSTA1*B heterozygous patients 
and 35% for GSTA1*B homozygous patients. No significant differences in other parameters and 
GSTA1 genotypes were detected (Table 3.3). No relationship was found between the investigated 
polymorphisms in GSTM1 and GSTP1 and busulfan clearance. In GSTM1-positive individuals, a 
mean busulfan clearance of 0.18 ± 0.049 L/h/kg was found, whereas in patients with a deletion 
mutation busulfan clearance was 0.19 ± 0.049 L/h/kg. Busulfan clearance in patients with 
different GSTP1 genotypes were similar: 0.19 ± 0.050 L/h/kg for the AA genotype, 0.18 ± 0.041 
L/h/kg for the AG genotype and 0.21 ± 0.067 L/h/kg for the GG genotype (p = 0.162; Figure 3.1). 
table 3.2 Distribution of GSTA1, GSTM1 and GSTP1 genotype in allo-HSCT patients
Gene Genotype Patients % (n)
GSTA1 CC 30 (20)
CT 49 (32)
TT 18 (12) 
GSTM1 Positive 58 (38)
Deletion 41 (27)
GSTP1 AA 32 (21)
AG 45 (30)
GG 11 (7)
GSTA1 genotype could not be determined in two patients (3%) and GSTM1 genotype could not be determined 
in one patient (1.5%) because of assay failure. GTSP1 genotype could not be determined in eight patients 
(12%) because of the lack of material.
table 3.3 Effect of GSTA1 genotypes on busulfan pharmacokinetic parameters and HSCT patient 
parameters
Parameter Overall (n = 64) CC (n = 20) CT (n = 32) TT (n = 12) P-value
Age (years) 53.3 (10.3) 53.8 (11.7) 53.3 (9.1) 52.6 (11.6) 0.95
Weight (kg) 73.7 (12.6) 71.5 (12.8) 74.6 (11.5) 75.0 (15.6) 0.63
Dose (mg) 59.3 (9.9) 57.9 (10.1) 59.9 (9.2) 60.1 (12.0) 0.74
Cl (L/h/kg) 0.18 (0.05) 0.21 (0.055) 0.18 (0.041) 0.15 0.039) 0.002
AUC (μmol*min/L) 1149 (336) 996 (311) 1172 (301) 1346 (368) 0.013
Sex (% of male gender) 55 60 59 33 0.26**
All numbers presented are mean (s.d.) unless otherwise indicated and statistical tests were carried out with 
analysis of variance unless otherwise indicated.
**χ2-test.
P value < 0.05 is regarded as significant and indicated in bold font.
AUC: area under curve.
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Figure 3.1 The relationship between GSTA1, GSTM1 and GSTP1 genotype and busulfan 
pharmacokinetic parameters. a) Relationship between GSTA1 and clearance per kg of busulfan. b) 
Relationship between GSTA1 AUC of busulfan mmol*min/L). c) Relationship between GSTM1 and 
clearance per kg of busulfan. d) Relationship between GSTP1 and clearance per kg of busulfan. 
Bars indicate mean values for each category.
effect of GstA1 on clinical outcome
VOD did not occur in any of the patients in this study and eight patients were diagnosed 
with mild aGVHD (grade one). In one patient engraftment did not occur and three patients 
experienced a secondary rejection of their transplant several months after transplantation. 
Of the HSCT patients with mild aGvHD, one patient was GSTA1*A/*A genotyped, five patients 
GSTA1*A/*B and two patients were GSTA1*B/*B (p = 0.2). The three patients with rejection were 
GSTA1*B/*B genotyped (p = 0.001), whereas the patient with non-engraftment was a GSTA1*B 
heterozygote. After a follow-up of 3 years 36 of 66 patients died, the OS was 45%. No effect of 




In our adult Caucasian population, polymorphism in the GSTA1 gene resulted in a significantly 
lower busulfan clearance, hence a significantly higher exposure to busulfan. However, the effect 
of GSTA1 genotype on busulfan pharmacokinetics did not seem to influence busulfan toxicity 
in this study. However, all patients who experienced rejection were GSTA1*B homozygotes. In 
addition, no relation was found between polymorphisms in GSTM1 and GSTP1 genes and busulfan 
pharmacokinetic parameters. Therefore, interpatient variability in busulfan pharmacokinetics 
could be partly assigned to variances in the gene encoding the GSTA1 isoenzyme. Busulfan 
shows large interpatient variability in clearance, which causes unpredictable exposure of 
busulfan resulting in either toxicity or therapy failure. It is hypothesized that differences in 
activity of the enzymes involved in busulfan metabolism (GSTA1, GSTM1 and GSTP1), caused 
by genetic polymorphisms, could explain the large interpatient variability. This is the first study 
investigating the effect of polymorphisms in the genes encoding for these three GST isoenzymes 
on busulfan pharmacokinetics in Caucasian adults.
The effect of polymorphisms in GSTA1 and GSTM1 on busulfan pharmacokinetics in adults has 
been studied before by Kusama et al.,20 Kim et al.21 and Abassi et al.18 The first two studies were 
carried out on Asian patients. In both studies no GSTA1*B homozygotes were observed. Kusuma 
et al. investigated the effect of the polymorphisms in 12 adult Japanese patients receiving 
busulfan orally and showed a reduction in clearance (Cl/F) of 40% in GSTA1*A/*B patients 
at steady state. Kim et al. showed a decrease in clearance of 12% after intravenous busulfan 
administration for GSTA1*A/*B patients. These results are in line with our results, though the 
reduction in clearance per GSTA1*B allele is somewhat less pronounced in comparison with the 
Japenese study in which busulfan is administered orally: 14% for GSTA1*A/*B genotype and 29% 
for GSTA1*B/*B genotype as measured after the first dose. Clearance after oral administration 
(CL/F) might be influenced differently by GST polymorphisms compared with clearance 
after intravenous administration, as busulfan is conjugated locally in the small intestine with 
glutathione and genetic variances could alter the first-pass effect. Furthermore, our patient 
population is Caucasian, which might result in a different effect of polymorphisms in the GSTs 
and busulfan pharmacokinetics than in Japanese patients.
Abassi et al. investigated the effect of genetic variances in GSTA1 and GSTM1 in a combined 
pediatric and adult population. No significant association between the genetic variances and 
intravenous busulfan clearance was found. Oral busulfan clearance was associated with the 
GSTA1 haplotype, busulfan this was not considered clinically relevant.
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In our previous study,10 the effect of GSTA1 genotype on busulfan pharmacokinetic parameters 
in children was investigated; no significant effect of the polymorphism on busulfan clearance 
was detected. However, a small association of genetic variances in GSTA1 and busulfan clearance 
in older children was seen. This observation was the main reason for this study; to investigate 
the effect of the genetic variances in GSTs on busulfan clearance in adults. 
However, the clinical relevance of these findings is not clear, as in our study no clear effect of 
GSTA1 genotype on clinical outcome was observed. Ultimately, pharmacogenetics aims for 
prevention of aberrant drug response. We presume that the effect of polymorphisms in GSTA1 is 
probably relevant for the more toxic regimes only, since overall, a low incidence of toxicity and 
therapy failure was seen in our patient population. Nevertheless, we demonstrated that part of 
the interpatient variability in busulfan exposure can be explained by genetic variances in GSTA1 
(18%). Busulfan therapy is often individualized by therapeutic drug monitoring. Eventually, 
the aim is to optimize individual therapy by determining the pharmacogenetic profile of the 
patient and predict pharmacokinetics of the drug before administering busulfan. Additional 
studies are needed to investigate the effect of GSTA1 genotype on busulfan pharmacokinetics 
and outcome in more toxic regimes and to optimize genotype-based dosing of busulfan.
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Busulfan is used in preparative regimens before stem cell transplantation. There is significant 
interpatient variability in busulfan pharmacokinetics (PK) and exposure is related to outcome. 
Polymorphisms in genes encoding glutathione-S-transferases have been associated with 
busulfan PK but only explain a limited portion of the observed variability. The aim of this study 
is to identify additional genetic variants associated with busulfan PK by interrogating 1,936 
variants in 225 genes involved in drug absorption, distribution, metabolism, and excretion 
(ADME). In an exploratory cohort (n = 65), patients who received busulfan were genotyped with 
the DMET array. Top SNPs and haplotypes associated with busulfan clearance were validated 
in an independent validation cohort (n = 78). In the exploratory cohort, seven variants were 
identified to be associated with busulfan clearance (p < 0.001). In the validation cohort, only 
GSTA5 (rs4715354 and rs7746993) remained significantly associated with busulfan clearance 
(p = 0.025). This is the first study using an exploratory pharmacogenetic approach to explain 
the interindividual variability in busulfan PK. The role of glutathione-S transferases was 
confirmed, but no additional genetic markers involved in drug ADME appear to be associated 
with busulfan PK.
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IntroductIon
Busulfan is an alkylating agent used widely in high doses in conditioning regimens beforeal-
logenic hematopoietic stem cell transplantation (allo-HSCT) in adult and pediatric patients. 
Interpatient variability is significant in busulfan pharmacokinetics (PK); even when busulfan is 
administered intravenously and body weight adjusted dosing is applied, interpatient variability 
in exposure or clearance remains between 20 and 30%.1,2 Furthermore, busulfan exposure is 
related to outcome. High busulfan exposure appears to result in a higher incidence of toxicities 
such as sinusoidal obstruction syndrome and mucositis, whereas low busulfan exposure 
apparently leads to higher rates of graft failure and rejection.3–5 Therefore, often, therapeutic 
drug monitoring is applied to individualize busulfan therapy and optimize clinical outcome. 
Many efforts have been made to develop a population PK model to further characterize busulfan 
PK.6,7 The facilities needed for applying therapeutic drug monitoring in a clinical setting are, to 
date, a barrier to universal acceptance. Furthermore, up-front-dose adaption is not possible. 
In addition to targeting busulfan doses on the basis of PK-models, pharmacogenetic profiling 
of patients could play a more important role. 
Multiple studies have been carried out to search for a pharmacogenetic explanation for the high 
variability in busulfan PK. To date, mainly polymorphisms in genes encoding for glutathione-
S-transferases (GSTs) have been studied.8–12 Busulfan is metabolized by conjugation to 
glutathione. This reaction is catalyzed by different GSTs enzymes, of which GSTA1 is the 
predominant enzyme responsible for 46% of busulfan conjugation.8 After conjugation, the 
complex is oxidized in the liver and metabolites are mainly excreted in the urine. In several 
studies, a single nucleotide polymorphism (SNP) in GSTA1 (rs3957357) was shown to be related 
to busulfan PK in adult patients receiving busulfan before their HSCT.9,10 We confirmed this 
in an independent cohort of adult patients.11 In this study, three SNPs in three different GST 
genes were tested for association with busulfan clearance. Only rs3957357 in GSTA1 was found 
to be associated with busulfan clearance; however, this SNP could only explain 14% of its 
variability. Most of the available studies investigating variability in busulfan PK have applied 
the candidate gene method. Although this method has proven to be successful in the past, its 
major limitation is that it cannot identify genetic markers in genes not previously associated 
with busulfan PK. We hypothesized that other absorption, distribution, metabolism, and 
excretion (ADME) genes involved in drug metabolism or transport of busulfan could add to 
the variability of PK, meaning that a set of genetic variants may be more important to explain 
interindividual differences in busulfan exposure than a single gene. Genetic profiling with the 
Affymetrix drug metabolizing enzymes and transporters genotyping array offers the ability to 
determine 1,936 variants in 225 genes involved in drug metabolism and disposition.12 In this 
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report, we present the results of the exploration of genetic factors associated with busulfan 
PK using this genotyping array.
PAtIents And methods
Patient and disease characteristic
Patients receiving allo-HSCT between 2004 and 2011 in the Leiden University Medical Center 
were included on the basis of the following selection criteria: age between 18 and 70 years, 
receiving busulfan as conditioning before their allo-HSCT with measured busulfan serum 
samples, and presence of DNA for genotyping. The Institutional Ethics Committee approved the 
study protocol. Written informed consent was obtained from all study participants according 
to the Helsinki Declaration. Diagnoses that required allo-HSCT were malignant: acute myeloid 
leukemia, chronic myeloid leukemia, chronic lymphoid leukemia, acute lymphoblastic leukemia, 
chronic myelomonocytic leukemia, non-Hodgkin’s lymphoma or multiple myeloma or non-
malignant: aplastic anemia, β-thalassemia or sickle cell anemia. Patients receiving busulfan 
between 2004 and 2008 were included in the exploratory cohort. This cohort was genotyped 
using de DMET plus arrays (Affymetrix UK Ltd, High Wycombe, UK). Patients receiving busulfan 
between 2008 and 2011 were included in the validation cohort. In this cohort, the positive 
findings of the exploratory cohort were tested. 
treatment regimens
Patients received either myeloablative conditioning or non-myeloablative conditioning. The 
non-myeloablative conditioning consisted of intravenous busulfan 0.8 mg/kg four times 
daily on days -6 and -5 before allo-HSCT, oral fludarabine 50 mg/m2 on days -10 to -5, and 
alemtuzumab 15 mg for 2 days. In case of a matched unrelated donor, antithymocyte globulin 
1–3 mg/kg was added. Alternatively, busulfan on days -6 and -5 before allo-HSCT was combined 
with oral fludarabine 50 mg/m2 on day -10 to -5, intravenous cyclophosphamide 750 mg/m2 
on days -4 and -3, and alemtuzumab 15 mg during 2 days. The myeloablative conditioning 
consisted of intravenous busulfan 0.8 mg/kg four times daily on days -9 to -6 before allo-HSCT, 
intravenous cyclophosphamide 60 mg/kg on days -4 and -3, and alemtuzumab 15 mg during 2 
days. Dosing of the different drugs, including busulfan, is based on the actual body weight. All 
patients received 92 mg phenytoin three times daily for seizure prophylaxis starting one day 
before busulfan administration. Busulfan was administered intravenously in a 2-hour infusion. 
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Serum drug level measurements were performed at 2.5 and 4.0 h after the start of the first 
infusion on the first day of treatment. Busulfan was analyzed in 200 ml serum using a validated 
high-performance liquid chroma tographic assay involving precolumnderivatization with 
diethyldithiocarbamate, liquid/liquid extraction, and UV detection, described previously by our 
group13 and on the basis of the method of Chow et al.14 The assay is linear between 30 and 8000 
mg/L and the limit of quanti fication is 30 mg/L. Accuracy at 200 and 1500 mg/L was 94 and 98%, 
respectively. Intraday variability in precision is 3.5 and 0.8% and interday variability in precision 
is 4.4 and 2.4% at 200 and 1500 mg/L, respectively. A validated limited sampling model was 
used to minimize the number of blood samples necessary to calculate the busulfanclearance.13 
A one-compartment population PK model for busulfan with linear elimination, developed and 
validated in MW/Pharm version 3.6 (Mediware, Groningen, the Netherlands), was used.11,13,15,16 
The calculated mean population PK parameters, clearance, volume of distribution, and half-life, 
were individualized according to the maximum a posteriori Bayesian fitting method.17 No dose 
adjustments were made on the basis of the individual PK parameters. 
Genotyping methods
DNA was isolated from EDTA blood using Maxwell (Promega, Leiden, the Netherlands) or 
Magnapure compact (Roche, Almere, the Netherlands). All samples were anonymized according 
to the instructions in the Codes for Proper Use and Proper Conduct (http:// www.federa.org). 
DNA samples of the exploratory cohort were analyzed using DMET plus arrays (Affymetrix UK 
Ltd) according to the manufacturers’ prescription and described in detail by Caldwell et al.18 
and Dumaual et al.19
Genotypes were calculated with DMET console software version 1.1 using the Dynamic 
Genotype Boundaries algorithm (Affymetrix UK Ltd). Patients with a call rate of less than 
90% were excluded from the analyses. All individual SNPs were tested for Hardy–Weinberg 
equilibrium in gPlink 2.05020; SNPs that were not in equilibrium (p < 0.001) were excluded 
from further analysis. 
In the validation cohort, SNPs were determined by high-resolution melting (HRM) of small 
amplicons with the LightScanner (HR-96; Idaho Technology, Salt Lake City, Utah, USA). 
Oligonucleotides used for small amplicon (40–60 bp) genotyping were chosen adjacent to 
the SNP. Melting curves were analyzed with LightScanner Software using Call-IT 2.0 (Idaho 
Technology). As a quality control measure, 10% of samples were genotyped in duplicate. 
Traditional Sanger sequencing was used to confirm HRM results for each SNPs. An overview 
of primers used in HRM and sequencing is presented in Table 4.1. 
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In both cohorts, more than 93% of the patients were of White ethnicity. Ethnicity was declared by 
the physician of the patient, but ethnicity was not studied as such in this study. To evaluate the 
ethnicity and to exclude the possibility of population stratification of the samples in the exploratory 
cohort, multidimensional scaling (MDS) was used, as implemented in software package plink. 
Four MDS coordinates were used and plots were created for adjacent MDS components. 
haplotype estimation
In the exploratory cohort, haploblocks were composed of SNPs associated with busulfan 
clearance within one gene. The haploblocks were tested to detect linkage disequilibrium. 





Number of patients 62 78
























Flu Bu (ATG or Alemtuzumab) 59 74
0.55Flu Bu CY 2 3
Bu Cy Alemtuzumab 1 1
AML: acute myeloid leukemia, CML: chronic myeloid leukemia, CLL: Chronic lymphocytic leukemia, ALL: 
acute lymphoblastic leukemia , MM: Multiple Myeloma , NHL: Non-Hodgkin lymphoma , CMML: chronic 
myelomonocytic leukemia, AA: aplastic anemia, β-thl: β-thalassemia , SCA: sickle cell anemia, Flu: fludarabine, 
Bu: busulfan, Cy: cyclofosfamide, ATG: anti-thymocyteglobuline.
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If linkage disequilibrium between SNPs was present, haploblocks (with several haplotypes) 
were determined. A haplotype was set if the haplotype uncertainty parameter Rh2 was greater 
than 0.95. Haplotypes with an Rh2 of 0.95 or less were not considered for further analysis. 
Rare haplotypes (frequency < 10%) were pooled into one group in the association analysis. 
The following SNPs were analyzed in haploblocks: ABCB1 rs2032588 and rs2235015; ABCB4 
rs45595532, rs2109505, and rs1202283; ABCC2 rs7899457 and rs8187706; ABCC6 rs8058694 and 
rs8058696; CYP2B6 rs8058694 and rs8058696; CYP39A1 haploblock 1 rs2277119 and rs59926524; 
CYP39A1 haploblock 2 rs9381468 and rs953062; CYP3A7 rs45467892 and rs45494802; CYP4F2 
rs2108622 and rs3093106; FMO1 rs742350 and rs1126692, GSTA1 rs4715332 and rs4715333; 
GSTA5 rs4715354 and rs7746993; NR3C1 rs6195, rs6190 and rs6189; PPARD rs7746988, rs6901410, 
rs6457815, rs7757196, rs7754530, rs7739752, rs6913026, rs6922548, rs6940722, rs6915115, 
rs6457816, rs6906237, and rs1053046; and UGT2B15 rs4148269, rs3100, and rs4148269. 
In the validation cohort, a tagging SNP was identified in each haploblock to determine 
haplotypes. The tagging SNP was selected on the basis of the frequencies of the different 
haplotypes in the exploratory cohort. In case it was not possible to determine haplotypes in the 
exploratory cohort on the basis of one tagging SNP, two SNPs were selected for determination 
of the haplotype. Care was taken such that the same SNPs could be analyzed in the exploratory 
and validation cohorts. This resulted in the following analysis in the validation cohort: Three 
haploblocks contained two SNPs: GSTA5: two tagging SNPs (rs4715354 and rs7746993), CYP39A1 
block 1: one tagging SNP (rs2277119) and block 2: two tagging SNPs (rs9381468 and rs953062). 
One haploblock (ABCB4) contained three SNPs, of which two were determined (rs2109505 
and rs1202283). For each indivi dual patient, haplotypes were estimated and haplotype Rh2 
was calculated using gPlink haplotypes; with Rh2 more than 0.95 haplotypes were considered 
present. 
In Table 4.2, an overview is presented of the number of SNPs and also the frequencies of the 
different haplotypes in both the exploratory and the validation cohort. 
statistical analysis
PK parameters are presented as means (± SD) (normal distribution) or geometric mean in case 
of log-normal distribution (± SD) of the parameter. In the exploratory cohort, associations with 
busulfan clearance and SNPs were tested initially by linear regression analysis with the SNPs 
in the additive model using gPlink. The effect of the number of copies of the haplotypes was 
tested in the same manner and the effect of gene copy number variation on busulfan clearance 
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Illinois, USA). Candidate markers with a p-value less than 0.05 (SNPs or haplotypes) and SNPs 
with a minor allele frequency more than 10%, to maintain a high enough power, were included 
in a multivariate linear regression analysis using a stepwise forward conditional approach with 
busulfan clearance as a dependent variable. The combination of SNPs and haplotypes explaining 
the largest portion of total variability in clearance was selected (highest R2). The selection of 
these most informative SNPs and haplotypes was used to create a pharmacogenetic model 
predicting busulfan clearance (ClPG). This model was tested in the validation cohort. 
All results from the multivariate analyses with a p-value less than 0.05 were considered 
significant. As this was an exploratory study, no correction for multiple testing was performed. In 
addition, this exploratory study used an uninformative approach, meaning that no adjustments 
for confounding factors and assumptions of polymorphism effects were made. 
In the validation cohort, a predicted busulfan clearance was calculated for each patient with 
the regression model developed in the exploratory cohort (ClPG). The algo rithm to calculate 
ClPG was based on the βs of each genetic marker from the multivariate analyses (Table 4.2) and 
a constant of 0.211; an additive model was assumed, according to Eq 4.1. 
ClPG =0.016*GSTA5 – 0.021*SLC22A4 – 0.025*ABCB4 + 0.013*SLC7A8   ( Eq 4.1)
– 0.018*CYP39A1_TC + 0.023*CYP2C19 + 0.018*CYP39A1_GC
The value of each genetic marker is 0, 1, or 2 depending on the number of variant alleles. The 
busulfan clearances calculated using the pharmaco genetic model (ClPG) and the busulfan 
clearances calculated using the population pharmacokinetic model (ClPK) of each patient were 
compared on a case-by-case base with Pearson correlation. Furthermore, the associa tion of 
the seven genetic markers with busulfan clearance was tested individually by linear regression 
analysis with the marker in the additive model in gPlink.
results
description of the patient population
We carried out a two-stage approach, an exploratory analysis, and an independent validation 
study. Sixty-five adult patients were included in the exploratory cohort. Three patients were 
excluded because of a genotype call rate of less than 90%. The validation cohort included 78 
adult patients. Patient characteristics of both cohorts are shown in Table 4.3. In the exploratory 
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of the patient population was 53 ± 10 and 57 ± 11 years for the respective cohorts (p = 0.04). 
The mean busulfan clearance (ClPK) was similar in the exploratory cohort (0.19 ± 0.05 L/h/kg) 
and in the validation cohort (0.17 ± 0.04 L/h/kg) (p = 0.16). 
The two different cohorts were created sequentially on the basis of the date of HSCT and 
busulfan administra tion. The two cohorts were similar in terms of sex distribution, average 
busulfan clearance, indication, and conditioning regimen. There was a significant difference 
in the average age between the two cohorts. However, age is not associated with busulfan 
clearance in adult patients. 
Genotyping 
In the exploratory cohort, of the 1936 SNPs determined, 46 SNPs were X-chromosomal. As there 
was no sex difference in busulfan clearance levels (p = 0.19), these SNPs were excluded from 
the analysis. All 62 patients passed QC metrics and produced useable genotypes. 
The average call rate of the remaining 1890 SNP assays was more than 98%. One SNP 
(RS7436963/UGT2B17) failed to meet Hardy–Weinberg equilibrium (p < 0.001) and was excluded 
from further analysis. Of the remaining 1889 SNPs, 851 SNPs were polymorphic in the study 
population and were used in the association study. An overview is presented in Figure 4.1.
Figure 4.1 Flow charts of genotyping results in the exploratory cohort. HW: Hardy-Weinberg, 
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To exclude population stratification, MDS plots were created (Supplemental Figure 4.1). The 
plots do not indicate the presence of strong population stratification. If population stratifica-
tion would be present, clear separated clusters would be observed in the graphs, indicating a 
difference in allele frequencies between subpopulations. 
In the validation cohort, 10 SNPs, which were selected in the exploratory cohort, were 
determined. The average call rate was more than 99%; all variants showed Hardy–Weinberg 
equilibrium (p > 0.05). 
Association of genetic variants with busulfan clearance in the exploratory cohort 
Of the 851 SNPs, 86 SNPs in 52 different genes showed a significant association with busulfan 
clearance (p < 0.05; see also Figure 4.2). Of the 45 SNPs, 15 haploblocks, containing 29 haplotypes, 
located in 14 different genes, were formed. In the next step of association analysis, SNPs and 
haplotypes that fulfilled the selection criteria (p < 0.05, minor allele frequency > 10%) were 
applied in the multivariate analyses. Seven variants (three SNPs and four haplotypes) in six genes 
were selected as the top genetic markers, explaining 64% (adjusted R2) of variance in busulfan 
clearance in the exploratory cohort (p < 0.001) (Table 4.2). To be more specific, three genes of the 
model are involved in drug metabolism processes in general: GSTA5 (rs4715354 and rs7746993) 
and two cytochrome P450 genes: CYP2C19 (rs12248560) and CYP39A1 (rs2277119 and rs9381468 
and rs953062) and three genes were found to be involved in drug transport: ABCB4 (rs2109505 
and rs1202283), SLC22A4 (rs1050152), and SLC7A8 (rs7141505). The effects of each individual 
genetic marker on busulfan clearance are presented in individual graphs in Figure 4.3. 
Predication of busulfan clearance in validation cohort
In the validation cohort, busulfan clearance was calcu lated using the prediction algorithm and 
the individual genotypes of the seven markers. The average predicted clearance (ClPG) was 0.19 
± 0.04 L/h/kg. A correlation graph and a Bland–Altman plot are provided in Supple mental Figure 
4.2 showing a poor correlation between ClPG and clearance calculated using the PK model (ClPK), 
R2 = 0.024, but no systematic bias between the two methods. 
When the seven genetic markers were tested separately, one haplotype in GSTA5 (rs4715354 and 
rs7746993) remained statistically significant (p = 0.025) for correla tion with busulfan clearance. 
Busulfan clearance of patients with one variant allele was decreased by 11% and 18% in patients 
with two variant alleles as compared with GSTA5 wild-type patients. In the validation cohort, 
the GSTA5 haplotype could explain 6.5% of variability in busulfan clearance.
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This is the first study using an exploratory pharmacoge netic approach including a wide range 
of genes involved in drug ADME to investigate the interindividual varia bility in busulfan 
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clearance both in the exploratory and in the validation cohort. No additional genetic markers 
involved in drug metabolism and transport appeared to be associated with busulfan clearance. 
Busulfan is metabolized primarily by conjugation with glutathione, catalyzed by GSTs. Different 
GST enzymes are involved in busulfan metabolism, GSTA1 being the predominant enzyme.8 
The effect of SNPs in genes encoding for three GST enzymes (GSTA1, GSTM1, and GSTP1) on 
busulfan PK has been studied before, leading to ambiguous results. Our group11 and Kim et al.10 
showed an effect of a GSTA1 SNP (rs3957357) on busulfan clearance in adult patients receiving 
busulfan intravenously; the other two SNPs showed no effects. Our group21 and Ansari et al.22 
studied the same SNPs in a pediatric population. Both studies showed no association between 
the GSTA1 SNP and busulfan PK. 
Moreover, Hassan et al.23 suggested the involvement of transporter enzymes in busulfan 
metabolism, transporting the glutathione–busulfan conjugate out of the cell. Only one study 
investigated the effect of a transporter on busulfan PK. In this study, the effect of three GST 
SNPs and two ABCB1 SNPs (rs1045642 and rs2032582) was investigated and it was found that 
combined polymorph isms in GSTM1 and ABCB1 were associated with busulfan PK.24 
In the exploratory cohort, genetic markers in different transporters (two solute carriers and 
one ABC transpor ter) were identified to be potentially related to variance in busulfan PK. These 
findings could not be confirmed in the validation cohort, thus suggesting that the involve ment 
of transporters in busulfan PK is not likely. 
In our study, genetic variants were tested in relation to busulfan clearance. Unfortunately, our 
study does not have sufficient statistical power to relate genetic varia tions to clinical outcome 
parameters such as toxicity, efficacy (engraftment), or relapse. Instead, we explored relationships 
with busulfan clearance. However, for busulfan, a clear relationship between PK and clinical 
outcome has been described.3–5
The GSTA5 haplotype was found to be associated significantly with busulfan clearance. The 
GSTA5 gene is a member of the same family as GSTA1 and GSTA5 protein is absent in human 
tissue.25 However, the previously studied GSTA1 SNP (rs3957357, -69C/T), a tagging SNP in a 
haploblock with three other SNPs in the promoter of GSTA1 (-631T/G, -567T/G, -69C/T, and 
-52G/A), and the tagging SNP of GSTA5 (rs4715354) are linked; haploview linkage disequilibrium 
of these SNPs is D’= 1 and r2 = 0.69. Thus, the association with the GSTA5 SNP is in fact a positive 
control for earlier findings for the association of GSTA1 SNP and busulfan PK. The GSTA1 SNP 
(rs3957357) is not present on the DMET array and was therefore analyzed separately. The absence 
of the tagging SNP of the GSTA1 gene on the DMET array and the relatively small sample size 
resulted in a slightly larger effect size of GSTA5 in comparison with other GSTA1 SNPs on the 
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DMET array in the exploratory cohort. Separate analyses of GSTA1 (rs3957357) showed an 
association with busulfan clearance in the exploratory cohort (p < 0.01) and in the validation 
cohort (p = 0.02). Linkage of the two SNPs could be confirmed in both cohorts, resulting in 
D’=1 and r2 = 0.57 in the exploratory cohort and D’= 1 and r2 = 0.71 in the validation cohort. 
Previous studies indicate that only a small proportion of variability in busulfan PK can be 
attributed to genetic variants in GSTs. We hypothesized that several yet unknown metabolic 
enzymes and drug transporters could be involved in busulfan PK, each with a small influence. 
Therefore, in this study, we used an unsupervised genetic association approach. The advantage 
of such an approach is the possibility of discovering new pathways and genetic variants that 
might contribute toward variability in busulfan exposure. One of the first examples of the 
possibility of finding a novel unexpected relationship using the DMET array is given by Ross 
et al.26, showing an association between cisplatin ototoxicity and genetic variants in TPMT and 
COMT using the same genotyping platform. 
A disadvantage of this exploratory approach is the difficult interpretation of its results as the 
effects of the identified variants on gene function or expression are not always clear. Hence, 
the effect of variants found in the exploratory cohort on busulfan metabolism can only be 
hypothesis-generating and should be confirmed in a validation study, as we performed in the 
current study. 
An overview of the function and possible effects on busulfan clearance of the seven genes that 
were found in the exploratory study is shown in Supplemental Table 4.1.
Concomitant medications have been associated with busulfan PK. Especially antifungals, 
but also antiepileptic drugs are known for drug–drug interactions with busulfan. All patients 
included in our study received 92 mg phenytoin three times daily for seizure prophylaxis, starting 
one day before busulfan administration. Phenytoin could induce the metabolism of busulfan. 
However, the effect of phenytoin is not very strong. Furthermore, if this interaction would 
affect busulfan PK, it will be the same in all patients included in this study. A more significant 
interaction is the effect of antifungals on busulfan PK. Antifungals such as ketoconazole can 
increase busulfan exposure, probably because of inhibition of busulfan metabolism in the 
liver. In our study population, the only antifungal administered to the patients concomitantly 
with busulfan was oral amphotericin B. This drug is not absorbed and will therefore not affect 
busulfan metabo lism in the liver. 
In our study, a large number of SNPs were evaluated in the exploratory cohort, which introduces 
the potential problem of multiple testing and an increase in the risk of false-positive findings. To 
enrich our SNP set with predictive SNPs to be used by a prediction model for busulfan clearance, 
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we applied a mild statistical threshold of p less than 0.05 in the exploratory cohort. P-value 
thresholds in an exploratory set are meant to enrich for associated SNPs not strictly controlling 
type I error (following Purcell et al.27). Evaluation of the association of scores in the exploratory 
set has descriptive merits and formal evaluation of significance is carried out in the validation 
set. It is possible to use alternative strategies for the construction of a prediction model by using 
different model selection techniques (such as penalized regression or ensemble methods); 
however, by testing external validity in an independent data set, we offer a conservative and 
robust approach to model evaluation. Construction of a simple model has the advantage of 
overfitting and making our results more comparable with similar studies (compare Purcell et al.27). 
Evaluation of the associations in the validation cohort resulted in confirming one of the seven 
genetic markers (e.g. GSTA5 haplotype). However, the explained variability of GSTA5 in the 
validation cohort was relatively small in comparison with the findings in the exploratory cohort. 
This decrease in explained variability could be because of unmeasured confounders that are 
different between the two different cohorts. Furthermore, the explained varia bility of 64% in 
the exploratory cohort might be an overestimate because of the so-called winners curse. To 
assess the magnitude of this phenomenon, we performed a data-split by fitting the model in the 
first half and computing the R2 of the resulting predictor in the second half. With this analysis, 
the R2 decreased from 75 to 37%, indicating the presence of overfitting (aka winner’s curse). 
Still, this analysis confirms that the model has considerable explanatory power. The findings 
of involvement of GSTA5 on busulfan PK will not directly have an impact on clinical practice. 
This is the first study using an exploratory pharmacogenetic approach in 225 genes involved 
in ADME to find an explanation for the interindividual variability in busulfan clearance. The 
GSTA5 haplotype, and thus GSTA1, was significantly associated with busulfan clearance both 
in the exploratory and in the validation cohort. No additional genetic markers involved in drug 
metabolism and trans port were found to be associated with busulfan clearance.
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supplemental Figure 4.1 Multidimensional scaling (MDS) plots of adjacent MDS components
The plots do not indicate the presence of strong population stratification. If stratification would 
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4supplemental Figure 4.2 Correlation graph and Bland Altman Plot. Correlation graph showing 
busulfan clearance based on PK data (ClPK) on the x-axis and clearance predicted with genetic 
markers (ClPG) on the y-axis, R
2 = 0.024. Bland Altman plot: on the x-axis: average of ClPG and ClPK 
per individual and on the y-axis the difference between ClPG and ClPK per individual. Middle line: 
the average difference and the two dashed lines: upper and lower limits of agreement (-2SD and 
+2SD).

































supplemental table 4.1 An overview of the function and possible effects on busulfan clearance 
of the 7 genes that were found in the exploratory cohort
Gene Role gene1 Postulated effect 
GSTA5 Part of the alpha class of gluthationetransferases, 
catalyze conjugation with gluthation. 
No functional protein identified 
in human.2
SLC22A4 Influx transporter also known as carnitine/organic 
cation transporter (OCTN1), present in liver, kidney, 
intestine and other organs. Critical for elimination of 
many small organic cations.3
ABCB4 ATP-binding cassette, sub-family B (MDR/TAP). This 
gene encodes a full transporter and member of the 
p-glycoprotein family; it may involve transport of 
phospholipids from liver hepatocytes into bile.
p-GP is a transporter of 
gluthatione conjugates out 
of the cell and may transport 
busulfan conjugate.4
SLC7A8 Cationic amino acid transporter, also known as LAT2 
gene.
SNP located in haploblock in 
promoter region of gene; no 
evidence for effect of SNP on 
expression of gene.5
CYP39A1
Block A & B
A member of the cytochrome P450 superfamily 
of enzymes. This endoplasmic reticulum protein 
is involved in the conversion of cholesterol to bile 
acids.
CYP2C19 This protein localizes to the endoplasmic reticulum 
and is known to metabolize many xenobiotics 
including omeprazol and anticonvulsive drugs.
*17 allele: increased transcription 
and ultrarapid allele.6
Busulfan conjugate is oxidized in 
the liver, which may be facilitated 
by CYP2C19.
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Effect of genetic variants GSTA1 and CYP39A1 
and age on busulfan clearance in pediatric 
patients undergoing hematopoietic stem cell 
transplantation
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Busulfanis used in preparative regimens prior to hematopoietic stem cell transplantation in 
pediatric patients. There is significant interpatient variability in busulfan pharmacokinetics 
(PK) and exposure is related to outcome. To date, only polymorphisms in genes encoding for 
glutathione-S-transferases were studied, but could only explain a small portion of the variability 
in PK. In this study we investigate the effect of seven genetic markers on busulfan clearance and 
the effect of ontogenesis on these genetic variants in a pediatric population. In an earlier study 
of our group seven genetic markers in GSTA1, CYP2C19, CYP39A1, ABCB4, SLC22A4 and SLC7A8 
were associated with busulfan clearance in adult patients. Eighty four pediatric patients were 
genotyped for these markers and genotype was associated with busulfan clearance. GSTA1 
and CYP39A1 were found to be associated with busulfan clearance. When combined, the two 
haplotypes explained 17% of the variability in busulfan clearance. Furthermore, the effect of 
GSTA1 haplotype on clearance was dependent on age.
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IntroductIon
Busulfan is an alkylating agent commonly used in high doses in conditioning regimens prior to 
allogeneic hematopoietic stem cell transplantation (allo-HSCT) in adult and pediatric patients. 
Busulfan has a narrow therapeutic index and its exposure is related to clinical outcome. Indeed, 
an increased risk for busulfan toxicity such as (hepatic) sinusoidal obstruction syndrome and 
mucositis are related to high busulfan exposure whereas rejection of the graft and disease 
recurrence is related to low busulfan exposure.1–4 Furthermore, interpatient variability 
in busulfan pharmacokinetics (PK) is considerable. Even when busulfan is administered 
intravenously, and thus excluding potential variation in absorption, interpatient variability in 
exposure remains between 20–30%.5,6 To limit variation in busulfan exposure and to optimize 
clinical outcome,7 therapeutic drug monitoring is often applied in the clinical setting and 
population PK models have been developed.5,8 Furthermore, pharmacodynamics of busulfan 
differs based on the conditioning regimen prior to stem cell transplantation, the age of the 
patient and the recipients underlying disease.9
Variability in busulfan clearance could possibly be explained by genetic variation in genes 
involved in the PK of busulfan. A tagging SNP (rs3957357, -69C/T) in a haplotype of the gene 
coding for GSTA1, an enzyme predominantly involved in busulfan metabolism, was found to be 
associated with busulfan clearance in earlier studies in adult populations.10,11 The percentage 
of variability in busulfan PK explained by genetic variation in GSTA1 differs per study, possibly 
owing to differences in ethnicity of the studied population or administration route in the 
different studies (oral versus intravenous administration of busulfan). 
In pediatric patients the contribution of rs3957357 on busulfan PK is not as apparent as in adults: 
studies showed conflicting results for the effect of the GSTA1 haplotype on busulfan PK.12–15 This 
could be owing to other factors having a more profound effect on busulfan clearance in pediatric 
patients, such as bodyweight. In the pediatric population variation in bodyweight is much larger 
than in adults and it is known that busulfan clearance is significantly related to bodyweight in 
children. Furthermore, developmental changes affect PK pathways in young children.16 Also 
the role of pharmacogenetics could be influenced by ontogenesis in young children. To date, 
studies looking for pharmacogenetic biomarkers related to busulfan PK have been limited by a 
candidate gene approach. In a recent study of ten Brink et al.17, the Drug Metabolizing Enzymes 
and Transporters (DMET) genotyping array (Affymetrix) was used to interrogate 1936 genetic 
markers in 225 genes involved in drug transport and metabolism in an adult population. Through 
systematic screening, seven potential genetic markers in six genes were identified. The identified 
markers were located in GSTA5, CYP2C19, CYP39A1, ABCB4, SLC22A4 and SLC7A8. 
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However, these results cannot be directly extrapolated to a pediatric population, since other factors 
such as ontogenesis or bodyweight can have a pronounced effect on busulfan PK. Therefore, the 
aim of the current study is to investigate the effect of seven genetic markers on busulfan clearance 
and the effect of ontogenesis on these genetic variants in the pediatric population.
MAterIAls And Methods
Patient characteristics
In this retrospective study, pediatric patients (≤ 18 years) receiving busulfan conditioning prior 
to their allo-HSCT from March 2006 to March 2012 at the Leiden University Medical Center in 
The Netherlands were included. Other criteria for inclusion were the availability of DNA and the 
availability of busulfan blood concentration measurements. The institutional ethics committee 
approved the study protocol. Written informed consent was obtained from all study participants 
according to the Helsinki Declaration. 
treatment regimens 
Patients received busulfan (Busulfex®; Pierre Fabre Oncology, CastresCedex, France) intrave-
nously (iv.) once daily in a 4-day course. The starting dose was 120 mg/m2 or 80 mg/m2 and 
the second to fourth dose was calculated target ing a cumulative area under the curve (AUC) 
over 4 days of 80–90 mg*h/L or 60–80 mg*h/L. 
All conditioning regimens were according to The European Group of Blood and Marrow 
Transplantation (EBMT) protocols. An overview of number of patients per regimen is given in 
Table 5.1. Busulfan was combined with cyclophosphamide alone: busulfan: day -9 until day -6 
and cyclophosphamide iv. 50 mg/kg/day at day -5 until day -2. When etoposide iv. was added 
to this regimen, it was administered at day -12 and -11, 350 mg/m2/day. Or busulfan (day -9 until 
-6) was combined with a 2-day course of cyclophosphamide iv. 60 mg/kg/day at day -4 until -3 
and melphalan iv. 140 mg/m2 at day -1. When busulfan was combined with fludarabine both 
drugs were always administered on the same days: day -7 until day -4. The fludarabine iv. dose 
was 40 mg/m2/day. Both drugs could be combined with thiotepa iv. 8 mg/kg (day -8), melphalan 
iv. 140 mg/m2 (day -1). When busul fan and fludarabine were combined with clofarabine iv. 
(30 mg/m2/day, also on day -7 until day -4), the fludarabine dose was 10 mg/m2/day. Serotherapy 
consisted of antithymocyte globulin or alemtuzumab. All patients received clonazepam 25 μg/kg 
(four-times daily) as seizure prophylaxis, 1 day before start of busulfan. 
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busulfan pharmacokinetics 
Busulfan was administered in a 3 h infusion. Serum drug level measurements were collected at 
4, 5 and 7 h after the start of busulfan infusion on the first day of treatment as part of routine 
patient care. A validated limited sampling model was used to limit the amount of samples 
necessary to calculate busulfan clearance and AUC.8
Busulfan concentrations were analyzed in serum by a validated high-performance liquid 
chromatographic assay involving precolumnderivatization, liquid/liquid extraction and UV 
detection, previously described by our group.18 Briefly, the limit of quantification was 30 μg/L 
table 5.1 Patient characteristics and conditioning regimens
Characteristic Mean  (s.d.)
Age (years) 6.14 (5.4)
Weight (kg) 25.4 (17.3)
Length (cm) 113 (32.9)
Sex (n and % male) 58  (69%)
Conditioning regimen Patients (n), (serotherapy)*
Bu Cy 15 (10)
Bu Cy Melphalan 13 (6)
Bu Cy Etoposide 8 (7)
Bu Flu 29 (24)
Bu Flu Thiotepa 14 (13)
Bu Flu Melphalan 4 (3)
Bu Flu Clofarabine 1 (1)
Diagnosis for HSCT Patients (n)
Immune deficiency 28
Hematological malignancy 31
Other non-malignant / hematological disease 4
Thalassemia 21
Graft type Patients (n)
Bone marrow 62
Peripheral blood stem cells 11
Cord blood 11
Donor matching
Matched unrelated donor 53
Identical related donor 24
Other related donor 7
*Serotherapy: antithymocyte globulin/Campath.




and precision at 200 and 1500 μg/L was 3.5 and 0.8%, respectively. Individual PK parameters 
were calculated using a one-compartment population PK model for busulfan with linear 
elimi nation, developed in MW/Pharm version 3.6 (Mediware, Groningen, The Netherlands).18,19 
The calculated mean population PK parameters, clearance and half-life, were individualized 
according to the maximum a posteriori Bayesian fitting method.20
Exposure (AUC) was calculated by dividing the busulfan dose by estimated busulfan clear ance 
and was used to individualize busulfan dosing after the first dose. Clearance was adjusted to 
body surface area (BSA), since BSA describes busulfan clearance in children well.21,22
Genotyping and haplotype estimation 
Patients were genotyped for the seven potential genetic markers, in GSTA5, ABCB4, CYP39A1, 
CYP2C219, SLC7A8 and SLC22A4, previously identified by our group.17 However, post hoc 
analysis revealed that GSTA5 is in linkage with GSTA1, which is the functionally active gene in 
humans. Therefore, we included GSTA1 (rs3957357) instead of GSTA5. Nine SNPs were analyzed 
in GSTA1 (rs3957357), ABCB4 (rs2109505 and rs45595532), CYP39A1 (rs9381468, rs953062 and 
rs2277119), CYP2C19 (rs12248560), SLC7A8 (rs7141505) and SLC22A4 (rs1050152). DNA was 
extracted from available patient material including blood, peripheral blood mononuclear cells 
and bone marrow cells. Patient material was acquired 1–2 weeks before the HSCT procedure 
was performed. Samples were stored in liquid nitrogen at approximately -180°C for preservation 
until DNA extraction. DNA was extracted using the MagNAPure (Roche, Basel, Switzerland) 
system or Maxwell 16 (Promega, Madison, WI, USA) system. 
Genotypes were determined with high-resolution melting (HRM) curve analysis of small 
amplicons with the LightScanner® (HR-96, Idaho Technology, UT, USA). Oligonucleotides used 
for small amplicon genotyping (40–60 bp) were chosen adjacent to the SNP. Melting curves 
were analyzed with LightScanner® Software using Call-IT 2.0. The GSTA1 SNP (rs3957357) was 
genotyped by pyrosequencing13 (Qiagen, Venlo, The Netherlands). 
As a quality control 10% of samples were genotyped in duplicate. SNPs with a call rate < 0.95 
were removed from the analysis. Tradi tional Sanger sequencing was used to confirm HRM 
results for each SNP. 
SNPs in CYP39A1 (rs9381468 and rs953062) and ABCB4 (rs2109505 and rs45595532) were 
included in the analysis as haplotypes. For each patient, haplotypes were estimated and 
haplotype Rh2 was calculated using gPlink.23 Haplotypes with Rh2 > 0.95 were considered 
present. 
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statistical analysis 
The primary end point of the study was the associations of each of the genetic markers with 
busulfan clearance. This was tested by univariate linear regression analysis with the SNP or 
haplotype in the additive model in PASW statistics, version 17.0.01 (SPSS Inc., IL, USA). Next, 
the significantly associated genetic markers were tested in a multivariate analysis. To explore 
the effect of ontogenesis in GSTA1, the effect of both haplotypes on busulfan clearance were 
studied in two different age groups (patients younger and older than 2 years). P-values less 
than 0.05 were considered statistically significant.
results
description of the patient population
In this study, 84 patients receiving busulfan therapy were included. The mean age of patients 
was 6.1 years (± 5.4) and 69% of the patients were male. The mean busulfan clearance was 
6.6 ± 1.8 L/h/m2 and mean AUC after the first dose was 19.9 ± 5.8 mg*h/L. Twenty of the patients 
were younger than 2 years of age. The busulfan clearance in the group of patients younger 
than 2 years was lower (5.8 ± 2.2 L/h/m2) than in the patient older than 2 years (6.8 ± 1.7 L/h/m2; 
p = 0.031). Detailed patient characteristics are shown in Table 5.1. 
Indications for HSCT were hematologic malignancies (acute lymphoblastic leukemia, chronic and 
acute myeloid leukemia, juvenile myelomonocytic leukemia and myelodysplastic syndrome (n = 
31), β-thalassemia (n = 21), immune deficiencies (n = 28)) and other non-malignant hematologic 
diseases (n = 4; Diamond–Blackfan anemia, Glanzmann and congenital amegakaryocytic 
thrombocytopenia). Patients with immune deficiencies had a significantly lower clearance 
(5.7 ± 1.8 L/h/m2) compared with the other indications; hematologic malignancies: 
7.1 ± 1.6 L/h/m2, β-thalassemia: 6.9 ± 2.0 L/h/m2 and other non-malignant hematologic diseases: 
6.3 ± 1.3 L/h/m2 (p = 0.02). 
Genotyping & association of genetic variants with busulfan clearance 
The call rate of all eight SNPs determined with HRM was at least 98%. The call rate of the GSTA1 
SNP with pyrosequencing was 96.4%. All SNPs showed Hardy–Weinberg equilibrium (p > 0.05). 
Univariate regression analysis of the seven markers identified two markers being associated 
with busulfan clearance: GSTA1 (rs3957357; p = 0.004) and CYP39A1 (rs9381468 and rs953062; 
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p = 0.011), see also Table 5.2. Patients who were heterozygous for GSTA1*A/*B had an 8% lower 
busulfan clearance compared with wild-type GSTA1 patients and homozygous *B/*B patients 
had a 26% lower clearance. Patients who were carriers of one of the variant CYP39A1 alleles 
had a 13% lower clearance and homozygous patients had a 17% lower clearance, compared 
with CYP39A1 wild-type patients. 
The genetic markers in GSTA1 and CYP39A1 combined could explain 17% of variability in 
busulfan clearance in this pediatric patient population. Patients who are homozygous carriers 
for both haplotypes of GSTA1 and CYP39A1 had a 39% lower busulfan clearance in comparison 
to patients who were wild-type for both haplotypes (7.8 ± 2.1 L/h/m2 vs 4.8 ± 1.1 L/h/m2). 
In patients with increasing numbers of variant alleles, the busulfan clearance was lower in 
comparison with patients with more wild-type alleles, see also Figure 5.1.
table 5.2 Effect of genotypes on busulfan clearance
SNP/Haplotype Genotype n (%)
Busulfan clearance (L/h/m2) 
(mean ± sd)
P-value
GSTA1 *A/*A 32 (39.5%) 7.2 ± 1.9
*A/*B 38 (46.9%) 6.6 ± 1.7 0.004
*B/*B 11 (13.6%) 5.2 ± 1.6
CYP39A1_TC WT/WT 21 (25.3%) 7.2 ± 2.0
WT/TC 32 (38.6%) 6.3 ± 1.6 0.011
TC/TC 30 (36.1%) 6.0 ± 1.6
CYP39A1 G/G 42 (50.0%) 6.7 ± 2.0
G/A 33 (39.3%) 6.7 ± 1.7 0.30
A/A 9 (10.7%) 5.7 ± 1.5
CYP2C19 C/C 52 (61.9%) 6.6 ± 2.1
C/T 27 (32.1%) 6.6 ± 1.5 0.81
T/T 5 (6.0%) 6.3 ± 1.1
ABCB4_GAT WT/WT 28 (34.1%) 6.4 ± 1.8
WT/GAT 33 (40.2%) 6.6 ± 1.8 0.4
GAT/GAT 21 (25.6%) 6.8 ± 2.0
SLC7A8 A/A 35 (41.7%) 6.7 ± 1.7
A/C 35 (41.7%) 6.6 ± 2.0 0.35
C/C 14 (16.6%) 6.1 ± 1.8
SLC22A4 C/C 33 (39.8%) 6.4 ± 1.9
C/T 39 (47.0%) 6.7 ± 1.8 0.47
T/T 11 (13.3%) 6.8 ± 2.0
Distribution of genotypes of each of the seven genetic markers and mean busulfan clearance per genotype. 
SD: Standard deviation, WT: wild-type.
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effect of ontogenesis on GSTA1 
Twenty children were younger than 2 years and 64 children were older than 2 years. In younger 
children it was noted that GSTA1 had a larger effect; explaining 20% of variability in clearance 
(p = 0.046) than in older children, explaining only 5.2% (p = 0.078), see also Figure 5.2.
In the children younger than 2 years, the mean clearance was 6.9 ± 2.3 L/h/m2 in the GSTA1 
wild-type group, 5.9 ± 2.2 L/h/m2 in the heterozygous group (*A/*B) and 4.1 ± 0.5 L/h/m2 in 
the homozygous *B/*B group. In the group of children older than 2 years *A/*A carriers had a 
mean clearance of 7.2 ± 1.9 L/h/m2, this was 6.8 ± 1.4 L/h/m2 in heterozygous patients and 5.9 
± 1.6 L/h/m2 in the *B/*B carriers. 
We performed a multivariate analysis taking GSTA1 genotype, CYP39A1 genotype, age (older or 
younger than 2 years) and underlying disease as covariates. Underlying disease was excluded as 
a covariate from the model and the two genotypes and age resulted in an explained variance 
of 21% (adjusted R2) and p = 0.004.
Figure 5.1 Association of the number of variant alleles in GSTA1 and CYP39A1 and busulfan 
clearance.























Figure 5.2 Relationship between GSTA1 genotype and clearance per m2 per age group. Closed 
circles: children younger than 2 years. Open triangles: children older than 2 years. Bars indicate 
mean values for each category.





















In this study, GSTA1 and CYP39A1 were found to be associated with busulfan clearance. The 
involvement of GSTA1 in busulfan PK confirms earlier findings in pediatric patients; the involve-
ment of a haplotype in CYP39A1 in busulfan PK is new. When combined, the two haplotypes 
explain 20% of the variability in busulfan clearance. 
Busulfan is primarily metabolized by conjugation with glutathione, catalyzed by glutathione-
S-transferases (GSTs). GSTA1 is the pre dominant GST isoenzyme involved; GSTM1 and GSTP1 
have 46% and 18% of the activity of GSTA1 in busulfan metabolism, respectively.24 The effect of 
SNPs in genes encoding for GST enzymes on busulfan PK have been studied previously, both in 
adults and pediatric patients, leading to unclear results. The amount of variability in busulfan 
clearance explained by the most important SNP in GSTA1 (rs395735) differs per study, possibly 
due to ethnicity, busulfan route of administration (oral versus iv.) and age differences in the 
studied populations. Especially in the pediatric population, the role of the GSTA1 haplotype 
in busulfan PK is unclear. 
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The first study in pediatric patients, carried out by Johnson et al., showed that children who 
were heterozygous or homozygous for the GSTA1*B haplotype (regardless of age) exhibited a 
30% decrease in busulfan clearance.12 We also investigated the effect of SNPs in different GST 
genes (GSTA1, GSTM1, GSTP1 and GSTT1) and we did not find an association of the SNPs with 
busulfan clearance.13 Also Ansari et al. did not find an effect of GSTA1 on busulfan clearance 
in pediatric patients, but showed lower busulfan clearances in patients with the GSTM1-null 
genotype.14 Gaziev et al. studied the effect of the GSTA1 SNP in pediatric thalassemia patients 
showing 10% lower busulfan clearance in patients with the GSTA1*B variant.15
An important difference between the positive and negative studies towards the effect of 
genetic variation in GSTA1 on busulfan clearance is the way in which clearance was expressed. 
In the positive studies clearance was normalized for weight, which was not the case in the 
negative studies. 
The effect of body size on busulfan clearance in pediatric patients has been studied extensively 
and could explain a major part of the variability.25 In this study busulfan clearance was adjusted 
for BSA, as suggested by Trame et al.21 and McCune et al.22 We hypothesize that, when clearance 
is not normalized for body size (expressed as BSA, bodyweight or allometric scaled bodyweight), 
variability is much larger and the effect of body size surpasses the probably smaller effect of 
the genetic variants. 
Several studies have identified factors affect ing the PK of busulfan; recipients underlying disease, 
age and concomitant administration of fludarabine.22,26,27 McCune et al. demonstrated a larger 
variability in clearance in infants (i.e., ≤ 12 kg bodyweight) in comparison to older children, 
also when normalized for BSA.22 This was also observed in our data; a variability in clearance 
of 36% was observed in younger children versus 25% in older children. 
In our population, patients with different underlying diseases, age and cyclophosphamide-
and fludarabine-based conditioning regimens were included. We did not see a difference 
in clearance in patients with cyclophosphamide-based conditioning versus patients with 
fludarabine-based conditioning (p = 0.9). 
Patients with immune deficiencies had an 18% lower clearance compared with patients with 
other underlying diseases (p = 0.02). Age also appeared to be related to clearance and clearance 
was 15% lower in patients younger than 2 years (p = 0.31). However, the proportion of patients 
with immune deficiencies was larger in patients younger than 2 years (p = 0.02) and in the 
multivariate analysis only age remained as an independent predictor of clearance. 
Apart from inherited differences in enzyme function, developmental changes in enzyme 
function also play an important role in the metabolic capacity of pediatric patients. Ontogenesis 
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in young children could influence the explanatory power of pharmacogenetic biomarkers 
affecting busulfan PK. Unfortunately there are no specific data on ontogenesis of GSTAs 
available. However, for most enzymes developmental changes in expression is complete 
in the first 2 years after birth. Therefore, we explored the potential role of ontogenesis on 
pharmacogenetic differences in GSTA1 by studying the effect of GSTA1 genotype in two different 
age groups (younger and older than 2 years of age). Our study shows for the first time an age-
dependent effect of genetic differences in GSTA1. The effect of GSTA1 on busulfan clearance 
was much stronger in younger children. This might be owing to an incomplete development of 
enzyme capacity in young children, resulting in a more pronounced effect of genetic variation 
on busulfan clearance. 
This study revealed a potential role of the CYP39A1 haplotype in busulfan PK. The functional 
effects of the SNPs in the CYP39A1 haplotype are currently unknown and warrant further study. 
Also, the role in busulfan metabolism needs clarification. Interestingly, the software of the 
DMET platform classifies both SNPs as being part of the CYP39A1 gene, but according to the 
NCBI SNP database, both SNPs are located in the SLC25A27 gene. In fact, the promoter region 
of CYP39A1 and the gene of SLC25A27 are overlapping. 
CYP39A1 encodes for a member of the CYP450 superfamily of enzymes, and it is involved in 
the conversion of cholesterol to bile acids. The synthesis and excretion of bile acids comprise 
the major pathway of cholesterol catabolism in humans. The SLC25A27 gene, which encodes 
member 27 of the solute carrier 25 family, is also known as UPC4. These proteins are part of 
the family of mitochondrial anion carrier proteins and are involved in the transfer of anions 
from the inner to the outer mitochondrial membrane.28 The effect of this identified haplotype 
should be further investigated. 
The combined haplotypes in GSTA1 and CYP39A1 could explain 17% of the remaining variability 
in busulfan clearance. The clearance in patients who are homozygous for both variant 
haplotypes was 39% lower in comparison with wild-type patients. The effect of these two SNPs 
on busulfan clearance calls for further research into their relationship with clinical outcomes 
such as engraftment and toxicity. 
Two haplotypes in CYP3391 and GSTA1 were found to be associated with busulfan clearance 
in pediatric patients. The CYP39A1 haplotype was not previously related with busulfan PK. The 
role of the haplotype in GSTA1 is in line with earlier findings. Furthermore, the effect of GSTA1 
haplotype on clearance was dependent on age. In young children this haplotype explained 
20% of the variability in busulfan clearance, in the older children GSTA1 explained 5.2% of the 
variability. 
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Busulfan is one of the cornerstones of conditioning regimens in HSCT in pediatric patients. 
Busulfan dosing can be optimized by increasing our knowledge of the variables affecting 
busulfan PK, including the effect of pharmacogenetic markers. The effect of GSTA1 and CYP39A1 
polymorphisms on busulfan-related treatment outcomes such as engraftment and toxicity 
should be investigated. Busulfan pharmacogenetics ultimately holds the potential to optimize 
conditioning of pediatric HSCT patients by decreasing toxicity and increasing efficacy.
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High-dose treosulfan is used in conditioning regimens before hematopoietic stem cell 
transplantation in children. Pharmacokinetic data to optimize treosulfan dosing are scarce 
in this patient population. The aims of this study were the development and validation of an 
analytical method for treosulfan in human serum and the development of a pharmacokinetic 
model for treosulfan in pediatric patients. Furthermore, we aimed to develop a limited sampling 
strategy to estimate treosulfan systemic exposure with a minimum of inconvenience and risk 
for the patient. 
A reversed phase high-performance liquid chromatography method using ultraviolet detection 
to determine treosulfan in human serum samples was developed and validated according to 
food and drug administration guidelines. Serum pharmacokinetics after the first treosulfan 
administration was investigated in 20 children using nonlinear mixed-effect modeling, and a 
limited sampling strategy was developed and validated. 
The assay was validated in a 10–500 mg/L concentration range with a lower limit of quantification 
of 10 mg/L. Accuracies were within the 90%–110% limit. The coefficients of variation of the 
within-day imprecision and between-days imprecision were less than 5%. Pharmacokinetics was 
adequately described with a 1-compartment model. The population estimates for clearance (CL) 
and volume of distribution were 6.85 L/h and 13.2 L for a typical patient of 20 kg, respectively. 
Treosulfan exposure could be adequately quantified with 2 samples, at 4 and 7 hours after the 
start of a 3-hour treosulfan infusion, with a mean deviation of 3% of individual CL and area 
under the curve based on limited sampling in comparison with the full data set in a total cohort. 
In conclusion, in this study a bioanalytical method, PK model, and limited sampling model 
were developed and validated. Furthermore, PK parameters of 20 pediatric patients were 
analyzed, demonstrating an interpatient variability in area under the curve of 14.5%. This study 
demonstrates the essential developments in the optimization of treosulfan therapy based on 
PK data.
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IntroductIon
For a broad spectrum of malignant and non-malignant disorders in pediatric patients, 
allogeneic hematopoietic stem cell transplantation (allo-HSCT) is the only curative option. 
However, allo-HSCT is accompanied with considerable acute and long-term toxicity, in which 
the chemotherapeutic agents given in the conditioning regimen play an important role.1–3 
Various conditioning regimens have been developed which differ in immunosuppressive and 
myeloablative potential. Myeloablative conditioning aims at maximum elimination of host 
hematopoiesis and malignant cells and is therefore associated with a relatively high risk of severe 
early and late toxicity. Non-myeloablative conditioning and reduced intensity conditioning 
have been developed to reduce treatment-related toxicities in patients with compromised 
organ function and for patients in whom full myeloablation is not required for cure of the 
underlying disease. However, the relapse rates and risk of graft failures in the latter conditioning 
regimens are higher.4 Therefore, conditioning regimens could still be improved by combining 
myeloablative and immunosuppressive capacities with a low toxicity. Treosulfan, a bifunctional 
alkylating drug, has a suitable profile for use in myeloablative regimens; it gives a rapid and stable 
myeloablation and exhibits strong immunosuppressive activity to allow donor engraftment.5 
Furthermore, treosulfan seems to have a favorable toxicity profile; diarrhea, mucositis, stomatitis, 
skin toxicity, and metabolic acidosis (due to the formation of methanesulfonic acid during 
treosulfan activation) are the most often reported toxicities and treosulfan rarely causes 
hepatotoxicity.6–8 Treosulfan is a structural analogue of busulfan. However, its mechanism of 
action is different; treosulfanis a prodrug and the mono- and diepoxybutane derivates are 
responsible for alkylation of DNA and DNA cross-linking.9 These active derivates are formed 
by a non-enzymatic intramolecular nucleophilic substitution which is pH and temperature 
dependent; no conversion of treosulfan occurs at a pH <6.0.7 Pharmacokinetic data of treosulfan 
are scarce; studies available in adult patients show a linear relationship between area under 
the curve (AUC) and dose.6 Only 2 reports describe the pharmacokinetics of treosulfan in 
pediatric patients.10,11 In these studies, the interpatient variability in exposure AUC of 5 children 
seems to be very large (CV = 70%), and therapeutic drug monitoring could therefore be of 
great importance to optimize treosulfan therapy for the individual patient. We developed 
and validated a reversed phase high performance liquid chromatography (RP-HPLC) method 
using ultraviolet (UV) detection for quantification of treosulfan inhuman serum. Furthermore, 
we developed and validated in an independent cohort a population pharmacokinetic model 





Pediatric patients (≤ 18 years) receiving treosulfan-based conditioning before their allo-HSCT 
in the Leiden University Medical Center in the Netherlands were included. The institutional 
ethics committee approved the study protocol. Written informed consent was obtained from 
all parents of the study patients and the patients themselves if they were older than 12 years 
according to the Helsinski Declaration. Indications for HSCT were hematologic malignancies, 
hemoglobinopathies, or immune deficiencies. All patients received treosulfan 14 g/m2 
intravenously from day 7 to day 5 before HSCT and combined with fludarabine 30 mg/m2 
intravenously from day 7 to day 3 and in some cases with additional thiotepa 8 mg/kg on 
day 8. Serotherapy consisted of antithymocyte globuline 2.5 mg/kg from day 6 to day 2 or 
alemtuzumab 0.2 mg/kg from day 5 to day 2. In one patient, treosulfan was combined with 
thoracoabdominal irradiation and alemtuzumab.
bioanalytical method development
The bioanaltyical method for treosulfan presented in this article is based on the method to 
determine busulfan developed in our department12 and the method for treosulfan presented 
by Glowka et al.11 and Hilger et al.13 Because treosulfan is non-enzymatically converted into 
its active metabolites, it is suggested that the concentration of treosulfan itself is a good 
representation of the alkylating activity.13
chromatographic conditions
An RP-HPLC method using UV detection to determine treosulfan in human serum samples was 
developed. Busulfan was used as an internal standard. Gradient elution with a mobile phase 
consisting of phosphate buffer (pH 4.0), acetonitrile, and methanol was used. The acetonitrile 
concentration in the eluant was kept constant throughout the analytical run. The flow rate was 
0.8 mL/min, and the eluent was monitored at 275 nm. For all types of samples, the injection 
volume was 10 mL and separation was performed on an ODS Hypersil column (3 mm, 100 x 
4.6 mm; Thermo Fischer Scientific, Waltham, MA) with a Prevail C18 precolumn (5 mm, 7.5 x 4.6 
mm; Alltech Associations Inc, Deerfield,IL). The runtime per sample was 15 minutes.
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serum sample preparation
To all 200 mL serum of patient, calibration (10, 20, 50, 100, 250, and 500 mg/L) and quality 
control (QC) samples (15, 80, and 400 mg/L), 30 mL of 1 mol/L citrate buffer (pH 5.5), and 200 
mL acetonitrile was added and the mixture was shaken vigorously; next 200 mL of 0.44 mol/L 
diethyldithiocarbamate (DDTC) was added to derivatize treosulfan by incubating the mixture 
for 15 minutes at 50°C. After cooling down to room temperature, 10 mL of busulfan 3 mg/mL, 
the internal standard, was added and the solution was vortex mixed during 30 seconds. To 
make treosulfan and busulfan detectable with UV, derivatization with DDTC was performed. 
Treosulfan and busulfan are derivatized separately; busulfan is added at the end of the treosulfan 
derivatization. In this way, complete derivatization of both compounds can be achieved. 
When busulfan is derivatized at the same conditions as treosulfan, the busulfan derivate is 
partly degraded, causing disturbance of the chromatograms. Two milliliters of ethyl acetate 
was added, vortexed for 30 seconds, and after centrifugation at 3220 g during 3 minutes, the 
organic layer was transferred into a new glass tube and evaporated to dryness at 50°C under 
nitrogen gas. The residue was dissolved in 300 mL of methanol of which 200 mL was transferred 
into a glass autoinjector vial.
Validation
The analytical assay was validated according to food and drug administration guidelines.14 
Serum QC samples were prepared with a concentration of 15, 80, and 400 mg/L. Accuracy, 
within-day imprecision and between-day imprecision were determined by analyzing each QC 
sample 5 times on 1 day and on 5 different days. Accuracy was defined as the mean measured 
concentration and should be between 90% and 110% of the nominal concentration. The 
imprecision was expressed as % CV and should be less than 10% for within-day imprecision 
and less than 15% for between-day imprecision. The lower limit of quantification was calculated 
from the residual standard deviation (using 99.9% confidence interval) and the slope of the 
calibration line. The recovery of treosulfan extraction was determined in triplicate by comparing 
processed serum samples of 15, 80, and 400 mg/L with reference samples in citrate buffer 
(pH 5.5) of the same concentration. Selectivity and matrix interference was investigated by 
measuring 2 different concentrations prepared in 6 different blank serum samples. When CV 
was less than 10%, the interferences of the matrix were considered insignificant. Short-term and 
long-term stability at 2 concentrations (20 and 400 mg/L) were studied at room temperature and 
4°C (short term) and at -20°C and -80°C (long term). Furthermore, postprocessing stability and 
freeze–thaw stability were also studied at the same 2 concentrations. All stability measurements 
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were performed in triplicate. When concentrations measured are within 100% ± 10% of the 
initial concentration, the samples were considered stable.
Pharmacokinetics
Blood sampling
All patients received 14 g/m2 treosulfan in a 3-hour infusion on 3 consecutive days. On day 1, 
patient blood samples were collected at 1.5, 3.5, 4, 5, 7, and 9 hours after the start of a 3-hour 
treosulfan infusion. Blood samples were collected in serum tubes without gel through the 
lumen of the catheter that was not used for intravenous treosulfan administration. Samples were 
centrifuged as quickly as possible after the collection of the patient sample, at least within 5 
hours. Serum was transferred into a polystyrene tube and stored directly at -80°C until analysis.
Pharmacokinetic model development
The treosulfan population pharmacokinetic model was developed by using nonlinear mixed-
effect modeling as implemented in the NONMEM software package (version 7 level 2; Icon 
Development Solutions, Ellicott City, MD). Diagnostic graphics, exploratory analyses, and post- 
processing of NONMEM output were performed using S-Plus (version 8.0 Professional; Insightful 
Corp, Seattle, WA). In the first step, the PK model was developed using the data from an initial 
cohort of 12 patients. The final PK model was validated using the data from a second independent 
cohort of 8 patients. Different linear compartmental models (1-, 2-, or 3-compartmental models) 
were explored to describe the PK of treosulfan. The parameters (clearance (CL) and volume of 
distribution (V)) among individuals were assumed to be log-normally distributed. Consequently, 
the random effects at the individual level were implemented as exponential terms (Equation 1):
        (1)
With ηi as the random effect describing the deviation of the individual parameter estimate (θi) 
of the parameter for the ith individual from the typical population parameter estimate θi. ηi is 
assumed to follow a normal distribution with mean zero and variance ω2. The magnitude of 
residual variability between observed and predicted values was modeled using a proportional 
model (Equation 2):
        (2)
where Cij is the j
th observation for the ith individual; Cpred,ij is the corresponding model predicted 
value and εij represents the residual deviation of the observed concentration from the predicted 
concentration. εij is assumed to follow a normal distribution with mean zero and variance σ
2. 
)exp( ii    
)1(, ijijpredij CC   
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Improvement in the fit of the model was assessed using the likelihood ratio test. This statistical 
test compares the fit of 2 models by evaluating the difference in the minimum value of objective 
function (MVOF), which is equal to minus twice the log-likelihood of the data.15 A difference 
of 10.8 points in MVOF was considered statistically significant (p < 0.001, given 1 degree of 
freedom, assuming χ2 distribution). In addition, standard goodness-of-fit plots were inspected 
visually to evaluate the model fit and the predictive performance of the developed model was 
evaluated using simulation-based diagnostics such as visual predictive check (VPC). In the 
VPC, it was investigated visually if the identified model predicts the median concentration and 
variability from the population that was used for model identification adequately. To this end, 
the PK of each individual was simulated 500 times by means of a Monte Carlo simulation. The 
distribution (median and 10th and 90th percentiles) of the simulated concentration–time profiles 
was compared with the distribution of the observed concentration–time profiles.
Limited sampling strategy
The aim of developing a LSS was to make adequate estimates of treosulfan exposure AUC with 
a minimal number of serum samples and thus with a minimal patient burden. A hundred data 
sets were simulated using the final population PK model. These 100 data sets were back fitted 
with the final model, resulting in 100 population estimates of CL and V. Different strategies of 
2, 3, and 4 time points were investigated. Per strategy, the resulting population estimates for CL 
and V (test CL and V) were compared with original population estimates for CL and V (reference 
CL and V). Predictive performance of the different strategies was assessed. The prediction 
bias was calculated as the mean prediction error (MPE); average difference between test and 
reference CL and V. The prediction precision was assessed as the mean absolute percentage 
error (MAPE); average absolute difference between test and reference CL and V.
External validation
The external validation of the population PK model to describe the concentration–time 
profiles of treosulfan was performed using a second independent cohort of 8 patients. It was 
investigated if the model could adequately predict individual concentrations and CLs in this 
external data set. Again, visual exploration of the distribution of the observed and predicted 
values in standard goodness-of-fit plots was used to evaluate the model fit. In addition, the 
LSS was validated. The individual CL and corresponding AUCs based on the full data set (6 
samples) were compared with the individual CL and AUC calculated based on a data set with 




description of the patient populations
The population PK model for treosulfan was developed using a first cohort of 12 pediatric 
patients. Details on the patient characteristics, conditioning regimens, diagnosis for HSCT, and 
donor information are presented in Table 6.1 for the first and second cohort separately and the 
total of 20 patients. Briefly, the mean age and weight of the patients in this first cohort were 6.9 
(± 5.5) years and 21.5 (± 14.2) kg, respectively, and 7 patients were male. In the second cohort, 
the mean age was 5.4 (± 5.5) years and the mean weight was 21.0 (± 14.3) kg and 6 patients were 
male. When looking at the combination of both cohorts, for 4 patients, the indication for HSCT 
was a hematologic malignancy: 3 patients were diagnosed with secondary (n = 1) or relapsed 
(n = 2) acute myelogenous leukemia and 1 patient with juvenile myelomonocytic leukemia. 
Twelve patients had a hemoglobinopathy; 11 patients with a homozygous β-thalassemia and 1 
patient with sickle cell disease. Three patients had a (severe) combined immunodeficiency and 
table 6.1 Patient characteristics and conditioning regimens
Total (n = 20) 1st cohort (n = 12) 2nd cohort (n = 8)
Characteristic Mean (s.d.)
Age (years) 6.2 (5.4) 6.9 (5.5) 5.4 (5.5)
Weight (kg) 21.3 (13.9) 21.5 (14.2) 21.0 (14.3)
Sex (n and % male) 13 (65%) 7 (58%) 6 (75%)
Conditioning regimen Patients (n)
Treo, Flu, Thio, ATG 12 6 6
Treo, Flu, Thio, Alem 2 1 1
Treo, Flu, ATG 4 3 1
Treo, Flu, Alem 1 1 -
Treo, TAI, Alem 1 1 -
Diagnosis for HSCT
Hemoglobinopathies 12 5 7
Hematologic malignancy 4 4 -
Immune deficiencies 4 3 1
Donor
HLA id sibling 7 4 3
UD 10/10 6 4 2
UD 9/10 6 4 2
HLA id Cord Blood 1 - 1
ATG: antithymocyte globuline, Alem: alemtuzumab, Flu: fludarabine, HLA id: human leukocyte antigen 
identical, TAI: thoracoabdominal irradiation, Thio: thiotepa, Treo: treosulfan, UD: unrelated donor.
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1 patient X-linked lymphoproliferative disease. Two patients received this conditioning regimen 
without thiotepa. In 1 case, treosulfan was combined with thoracoabdominal irradiation.
Validation of the treosulfan assay
A calibration range of 10–500 mg/L treosulfan in serum was selected. Average lower limit of 
quantification over 8 calibration lines was 10 mg/L, which is lower than the lowest calibrator. 
Chromatograms of blank, QC low, and a patient serum sample are shown in Supplemental 
Figure 6.1. No interference at the retention times of treosulfan and busulfan was observed. 
Accuracy of the samples with a concentration of 100% and 150% of the highest calibrator was 
100.3% and 95.5%. Accuracies for each of the 3 QC samples were within the 90%–110% limit. 
The coefficient of variation of the within-day imprecision and between-day imprecision was less 
than 5% (Table 6.2). The selectivity of the assay was appropriate, resulting in a CV of less than 5% 
when measuring treosulfan in 6 different blank samples at the lower limit of quantification level 
(10 mg/L). Furthermore, in the chromatogram of a patient, no interference due to comedication 
was observed (see Supplemental Figure 6.1). This is due to the selectivity of the derivatization 
of treosulfan and busulfan. No carryover was observed after the analytical run of a sample with 
a concentration of 400 mg/L. The recoveries of treosulfan were appropriate for all 3 QC levels 
showing recovery rates of 95%, 96%, and 84% at 15, 80, and 400 mg/L, respectively. An overview 
of stability data is shown Supplemental Table 6.1. Stock solutions of treosulfan in water and 
busulfan in n,n-dimethylacetamide stored at -20 or -80°C are stable for at least 1 year (data 
not shown). Treosulfan serum samples are stable for 5 hours at room temperature and 4°C. 
Serum samples stored at -20°C are stable during 2 months, storing at -80°C resulted in stable 
samples for at least 1 year. Treosulfan in whole blood samples is stable during 5 hours at room 
temperature (data not shown). With this information, we conclude that blood samples should 
be centrifuged within 5 hours after withdrawal and obtained serum should be stored directly 










15 mg/L 5 102.8 2.02 2.84
80 mg/L 5 106.2 3.33 2.31
400 mg/L 5 105.8 1.96 2.13
Accuracy, within-day imprecision, and between-day imprecision obtained with 5 samples at treosulfan 
concentrations of 15, 80, and 400 mg/L. CV: coefficient of variance.
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at -20°C for treosulfan determination. Additionally, treosulfan serum samples are stable after 
3 freeze and thaw cycles at -80°C and during 5 hours postprocessing.
Pharmacokinetic model
The time course of the plasma concentration of treosulfan was adequately described using 
a 1-compartment model. Using a 2-compartmental model, no significant improvement in 
model fit could be obtained, as judged from the difference in MVOF (difference in MVOF > 
-10.8). Parameters were allometrically scaled using body weight according to the following 
equation (Equation 3):
        (3)
Where θi is the individual CL or V and θj is the population CL or V, based on a weight of 20 kg. 
When scaling CL α is fixed to 0.75 and for V α is fixed to 1.0. The population PK model adequately 
describes the concentration–time profile of treosulfan in the first cohort of 12 patients (Figure 
6.1). As observed in the VPC (Figure 6.2), the predicted and observed intervals (median, 10th and 
90th percentiles) show good correspondence, demonstrating a good predictive performance 
of the final model. The population estimates of CL and V for a patient of 20 kg were 6.3 L/h and 
12.3 L, respectively. An overview of pharmacokinetic parameters is given in Table 6.3a.
limited sampling strategy
Predictive performance (MPE and MAPE) of the different limited sampling strategies is listed 
in Table 6.4. Two samples were sufficient to estimate the CL and V at the population level. Two 
time points at 4 and 7 hours are preferred from a practical perspective (no sampling during 
infusion). Samples taken between 4–5 hours and 6–7 hours after the start of a 3-hour infusion 
will give a good estimation of treosulfan exposure.
external validation
The model, developed using the data from the first cohort, was fitted to the data of a second 
cohort of 8 patients. The diagnostic plots (Figure 6.3) indicate a small bias in observed 
concentrations versus population predicted concentrations. However, individual concentrations 
could be well predicted. In addition, the limited sampling design with 2 samples around 4 and 
7 hours after the start of infusion allows estimation of the individual CLs and AUCs with little 
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the difference in AUC was above 10% (e.g. 14%). This patient was a relatively older child of 16 
years weighing 52 kg. The difference in AUC is probably attributable to the small data sets for 
model development and validation; especially the number of older patients was limited. The 
parameter estimates were updated by fitting the final model to the data from 2 cohorts (ntotal  = 
20) (Table 6.3b). In addition, the LSS was assessed using the updated model parameters based 
on the combined data set of 20 patients. As a result, with only 2 samples of each individual, a 
good estimate of individual CL and AUC was obtained. A mean deviation of 3% in individual CL 
and AUC was observed when comparing the reduced with the full data set (66 samples), with 
Figure 6.1 Diagnostic plots of treosulfan pharmacokinetic model. A) Observed concentrations 
versus individual predictions; data should be randomly distributed around the identity line. B) 
Observations concentrations versus population predictions (PRED); data should be randomly 
distributed around the identity line. C) Conditional weighted residuals (CWRES) versus time; 
data should be randomly distributed around zero line for the complete time course. D) CWRES 
versus PRED; data should be randomly distributed around zero line for all population predictions. 




Figure 6.2 Visual predictive check. VPC with 80% prediction interval (gray area). Black line 
represents the median of the model prediction. Gray dots: observed concentrations. Black dots: 
median of the observed concentrations per time point and black plus sign: lower and upper 
boundary observation interval (80%).
table 6.3a Population pharmacokinetic parameters for the treosulfan model based on the first 
cohort
Parameter Value SE CV 95% CI % variation
CL (20 kg) 6.3 0.462 7.33 5.39–7.21 NA
V (20 kg) 12.3 0.71 5.77 10.9–13.7 NA
Eta CL 0.0177 0.0107 60.5 -0.0033–0.0387 13.36
Residual error 0.0513 0.0092 17.8 0.0334–0.0692 22.94
CI: confidence interval, CV: coefficient of variance, Eta CL: random effect describing the deviation of the 
individual parameter estimate, SE: standard error, NA: not available.
table 6.3b Updated population model based on data set of 20 patients
Parameter Value SE CV 95% CI % variation
CL (20 kg) 6.85 0.388 5.7 6.09–7.61 NA
V (20 kg) 13.2 0.626 4.7 12.0–14.4 NA
Eta CL 0.0174 0.00864 49.7 0.0005–0.0343 13.25
Residual error 0.0477 0.00673 14.1 0.0345–0.0609
CI: confidence interval, CV: coefficient of variance, Eta CL: random effect describing the deviation of the 
individual parameter estimate, SE: standard error, NA: not available.
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a maximum of 13.1% for CL and 11.6% for AUC. Furthermore, no clear dependency between 
age/weight and deviation in AUC could be observed anymore. The population estimates for 
treosulfan CL in the total study cohort for CL and V were 6.85 L/h and 13.2 L for atypical patient 










1.5, 4, 5, 7h 0.92 3.92 -0.12 4.66 100
1.5, 5h 1.64 4.77 -0.66 6.72 87
4, 7h 1.10 6.36 0.1 10.2 97
5h -8.55 23.1 42.8 79.8 26
Four different limited sampling strategies were evaluated. Cov. suc: successful covariance steps, MPE: mean 
predictive error.
Figure 6.3 Diagnostic plots of external validation. A) Observed concentrations versus individual 
predictions; data should be randomly distributed around the identity line. B) Observations 
concentrations versus population predictions (PRED); data should be randomly distributed 
around the identity line. C) Conditional weighted residuals (CWRES) versus time; data should be 
randomly distributed around zero line for the complete time course. D) CWRES versus PRED; data 
should be randomly distributed around zero line for all population predictions. Gray open circles: 
observations; black line: identity or zero line; gray intermittent line: smoother trough the data.
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of 20 kg, respectively. The mean AUC in the studied population of 20 patients was 1639 ± 237 
mg*h/L (calculated by individual dose/individual CL). The interpatient variability in AUC was 
calculated as 14.5%. In Figure 6.4, graphical presentation of all individual AUCs is provided.
dIscussIon
We successfully developed and validated a bioanalytical method to quantify treosulfan 
concentrations in serum and a pharmacokinetic model to describe the concentration–time 
profile for treosulfan in pediatric patients. Furthermore, an LSS was developed to estimate 
treosulfan exposure, expressed as AUC, in pediatric patients based on only 2 serum samples. 
This bioanalytical method combined with a PK model is crucial to study whether outcome after 
conditioning with treosulfan is related to exposure and if treosulfan conditioning regimens can 
be optimized by targeting exposure. Furthermore, the limited sampling model is essential in 
studying treosulfan PK in pediatric patients, especially the youngest. 
Two analytical methods for analyzing treosulfan have been described previously. Glowka et 
al.11 presented methods for analyzing treosulfan in biologic fluids based on RP-HPLC with 
refractometric detection. Another article of Glowka et al.16 describes a HPLC method using UV 
detection at 264 nm. Treosulfan and its metabolites were made detectable by derivatization 
Figure 6.4 AUC values of 20 individual pediatric patients. Distribution of AUC per age. AUC 
calculated after dose 1, 14 mg/m2. Horizontal line: average AUC of 1640 mg*h/L.
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during 4 hours at 50°C with 3-nitrobenzenesulfonicacid (3-NBS) with an analytical runtime of 30 
minutes. UV detection is also used in the method described in this article because this is a more 
selective and sensitive detection method compared with refractometric detection. In addition, 
UV detection is more commonly available and therefore the method presented in this article is 
easier to implement in most laboratories. However, treosulfan and busulfan (IS) detection with 
UV is possible only after derivatization of the compounds, resulting in more extensive sample 
preparation. Our analytical method is less time consuming due to an optimized derivatization 
process using DDTC, resulting in derivatization of treosulfan at 50°C during only 15 minutes, 
and an analytical runtime of 15 minutes. 
Treosulfan itself is a prodrug, non-enzymatically, and pH dependent converted into its active 
metabolites. In one of the analytical methods of Glowka et al.16 also, the active metabolites 
were analyzed. However, in this study, diepoxide was not detected in patient samples because 
of fast elimination. Furthermore, it is assumed that the concentration of treosulfan itself is a 
good representation of the alkylatingactivity.13 The precise role of treosulfan or its metabolites 
in effectiveness of the conditioning is yet unclear. 
In both methods presented by Glowka et al., patient blood samples were pretreated immediately 
after collection with citric acid to stop degradation of treosulfan, which in the clinic can be a 
problematic logistic step. Therefore, we thoroughly studied the stability of treosulfan in different 
biologic fluids under various conditions. These experiments indicated stability of treosulfan in 
whole blood and serum after collecting the samples during 5 hours, resulting in a more feasible 
methodology for patient sample collection. 
The development of the pharmacokinetic model is based on the data from 12 patients. Despite 
the relative low number of subjects, multiple sampling in these subjects (approximately 6 
samples per patient) facilitated the development of a PK model that adequately describes the 
concentration–time profiles of treosulfan and the observed variability. It was observed that 
combining the first and second cohorts resulted in different population parameter estimates. 
By increasing the number of patients in the analysis, the level of confidence in the developed PK 
model and population parameters increases and it is therefore recommended to update model 
parameters in future after including the data of new (pediatric) patients. In the development of 
a limited sampling model, different strategies were tested on a population level. The strategy 
with sampling at 4 and 7 hours after the start of the infusion was chosen, although MPE and 
MAPE values of the t = 1.5 and 5 hours strategy were slightly better. The first strategy was chosen 
because of the practical reason of no sampling during treosulfan infusion. Furthermore, the 
predictive performance was assessed on a population level. When considering the individualized 
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values of CL and AUC in the total cohort, it is demonstrated that our LSS adequately predicts 
treosulfan CL and AUC based on the 2 samples at 4 and 7 hours. This resulted in a total cohort 
of 20 patients a mean deviation of 3% in individual CL and AUC when comparing the limited 
sampling set with the full data set. 
In our study, 6 blood samples of 1–2 mL on 1 day were collected. Therefore, one of the exclusion 
criteria was bodyweight under 10 kg. Because of this criterion, the treosulfan exposure and 
PK of patients under 10 kg body weight could not be studied. The LSS reduces the burden of 
sampling significantly and may allow investigating the PK of children with lower body weights 
in the future. 
To date, pharmacokinetic data of treosulfan are scarce. In adult patients, treosulfan shows 
predictable linear pharmacokinetics.6 For pediatric patients, only 1 study is published presenting 
PK data in a reasonable number of pediatric patients.10 In this study of Glowka et al., 7 patients 
were analyzed, receiving different doses of treosulfan (10, 12, or 14 g/m2), the exposure levels 
found were in accordance with the levels of the 20 patients in our study. The variability in 
exposure of 5 patients receiving the same dose was very large (CV = 70%). The cause of this 
large variability is unknown; however, it is based on a very small number of patients. In our 
study, the interpatient variability in exposure was found much smaller, 14%. This difference in 
variability could be due to the number of patients, Glowka et al. studied only 5 patients with the 
same dose. Alternatively, the trapezoidal rule was applied for AUC calculation of the individual 
patients, which could lead to less precise determination of the AUC. 
Treosulfan is an attractive candidate for use in conditioning regimens before HSCT and is more 
often used in pediatric patients due to its rapid and stable immunosuppressive activity and 
favorable toxicity profile. In the study, a bioanalytical method, population PK model, and LSS 
for treosulfan were developed and validated. In the future, more data need to be collected to 
study the relationship between outcome and treosulfan exposure, especially in the youngest 
children with an age under 2 years.
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suPPleMentAl MAterIAl
supplemental Figure 6.1 Chromatograms of treosulfan assay. 1) Blank with internal standard; 
2) Quality Control (low) 15 mg/L; 3) Patient sample. Retention time treosulfan: 5.0 min, retention 
time busulfan: 8.9 min.
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supplemental table 6.1 Short term, long term, freeze-thaw and post processing stability data 
of treosulfan samples
Percentage of initial concentration
Short term
Sample 















Percentage of initial concentration
Long term 
Sample 
concentration 1 week 2 weeks 2 months 6 months 1 year











































concentration 3 freeze-thaw cycles Post-processing (5 hours)
-20ºC 20 mg/L 83.7
(79.5–86.0)




400 mg/L treosulfan 100
(98.4–104.5)
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and early clinical outcomes











Treosulfan is an alkylating agent applied in regimens prior to allogeneic hematopoietic stem 
cell transplantation (allo-HSCT) in children. It has strong myeloablative and immunosuppressive 
activity and a relatively mild toxicity profile. In this article we describe the first results of an 
ongoing prospective study on the relation between the pharmacokinetic profile of treosulfan 
in pediatric patients undergoing HSCT and clinical outcome. 
A total of 21 patients were included in the study with a median age of 5.2 (0.13–16.8) years and a 
median follow-up of 1 year (168 days – 1.9 years). Patients received intravenous treosulfan prior 
to their HSCT for various malignant and non-malignant indications combined with fludarabine 
and thiotepa. Nine of 21 patients received treosulfan as a reduced toxicity conditioning, due 
to preexisting comorbidities. A one-compartment model was used and clearance and volume 
of distribution were allometrically scaled using body weight. The mean AUC was 1534 mg*h/L 
and the interpatient variability was 14%.
The overall toxicity profile was relatively mild and consisted mainly of liver toxicity (48%), skin 
toxicity (28%) and mucositis (38%). Of 19 evaluable patients, 95% had a primary engraftment. 
In this study we did not find a relation between treosulfan exposure and HSCT outcome 
parameters engraftment, chimerism, toxicity, and survival. This is the first study report in which 
the treosulfan pharmacokinetic profile in pediatric patients is described and exposure is related 
to clinical outcome. Analysis of larger cohorts of pediatric HSCT recipients is warranted to 
determine the relation between treosulfan exposure and HSCT outcome in age- and disease-
specific subgroups.
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IntroductIon
Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is a curative option for a variety 
of malignant and non-malignant hematologic diseases in pediatric patients. The conditioning 
regimen given prior to an allo-HSCT has two goals: suppression of the immune system of the 
host to prevent graft rejection and allow donor engraftment, and ablation or suppression of 
host hematopoiesis, including malignant cells. Based on differences in underlying diseases, 
various conditioning regimens have been developed which differ in immuno- and myeloablative 
potential. One of the strategies to improve HSCT outcome is reducing the toxicity caused by 
the conditioning regimen given prior to the HSCT. Treosulfan is an alkylating agent, which is 
increasingly applied in HSCT due to its beneficial toxicity profile in comparison to busulfan 
and total body irradiation. 
Treosulfan (L-threitol 1,4-bismethanesulphonate, Ovastat®) is a prodrug and a water-soluble 
alkylating agent. It is non-enzymatically, pH-dependent converted into a monoepoxide and a 
diepoxide, which are responsible for DNA alkylation and DNA crosslinking.1,2
In vivo, treosulfan gives a rapid and sustained myeloablation, which is comparable to busulfan. 
Furthermore, the immunosuppressive profile of treosulfan was demonstrated to be stronger 
in comparison to busulfan and more durable than cyclophosphamide.3 In vitro data suggest 
that treosulfan has a stronger cytotoxic effect against leukemic cells in pediatric patients than 
busulfan.4
In several studies treosulfan was applied in combination with other cytostatic and immunosup-
pressive drugs prior to allo-HSCT and demonstrated a safe and effective regimen.5–7 Clinical 
outcome of allo-HSCT using busulfan-based condtioning is associated with the exposure of 
busulfan, and therapeutic drug monitoring is often applied to target exposure. Similarly, we 
assume that clinical outcome after allo-HSCT with a treosulfan based regimen might also be 
dependent on treosulfan exposure. To date, only two studies investigated the pharmacokinetic 
profile in pediatric patients. However, these studies focused on PK and did not report the 
correlation of exposure with clinical outcome.8,9 In the first study, interpatient variability in 
exposure was large (CV = 70%). The second study was performed by our group and included 20 
patients.9 It comprised the development of a bioanalytical method to determine treosulfan in 
serum, a pharmacokinetic model and limited sampling strategy in order to determine treosulfan 
exposure in pediatric patients. 
In the present prospective study, we describe the pharmacokinetics treosulfan in pediatric 




Patients and donor characteristicsand conditioning regimen
Pediatric patients (≤ 18 years) receiving treosulfan based conditioning prior to their first allo-
HSCT in the Leiden University Medical Center in The Netherlands were included. The institutional 
Ethics Committee approved the treosulfan PK study protocol. Written informed consent was 
obtained from all parents of the study patients and patients themselves when they were older 
than 12 years according to the Helsinski Declaration.
Patients received an allo-HSCT for various malignant and non-malignant indications. Donor 
matching was based on HLA typing. All patients received treosulfan in a dose of 42 g/m2 or 
30 g/m2 if BSA < 0.5 m2, divided over 3 days. Treosulfan was combined with fludarabine and 
in some patient also thiotepa was added. Thiotepa (8 mg/kg) was administered at day -8, 
treosulfan was administered at day -7 to day -5 and fludarabine 30 mg/m2/day on day -7 to 
day -3. Serotherapy consisted of anti-thymocyteglobuline (ATG) 2.5 mg/kg/day from day -5 
till day -2 or alemtuzumab 0.2 mg/kg/day from day -6 till day -2. All drugs were intravenously 
administered.
Graft-versus-Host disease prophylaxes consisted of cyclosporine A (CsA:1.5 mg/kg i.v. twice 
daily, and following engraftment equivalent oral dose),with dose adjustments based on through 
levels, which were 100–150 µg/L in malignant disease and 150–200 µg/L in non-malignant 
disease. CsA was combined with methotrexate in T cell replete transplants (10 mg/m2 on day 
+1, +3 and +6) or prednisolone in cord blood transplants (1 mg/kg/day). In case of suspected 
toxicity or adverse events CsA was switched to mycophenolate mofetil or tacrolimus. In 9/21 
patients G-CSF (5 µg/kg/day) was given to support engraftment on individual indication, mostly 
because of co-morbidity.
All patients were cared for in high-efficiency, particle-free air (HEPA)-filtered positive-pressure 
isolation rooms with total gut decontamination using non-absorbable antimicrobials and 
antifungal prophylaxis using azoles according to institutional guidelines.
treosulfan assay
Patients received 10 or 14 g/m2 treosulfan in a 3 hour infusion on three consecutive days. On day 
one, patient blood samples were collected at 1.5, 3.5, 4, 5, 7 and 9 or at 4-5 and 6-7 hours after 
the start of a three hour treosulfan infusion. For determination of the inter-occasion variability 
(IOV) in a selection of patients (weight >10 kg) samples were also taken on day 3. Blood samples 
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were collected in serum tubes without gel through the lumen of the catheter that was not used 
for intravenous treosulfan administration. Samples were centrifuged as quickly as possible after 
collection, but at least within 5 hours. A reversed phase high pressure liquid chromatography 
(RP-HPLC) method using Ultraviolet (UV) detection was applied to determine treosulfan in 
serum, as previously described by our group.9 Briefly, treosulfan and the internal standard 
busulfan were made detectable with derivatization with sodium diethyldithiocarbamate (DDTC). 
Treosulfan can be determined over a range of 10 to 500 mg/L with a limit of quantification 
of 6.8 mg/L. Accuracies for each of the three QC samples were within the 90–110% limit. The 
coefficient of variation of the within-day imprecision and between-day imprecision was less 
than 5% for all three concentration levels.  
Pharmacokinetics of treosulfan
The individual pharmacokinetic profile of each patient was determined by a population 
pharmacokinetic model, using non-linear mixed-effects modelling as implemented in the 
NONMEM software package (version 7 level 2; Icon Development Solutions, Ellicott City, 
Maryland, USA). A one-compartment model was used and clearance and volume of distribution 
were allometrically scaled using body weight, as previously published.9 The scaling exponent 
for clearance was fixed at 0.75 and for volume of distribution at 1.0. For a number of patients, 
2 serum samples were collected and a limited sampling strategy (LSS) was applied to estimate 
individual pharmacokinetic parameters. Interpatient variability (IPV) was calculated by the 
CV% of the treosulfan exposure between individuals and IOV by the calculating the mean 
difference between the AUC on day 1 and day 3 of each individual. IOV calculations were based 
on measurements in 7 patients.
evaluation of clinical data
Clinical endpoints of this study were stem cell engraftment, chimerism, survival, relapse, 
treatment related mortality and toxicity (i.e. mucositis, skin toxicity, hepatic toxicity, neurologic 
toxicity and metabolic acidosis) and GVHD. 
Stem cell engraftment was defined as platelet count > 50 x 109/L, without platelet support for 
3 consecutive days together with neutrophils > 0.5 x 109/L on 2 consecutive measurements 
separated by at least 3 days (72 hours) without granulocyte support. Donor–recipient white 
blood cell chimerism was determined by VNTR polymorphism. Occurrence of aGvHD (within 100 
days) and chronic GvHD is diagnosed and graded according to the scale defined by Przepiorka 
et al.10 Toxicities were scored according to Bearman et al., in which toxicities are scored which 
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were likely due to the preparative regimen.11 For GvHD and toxicities, events were graded from 
0 (no adverse event) to 4 (severe).
statistical analysis
Normally distributed parameters are shown as mean ± standard deviation and all log-normally 
distributed parameters as median (minimum and maximum). IPV was determined by calculating 
the mean coefficient of variation of AUCs for the total cohort.
Study endpoints included stem cell engraftment, rejection, toxicity, and survival. The 
relationships between AUC and transplantation outcomes were characterized using linear 
regression analysis. When appropriate, an independent Student’s T-test was used. All p-values 
were 2-tailed and considered significant when p < 0.05. All statistical analyses were performed 
with ISB SPSS statistics, version 20.0 (IBM Corp., Armonk, NY, USA).
results
Patients characteristics, conditioning regimen and Gvhd prophylaxis
A total of 21 pediatric patients receiving their first HSCT were included in the study. The 
median age was 5.2 (0.13–16.8) years and 12 patients were male. HSCT indications included 
hemoglobinopathies (n = 12), acute myeloid leukemia (n = 3), primary immune deficiency 
(n = 4), and bone marrow failure (n = 2), see also Table 7.1. Patient received treosulfan based 
conditioning as first line choice according to institutional guidelines (n = 12) or as reduced 
toxicity conditioning because of individual patient comorbidity (n = 9).
Eight patients received a transplant from an HLA identical sibling, 13 patients received a 
transplant from a matched unrelated donor, i.e. 9/10 allelic matching (n = 6) and 10/10 allelic 
matching (n = 7). Seventeen of the 21 patients received a T cell replete bone marrow graft, one 
patient peripheral blood stem cells and 3 patients a cord blood transplant.
All patients except one received a treosulfan dose of 14 g/m2 per day during 3 consecutive days, 
the youngest patient, a 1.5-month-old boy with a body surface area of 0.3 m2, received a dose 
of 10 g/m2 per day. In 16 patients treosulfan was combined with fludarabine and thiotepa and 
5 patients received only treosulfan and fludarabine. Twenty patients received serotherapy; 19 
received ATG and 1 alemtuzumab.
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table 7.1 Patient characteristics
Total (n = 21)
Characteristic
Age (years, median (range) 5.2 (0.13–16.8)
Weight (kg, mean (sd)) 26.9 (18.3)















Primary Immune deficiency 4
Bone marrow failure 2
Treosulfan indication
Reduced toxicity 9






HLA id sib 8
MUD (≥ 9/10) 13
GvHD prophylaxis
CsA 4
CsA / MTX 16
CsA / Pred 1
Treo: treosulfan, Flu: fludarabine, Thio: thiotepa, ATG: Anti-thymocyteglobuline, BM: bone marrow, PBSC: pe-
ripheral blood stem cells, CB: cord blood, HLA id sib: Human leukocyte antigen identical sibling, MMFD: mis-
matched family donor, MUD: matched unrelated donor, GvHD: Graft-versus-Host Disease, CsA: Ciclosporin A, 




In total 28 AUCs were determined in 21 patients; in 7 patients also on day 3 treosulfan samples 
were taken for determination of the IOV. After development and validation of a limited sampling 
strategy, it was possible to calculate AUCs with LSS. In 17 patients, AUCs were calculated based 
on rich data curves. A total of 7 AUCs, in 4 patients, were analyzed based on the LSS. The 
median clearance and volume of distribution were 5.7 L/h (1.2–20.5 L/h) and 10.8 L (3.0–42.9 L), 
respectively. The mean AUC of treosulfan was 1534 mg*h/L and the interpatient variability (IPV) 
was 14%. The IOV was approximately 5%, based on the day 1 and day 3 results of 7 patients. 
One patient received a lower dose because of his young age and small body surface area i.e. 
10 g/m2. The AUC of this patient was 1578 mg*h/L, which is similar to the mean AUC seen in 
the population receiving 14 g/m2. There was a linear relationship between age and treosulfan 
exposure (p = 0.026, R2 = 23%), see Figure 7.1. Exposure was not different between the various 
disease groups, i.e. hemoglobinopathies, malignancies, immune deficiencies, and bone marrow 
failure (data not shown). 
clinical outcome and treosulfan PK
Two patients of the total cohort died on day +11 and +18 due to toxicity and infections prior 
to engraftment, respectively. Resulting in an overall survival of 90%, primary engraftment 
Figure 7.1 Treosulfan exposure versus age of the patient.
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was seen in 95% of the 19 evaluable patients. Of the 18 patients that engrafted the median 
neutrophil and platelet engraftment occurred on day 23 and 35, respectively. After 100 days 11 
patients had full donor chimerism and 7 patients had mixed chimerism which persisted until 
latest follow-up. The median follow-up time was 1 year (168 days – 1.9 years).
Of the 19 survivors, 74% are disease free (n = 14),four patients had a recurrence of their initial 
disease, and one patient had a primary rejection followed by rapid autologous reconstitution. 
The toxicities observed were mucositis, skin- and hepatic toxicity, as shown in Table 7.2. In 
38% of the patients mucositis grade 2 or 3 was observed. Twenty eight percent of the patients 
had any grade skin toxicity and 38% had a moderate transient hepatic toxicity within 100 
days after treosulfan administration. Two patients had severe hepatic toxicity of which one 
patient developed sinusoidal obstruction syndrome (SOS). Both patients received treosulfan 
as a reduced toxicity conditioning (RTC), one patient because of pre-existent liver damage due 
to Cryptosporidium parvum infection and the second patient due to heavily pre-treatment for 
secondary AML after initial osteosarcoma treatment. 
Gastro-intestinal bleeding occurred in 3 patients (14%) and in one patient neurological toxicity 
was observed. Only three patients (14%) were diagnosed with aGVHD (grade 2 (n = 1) and 
grade 3 (n = 2)) and one patient was diagnosed with a limited cGHVD. There is a trend towards 
higher toxicities in patients receiving treosulfan as a RTC in comparison to patients receiving 
treosulfan according to protocol, see Table 7.3. Furthermore, there was no significant difference 
table 7.2 Main toxicities and adverse events in pediatric patients receiving treosulfan based 
conditioning
Adverse event N Mean AUC 
± sd
N Mean AUC 
± sd
p-value
Mucositis Grade 0–1 13 1517 ± 187 Grade 2–3 8 1560 ± 262 0.70
SOS No 20 1528 ± 217 Yes 1 1668 NA
Hepatic toxicity No–mild 11 1465 ± 197 Moderate/severe 10 1610 ± 214 0.21
Skin toxicity No 15 1535 ± 234 Grade 1–2 6 1533 ± 169 0.98
GI-bleeding No 18 1558 ± 213 Grade 3–4 3 1392 ± 182 0.25
Neurologic toxicity No 20 1534 ± 219 Yes 1a 1538 NA
Viral reactivation No 15 1539 ± 210 Yes 6 1523 ± 243 0.89
aGvHD Grade 0–1 18 1517 ± 190 Grade 2–3 3 1636 ± 361 0.63
cGvHD No 20 1527 ± 216 Limited 1 1681 NA
Occurrence or grading of event, number of patients (N) and mean AUC ± standard deviation. a Hallucinations 
and disorientation in end stage disease. SOS: sinusoidal obstruction syndrome, aGvHD and cGvHD: acute and 
chronic graft-versus-host disease, NA: not applicable.
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in treosulfan exposure in these two groups. In this limited cohort, no relation was found 
between treosulfan exposure and HSCT outcome parameters, e.g. engraftment, chimerism, 
toxicity and survival.
dIscussIon
This is the first report in which treosulfan exposure was analyzed in a comprehensive cohort of 
pediatric HSCT recipients and related to toxicity and clinical outcome parameters. 
We found a relative small interpatient variability in PK of 14% only, which was much smaller than 
observed in an earlier study.8 In this study of Glowka et al. three different doses were applied 
(10, 12, and 14 g/m2/day) and they found a linear relationship between dose and exposure.11 
Interpatient variability based on treosulfan exposure measurements in 5 patients receiving 
12 g/m2 was 70%. The exposure in the patient receiving the highest dose of 14 g/m2/day was 
relative high (e.g. 1960 mg/L*h). 
In our patient population all, except one patient, received 14 g/m2/day and the mean AUC 
is lower (i.e. 1534 mg/L*h) in comparison to Glowka et al. The inter-occasion variability was 
approximately 5%, which is much smaller than inter-individual variability. However, IOV is 
based on measurements on day 1 and 3 in only 7 patients. Notably, we found that treosulfan 
exposure decreases with age. This was not reported previously, but shows similarities with 







(n = 9) p-value
Mucositis (grade 2–3) 25% 56% 0.33
SOS 0% 22% 0.88
Hepatic toxicity (moderate/severe) 33% 67% 0.28
Skin toxicity (grade 1–2) 17% 44% 0.36
GI-bleeding (grade 3–4) 8% 22% 0.79
Neurologic toxicity 0% 22% 0.88
Viral reactivation 25% 33% 1.0
aGvHD (grade 2–3) 8% 22% 0.79
cGvHD (limited) 8% 0% 1.0
SOS: sinusoidal obstruction syndrome, aGvHD and cGvHD: acute and chronic graft-versus-host disease.
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the reported data on busulfan exposure and its relation with age.12 In general, age and body 
weight are strongly correlated, and in the PK-model treosulfan clearance is allometrically 
scaled using body weight with a fixed scaling exponent of 0.75 to correct for the influence of 
growth.9 The age effect observed in this study could be due to dosing based on body surface 
area instead of allometrically scaled body weight, or that the appropriate scaling component in 
the patient population diverge from 0.75. PK-data in a larger cohort is required to confirm this 
age effect on treosulfan exposure. One very young child received a lower dose of 10 g/m2/day, 
but demonstrated an exposure similar to the older children having received 14 g/m2/day. From 
these results, it may be concluded that younger patients (< 1 year) require a lower treosulfan 
dose to obtain an adequate exposure. Furthermore, in older patients dose-escalation could 
be possible to further increase efficacy of treosulfan-based conditioning. Studies in a larger 
cohort of children including a broad spectrum of ages, and particularly infants, will provide 
more insight in the pharmacokinetics of treosulfan.
Particularly in pediatric patients, the relation between treosulfan exposure and clinical outcome 
parameters has so far been unresolved. In this first report of an ongoing prospective pediatric 
study, the OS rate was 90% and primary engraftment was 95% in the 19 evaluable patients. OS 
and primary engraftment are similar or even better in comparison to other studies applying 
treosulfan-based conditioning in pediatric populations with malignant and non-malignant 
diseases.13–15
The toxicity profile in this study group was relatively mild, with mild to moderate mucositis and 
hepatic toxicity being most often reported. In these children, the toxicity parameters could not 
be related to treosulfan exposure. The high incidence of hepatic toxicity could be due to the 
preexistent hepatic risk profile in affected patients, which precluded the use of busulfan-based 
conditioning. This reflects the fact that treosulfan-based conditioning was used as reduced 
toxicity conditioning (RTC) in almost half of the patients because of significant preexisting co-
morbidities. The incidence of acute and chronic aGvHD is low in comparison to other studies 
applying treosulfan based conditioning.13,14,16 Furthermore, no relationship with any clinical 
outcome and treosulfan exposure was observed. However, the cohort was limited in size as to 
observe subtle effects of exposure on clinical outcome.
In conclusion, the optimal treosulfan exposure in pediatric allo-HSCT recipients, in relation to 
age and primary diseases remains to be defined. In this study we demonstrated that treosulfan 
conditioning is effective and well tolerated. However, primary engraftment and (long term) 
chimerismcould be improved, and probably a higher exposure of treosulfan may be beneficial 
to achieve this goal. This is not only of relevance to prevent disease recurrence in patients 
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with hematologic malignancies, but also to achieve adequate and long term graft function in 
various non-malignant diseases. Therefore, prospective treosulfan PK studies in larger cohorts of 
pediatric patients are warranted with the aim to define the most effective treosulfan exposure 
and dose while keeping its beneficial toxicity profile.
Acknowledgements
Jacqueline Waaijer and the nursing staff of the pediatric department of the Leiden University 
Medical Center are acknowledged for collection of patient samples.
137
Treosulfan pharmacokinetics and outcome
7
reFerences
1.  Feit PW, Rastrup-Andersen N, Matagne R. Stud-
ies on epoxide formation from (2S,3S)-threitol 
1,4-bismethanesulfonate. The preparation and 
biological activity of (2S,3S)-1,2-epoxy-3,4-
butanediol 4-methanesulfonate. J Med Chem 
1970; 13: 1173–1175.
2  Hartley JA, O’Hare CC, Baumgart J. DNA 
alkylation and interstrand cross-linking by 
treosulfan. Br J Cancer 1999; 79: 264–266.
3  Sjöö F,  Hassan Z,  Abedi-Valugerdi M, 
Griskevicius L, Nilsson C, Remberger M et 
al. Myeloa blative and immunosuppressive 
properties of treosulfan in mice. Exp Hematol 
2006; 34: 115–121.
4  Munkelt D, Koehl U, Kloess S, Zimmermann S-Y, 
Kalaäoui RE, Wehner S et al. Cytotoxic effects 
of treosulfan and busulfan against leukemic 
cells of pediatric patients. Cancer Chemother 
Pharmacol 2008; 62: 821–830.
5  Bernardo ME, Zecca M, Piras E, Vacca A, 
Giorgiani G, Cugno C et al. Treosulfan-based 
conditioning regimen for allogeneic haemat-
opoietic stem cell transplantation in patients 
with thalassaemia major. Br J Haematol 2008; 
143: 548–551.
6  Wachowiak J, Sykora K-W, Cornish J, Chybicka 
A, Kowalczyk JR, Gorczyńska E et al. Treosulfan-
based preparative regimens for allo-HSCT 
in childhood hematological malignancies: 
a retrospective study on behalf of the EBMT 
pediatric diseases working party. Bone Marrow 
Transplant 2011; 46: 1510–1518.
7  Slatter MA, Rao K, Amrolia P, Flood T, Abinun 
M, Hambleton S et al. Treosulfan-based 
conditioning regimens for hematopoietic stem 
cell transplantation in children with primary 
immunodeficiency (PID): UK experience. Blood 
2011. doi:10.1182/blood-2010-10-312082.
8  Glowka FK, Karazniewicz-lada M, Grund G, 
Wrobel T, Wachowiak J. Pharmacokinetics of 
high-dose i.v. treosulfan in children undergo-
ing treosulfan-based preparative regimen for 
allogeneic haematopoietic SCT. Bone Marrow 
Transplant; 42: S67–S70.
9  Ten Brink MH, Ackaert O, Zwaveling J, 
Bredius RGM, Smiers FJ, den Hartigh J et al. 
Pharmacokinetics of Treosulfan in Pediatric 
Patients Undergoing Hematopoietic Stem 
Cell Transplantation. Ther Drug Monit 2014. 
doi:10.1097/FTD.0000000000000047.
10  Przepiorka D, Weisdorf D, Martin P, Klingemann 
HG, Beatty P, Hows J et al. 1994 Consensus 
Conference on Acute GVHD Grading. Bone 
Marrow Transplant 1995; 15: 825–828.
11  Bearman SI, Appelbaum FR, Buckner CD, 
Petersen FB, Fisher LD, Clift RA et al. Regimen-
related toxicity in patients undergoing bone 
marrow transplantation. J Clin Oncol 1988; 6: 
1562–1568.
12  Trame MN, Bergstrand M, Karlsson MO, Boos 
J, Hempel G. Population pharmacokinetics of 
busulfan in children: increased evidence for 
body surface area and allometric body weight 
dosing of busulfan in children. Clin Cancer Res 
2011; 17: 6867–6877.
13  Beier R, Schulz A, Hönig M, Eyrich M, Schlegel 
P-G, Holter W et al. Long-term follow-up 
of children conditioned with Treosulfan: 
German and Austrian experience. Bone Marrow 
Transplant 2013; 48: 491–501.
14  Mathews V, George B, Viswabandya A, Abraham 
A, Ahmed R, Ganapule A et al. Improved 
clinical outcomes of high risk β Thalassemia 
major patients undergoing a HLA matched 
related allogeneic stem cell transplant with a 
treosulfan based conditioning regimen and 
peripheral blood stem cell grafts. PLoS ONE 
2013; 8: e61637.
15  Wachowiak J, Sykora K-W, Cornish J, Chybicka 
A, Kowalczyk JR, Gorczyńska E et al. Treosulfan-
based preparative regimens for allo-HSCT 
in childhood hematological malignancies: 
a retrospective study on behalf of the EBMT 
pediatric diseases working party. Bone Marrow 
Transplant 2011; 46: 1510–1518.
16  Wachowiak J, Sykora K-W, Cornish J, Chybicka 
A, Kowalczyk JR, Gorczyńska E et al. Treosulfan-
based preparative regimens for allo-HSCT 
in childhood hematological malignancies: 
a retrospective study on behalf of the EBMT 





Pharmacogenetics of glucocorticoid 
responsiveness in treatment of acute 
Graft-versus-Host Disease in 
pediatric patients




Tahar van der Straaten
Robbert G. M. Bredius







Acute Graft-versus-Host Disease (aGvHD), caused by the tissue destructive effect of alloreactive 
donor T lymphocytes is the major cause of non-relapse morbidity and mortality in pediatric 
allogeneic hematopoietic stem cell transplantation (allo-HSCT). Despite routine administration 
of pharmacological prophylaxis, 15–25% of pediatric HSCT recipients develop aGvHD ≥ grade 
II. Systemic treatment with high-dose glucocorticoids (GCs) is currently the gold standard as 
first line treatment. However, approximately half of the patients turn out to be non-responsive 
to high-dose GCs. To explore whether individual GC responsiveness can be predicted based on 
the GC pharmacogenetic signature, we studied the effect of genetic polymorphisms on gene 
expression in peripheral blood mononuclear cells, from healthy volunteers, cultured with or 
without GCs. Those polymorphisms that affect the transcriptional response to GC in this system 
were further studied in 56 pediatric patients with aGvHD treated with GC. We found that seven 
cis-regulatory interaction eQTLs represented regulatory polymorphisms only active in the 
presence of GCs, in healthy volunteers. In the pediatric patient, the HSCT donor genotypes for 
polymorphisms affecting the transcriptional response of the TMEM71 and DPYSL3 genes were 
found to be associated with the GC response status of the corresponding patients. The predictive 
value of two donor genotypes was 63%. These polymorphisms are potential predictors of clinical 
response to GCs in aGvHD patients and could be used to identify patients that are likely to be 
GC-insensitive, and therefore qualify for alternative therapies.
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IntroductIon
Despite improvements in HLA typing, donor selection, pharmacological graft-versus-host 
disease (GvHD) prophylaxis and supportive care, acute GvHD (aGvHD) remains the major 
complication after allogeneic hematopoietic stem cell transplantation (allo-HSCT), with 
significant morbidity and mortality.1,2 aGvHD is an immunological disorder in which recipient 
and donor antigen-presenting cells, cytokines, and alloreactive donor T lymphocytes play a 
pivotal role. Triggering and activation of mature donor T cells will lead to cytokine release 
and tissue damage.2,3 aGvHD affects many organ systems, including the gastrointestinal 
tract, skin, liver, and lungs. Despite immunosuppressive prophylaxis, severe aGvHD (i.e. grade 
2–4) occurs in up to 25% of pediatric HSCT recipients,4 depending on conditioning regimen, 
donor type, HLA matching, age, and other risk factors. Rapid and persistent control of aGvHD 
is crucial to limit morbidity and mortality associated with aGvHD and its treatment. Systemic 
use of glucocorticoids (GCs) (e.g. prednisolone and methylprednisolone), with their anti-
lymphocyte and anti-inflammatory activity, is the gold standard for first-line treatment of 
moderate to severe aGvHD.5–7 However, only half of the patients show a satisfactory response 
to GC therapy and an even smaller number shows a complete long-term response.8,9 When 
a patient does not respond to high dose GC, a second line therapy will be added, including 
conventional immunosuppressive drugs or mesenchymal stromal cells (MSC).10 Early non-
responsiveness to GCs is associated with high morbidity and mortality as a consequence of 
both ongoing aGvHD and infectious complications secondary to prolonged treatment with 
GCs and other immunosuppressive agents.11 Therefore, early detection or prediction of GC 
non-responsiveness would allow for timely initiation of alternative therapeutic strategies. 
However, reliable clinical parameters and biomarkers to early identify individuals at risk are 
currently lacking.
GCs enter the cell by passive diffusion and bind intracellular to the nuclear glucocorticoid 
receptor (GR), which is encoded by the NR3C1 gene. Binding of GCs to the GR leads to formation 
and transport of the GC-GR complex to the nucleus, where it functions as a transcription factor.12 
Several studies investigated the role of germline genetic variations in GC responsiveness. 
Polymorphisms in the GR gene itself and genes involved in the mechanisms upstream or 
downstream of the binding of GC to its receptor were identified as potential variants for GC 
resistance.13,14 However, most of these studies identified rare variants which do not explain 
common non-responsiveness in the general population. 
Recently, Maranville et al. studied the molecular basis for variation in in vitro GC responsiveness 
among healthy individuals.15,16 This study identified a quantitative trait locus (QTL) for 
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lymphocyte GC sensitivity. This expression QTL (rs11129354) lies 68kb upstream of the RBMS3 
gene and affects transcriptional response through GC-dependent cis-regulatory effects on 
RBMS3. RBMS3 in turn mediates effects in trans on transcriptional response at other genes, and 
ultimately influences lymphocyte proliferation as a negative regulator. 
In this study we used expression and genotype data from this previous study (Maranville et al.16) 
to identify additional regulatory polymorphisms and investigated the predictive value of these 
regulatory polymorphisms for GC non-responsiveness in a retrospective cohort of pediatric 
patients diagnosed with aGvHD who received systemic GC therapy.
PAtIents And methods
Gc interaction eQtLs
To identify interaction expression QTLs (eQTLs), we tested for associations between genetic 
polymorphisms and expression of each gene in peripheral blood mononuclear cells (PBMCs) 
from healthy donors that were cultured in vitro in the presence and absence of GCs, as 
previously described.16 Briefly, peripheral blood was collected from 88 healthy volunteers that 
self-identified as African-Americans (AA) and lymphocyte GC sensitivity (LGS) was measured 
in cells treated with phytohemoagglutinin (PHA) and either vehicle (EtOH) or dexamethasone 
(a synthetic GC) in different concentrations, as described previously. Cellular proliferation 
was measured after 48 hours of treatment using H3-thymidine incorporation. DNA from each 
individual was genotyped with Illumina Omni1-Quad BeadChip arrays (n = 58) or Illumina 
Omini2.5-QuadBead Chip arrays (n = 30) and SNPs genotypes were imputed from the 1000 
genome project using the program IMPUTE2.17
For gene expression measurements, RNA was extracted from dexamethasone- and vehicle-
treated PBMCs. Expression was profiled using Illumina HumanHT-12 v4 Expression BeadChips. 
Low-level microarray analysis was performed as previously described.
To identify genes that were differentially expressed between treatment conditions, expression 
levels for each gene were corrected for measured covariates and principal components to 
account for unmeasured covariates. We then used the Bayesian statistical framework BRIdGE15 
to identify cis-regulatory polymorphisms that interact with treatment, testing all SNPs within 
100kb of the transcriptional start and end sites of each autosomal gene. This method compares 
distinct patterns of interaction between treatment and genotype to a null model of no effect 
as well as to each other. 
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aGvhd patient characteristics
Pediatric patients receiving allo-HSCT between 2001 and 2013 in the Leiden University Medical 
Center and diagnosed with aGvHD grade 2 or higher were included in this retrospective study. 
Patients received an allo-HSCT for various malignant and non-malignant indications. Graft-
versus-Host disease prophylaxes consisted of cyclosporine A (CsA: 1.5 mg/kg i.v. twice daily, 
and following engraftment equivalent oral dose), with dose adjustments based on through 
levels, which were 100–150 µg/L in malignant disease and 150–200 µg/L in non-malignant 
disease. CsA was combined with methotrexate in T-cell-replete transplants (10 mg/m2 on day 
+1, +3 and +6) or prednisolone in cord blood transplants (1 mg/kg/day). When CsA caused 
toxicity or adverse events, patients were switched to mycophenolate mofetil or tacrolimus. 
The grade of aGvHD was defined according to the scale described by Przepiorka et al.18 To 
treat aGvHD grade 2 or higher all patients received prednisolone 2 mg/kg/day divided into 
two doses, orally or intravenously. Response was defined as a decrease of at least one grade 
within the first 5–7 days. When patients did not respond to prednisolone within 5–7 days they 
were classified as non-responders, and a second line therapy for aGvHD was started. In most 
of the patients (89%) this consisted of administration of mesenchymal stromal cells.10 The 
applied conditioning regimen was based on the guidelines of EBMT – Working Party Inborn 
Errors and Pediatric Diseases.  
Genotyping of retrospective cohort
DNA extracted from donor and recipient PBMC was used for genotyping. Blood samples of 
the patients were taken before their allo-HSCT and in the case of malignant disease, when the 
patient was in remission. 
Patients and donors were genotyped for 8 eQTLs: rs11129354 in RBMS3 as reported by Maranville 
et al.16 and 7 cis-eQTLs first reported in this paper: rs2739024 for TMEM71, rs2288807 for DPYSL3, 
rs13354714 for GZMA, rs12022333 for TTF2, rs9963737 for LPIN2, rs3766236 for MOB3C, and 
rs116735324 for FAM117B, see also Table 8.1. 
All samples were anonymized according to the instructions stated in the Codes for Proper Use 
and Proper Conduct (www.federa.org). eQTLs for RBMS3, TMEM71, DPYSL3, GZMA, TTF2, LPIN2, 
and MOB3C were determined using commercially available realtime PCR genotyping assays 
(Lifetechnologies, Bleiswijk, the Netherlands) and analyzed on Lightcycler 480 (Roche, Almere 
the Netherlands). Because the available amount of DNA was limited, a pre-amplification step 
was performed prior to genotyping analysis. Briefly, genotyping assays were pooled and 200 
times diluted. Amplification was performed using 3 ml genotyping mastermix (Lifetechnologies, 
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table 8.1 Patient characteristics
Characteristic Total Responders Non-responders p-value
Number of patients 56 28 (50%) 28 (50%)
Age (years) 8.8 (5.4) 8.3 (5.1) 8.8 (5.8) 0.70
Sex (% male) 66% 82% 54% 0.045
Diagnosis for HSCT (n)
Hematological malignancy 41 21 20 0.77
Bone marrow failure 4 1 3
Hemoglobinopathy 2 1 1
PID/inborn errors 9 5 4
Graft type
Bone marrow 34 22 12 0.002
Peripheral blood stem cells 9 4 5
Cord blood 6 1 5
DLI/Boost 7 1 6
Donor matching
Identical related donor (10/10) 17 9 8
Matched unrelated donor 0.12
10/10 or 6/6 22 14 8
9/10 or 5/6 15 5 10
8/10 2 0 2
GvHD prophylaxes
CsA 16 8 8 0.20
CsA+MTX 30 18 12
CsA+pred 6 1 5
No* 4 1 3
Maximum aGvHD grade
2 21 20 1 <0.001
3 24 8 16
4 11 0 11
Bleiswijk, the Netherlands), 2 ml of DNA, and 1 ml of assay pool. PCR conditions were as follows, 
10 minutes at 95°C followed by 18 cycles of 15 seconds at 95°C, and 4 minutes at 60°C. After 
this, 114 ml water was added and 4 ml was used for further analyses using standard conditions.
Since no real-time PCR genotyping assay could be designed for FAM117B, this SNP was genotyped 
by pyrosequencing  using standard conditions  (Qiagen, Venlo, The Netherlands).  Used PCR 
primers were GTGTGAGCAGAACCTAGTG (forward, biotinylated)and GTAGCTGGGATTACGGGC 
(reverse). Pyrosequence primer was ACCTCGGCCTCCCAGAAT with sequence to analyse 
T/GCTAGGATTAC.
Table 8.1 continues on next page
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Initial call rate of RBMS3 by real-time PCR genotyping assay was insufficient and therefore RBMS3 
was genotyped by pyrosequencing. Pyrosequence primer was TCAGCAAAGTCAGAAAAT with 
sequence to analyze TAGT/CAGTGTTACCA. A pre-amplification step was performed prior to 
pyrosequencing using 1 pmol of primers and 18 cycles. Pre-amplified DNA was 20-fold diluted 
and 4 μL were used for second PCR. Of note, PCR was performed at 63°C because of aspecific 
PCR products at lower temperatures.
As quality control at least 5% of the samples were genotyped in duplicate and negative controls 
(water) were used. 
Gc responsiveness and eQtLs
The genotypes were tested for association with response status by logistic regression. Donor 
genotypes and patient genotypes were tested separately. In a full model the most strongly 
associated eQTLs were selected (p < 0.05). Akaike information criterion (AIC) and Bayesian 
table 8.1 Continued
Characteristic Total Responders Non-responders p-value
aGvHD organ involvement
Skin 45 26 19 0.04
Liver 15 4 11 0.07
Gut 43 15 28 <0.001
Conditioning regimen
TBI-based 18 12 6 0.06
Busulfan-based 27 13 14
Treosulfan-based 1 0 1
Other 2 1 1
No conditioning** 8 2 6
Serotherapy 46% 61% 57% 1.0
Overall survival 52% 68% 36% 0.032
Malignant diseases: acute lymphoblastic leukemia (n = 18), acute myeloid leukemia (n = 9), chronic myeloid 
leukemia (n = 3), juvenile myelomonocytic leukemia (n = 3) and myelodysplastic syndrome (n = 10). 
Non-malignant diseases: 2 patients with congenital anemia, 1 patient with Blackfan Diamond anemia and 
1 with Fanconi anemia, 1 patient with congenital amegakaryocytic thrombocytopenia, 2 patients with 
β-thalassemia, 9 patients with a primary immune deficiency. 
CsA: Ciclosporine A, MTX: methotrexate, pred: prednisolone, TBI: total-body-irradiation.
* Three patients receiving donor lymphocyte infusion or a boost and one patient with severe combined 
immune deficiency and an identical related donor did not receive GvHD prophylaxis.
** Patient that received donor lymphocyte infusion or a boost did not receive conditioning and one patient 




information criterion (BIC) were applied to select the model that best fit the data. Model 
performance was assessed with leave-one-out cross validation and by calculating the area 
under the curve (AUC) of the receiver operating characteristic (ROC) curve. Results were analyzed 
using statistical software package R (v2.10.1).
resuLts
Gc interaction eQtLs and genotyping of patient material
To identify candidate genetic variants for predicting GC non-responsiveness in patients 
with aGvHD, we used a Bayesian regression method (implemented in BRIdGE) to identify GC 
interaction eQTLs in PBMCs from healthy donors. We found that all cis-regulatory interaction 
eQTLs represented regulatory polymorphisms only active in the presence of GCs; 7 eQTLs 
were only active in the presence of GCs (false discovery rate (FDR) = 0.14) and no eQTLs were 
found that were only active in presence of the control (posterior probability > 0.7). None of 
these interaction eQTLs were significantly associated with in vitro lymphocyte GC sensitivity 
(e.g. Imax, corrected p > 0.1). The cis-eQTLs affect the expression of the following genes: LPIN2, 
DPYSL3, TMEM71, GZMA, MOB3C, TTF2, and FAM117B, see Figure 8.1.
When genotyping the pediatric patients, one SNP (FAM117B) had only one heterozygous 
individual, all other individuals were homozygous wild type; this SNP was excluded from 
further analysis. 
All other SNPs had a call rate between 80–100%, and genotype frequencies were in Hardy-
Weinberg equilibrium (p > 0.05). A summary of minor allele frequencies and call rates of the 
seven remaining SNPs is given in Table 8.2.
aGvhd patient characteristics and Gc responsiveness 
Fifty-six pediatric patients diagnosed with aGvHD grade 2 or higher were included in the study. 
The mean age of the study cohort was 8.8 (± 5.4) years and 68% of the patients were male. 
Seventy-three percent of the patients had a malignant disease for which they received the allo-
HSCT. The remaining 16 patients were diagnosed with non-malignant diseases. A summary of 
the transplantation characteristics is given in Table 8.1. Systemic prednisolone treatment was 
started in patients diagnosed with aGvHD grade 2. Furthermore, the maximum aGvHD grade 
of each patient was registered; 38% of the patients had grade 2 aGvHD, 43% had grade 3, and 
20% of patients had grade 4 aGvHD. Twenty-eight patients (50%) patients did not respond 
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adequately to prednisolone within 7 days after initiation of the therapy and were considered 
GC non-responders. In accordance with response-status, maximum grade of aGvHD was higher 
in the non-responders (p < 0.001). In line with this observation the gastrointestinal tract was 
always affected in the non-responders (versus 54% in the responders, p < 0.001), whereas in the 
responders aGvHD grade 2 often remained limited to the skin. The overall survival of the study 
cohort was 52% and was significantly lower in the non-responders (36% versus 68%, p = 0.036).
Figure 8.1 Effect of eQTLs on expression in PBMCs of healthy volunteers. a) Boxplot of effect of 
eQTL genotype on log 2 fold change in expression of the corresponding gene in absence and 
presence of dexamethasone, for DPYSL3, GZMA, TTF2, LPIN2, TMEM71, and MOB3C. b) Boxplot of 




Gender and stem cell source were the only variables that were significantly different between 
responders and non-responders. Patients developing aGvHD after a donor lymphocyte infusion 
or a stem cell boost were more likely to be non-responder.
Gc responsiveness and patient and donor genotypes
The eQTL genotype of each patient and its donor was determined. Donor and patient immune 
cells are both involved in the process of aGvHD. However, donor T cells are considered the major 
target of GC therapy. At first, we compared the predictive value of all 7 eQTLs in patients and in 
donors separately. When excluding individuals with missing data in any of the donor genotypes, 
34 individuals remained for further analysis. Forty-two patients were analyzed for association 
with patient genotype, due to missing data in 14 patients of any of the patients’ genotype. 
Based on likelihood ratio tests, the donors’ genotypes were significantly associated with 
responsiveness (p = 0.011), this was not the case for patients’ genotypes (p = 0.56). 
Predictive model
We conducted further analyses to determine which eQTLs genotype in the donors contributed 
most to the patient responsiveness to GC therapy (see Table 8.3). Donor eQTLs for TMEM71 (p 
= 0.008) and DPYSL3 (p = 0.022) were significantly associated with responsiveness. TMEM71 
genotype was borderline significantly associated when correcting for multiple testing for 
7 eQTLs (p = 0.055). Furthermore, based on both AIC and BIC, TMEM71 and DPYSL3 donor 
genotype were found to be most strongly associated. 
table 8.2 Minor allele frequencies and call rates of 7 eQTLs
Minor allele frequencies







RBMS3 rs11129354 48% 37% 80% G
LPIN2 rs9963737 33% 43% 91% C
TMEM71 rs2739024 18% 38% 93% A
DPYSL3 rs2288807 29% 43% 96% C
GZMA rs13354714 23% 15% 100% C
MOB3C rs3766236 39% 31% 99% G
TTF2 rs12022333 20% 9% 93% C
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When TMEM71 and DPYSL3 donor genotype were tested separately, TMEM71 genotype remained 
significantly associated with response status (p = 0.023, n = 52) but DPYSL3 genotype was not 
(p = 0.08, n = 56). 
In order to give an estimate of the predictive value of both eQTLs in donors, leave-one-out cross 
validation was performed. The predictive value of TMEM71 genotype alone was 65%; when 
the two donor genotypes were combined the predictive value was 63%. The AUC of the ROC 
curve for the combination of both donor genotypes was higher (70% (52% – 85%)) than for 
TMEM71 genotype alone (66% (53 – 79%)), however confidence intervals were overlapping. 
TMEM71 and DPYSL3 expression
Patients in whom their donor is a carrier of the minor allele of the TMEM71 eQTL are more 
likely to be responders of GC therapy, see also Figure 8.2. Furthermore, when the patients 
themselves were carriers of the minor allele of TMEM71 eQTL, it was more likely that the patients 
are responders, however, this relationship was not significant. In the healthy volunteers, the 
minor allele was associated with down regulation of TMEM71 in GC treated lymphocytes, 
see Figure 8.1. These findings suggest that down regulation of TMEM71, results in increased 
responsiveness towards GCs.
Donors that were DPYSL3 major allele homozygous were more likely to be GC responders. In 
the healthy volunteers the major allele was associated with a higher expression of the DPYSL3 
gene in comparison to individuals carrying the minor allele. Therefore, increased expression 
of DPYSL3 could lead to improved responsiveness towards GCs.
table 8.3 Logistic regression of donor genotype and patient responsiveness
Gene eQTL Direction of 
expression data
OR (CI) p-value (one-tailed)
RBMS3 rs11129354 - 0.61 (0.11–3.30) 0.283
LPIN2 rs9963737 - 1.60 (0.30–8.46) 1.158
TMEM71 rs2739024 + 27.92 (1.88–416) 0.008 **
DPYSL3 rs2288807 - 0.12 (0.01–0.95) 0.022 *
GZMA rs13354714 + 2.66 (0.29–24.39) 0.193
MOB3C rs3766236 - 1.65 (0.31–8.80) 0.280
TTF2 rs12022333 + 1.59 (0.08–29.9) 0.379
Based on n = 34, due to missing data in individuals. The direction of DPYSL3 expression data is based on the 
effect of the C-allele. OR (CI): odds ratio (confidence interval).
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As a further validation of the effect of eQTLs, we compared the expected direction of effect of 
the eQTLs based on transcriptional data (e.g. is the minor allele associated with greater or lesser 
response). In donors, we found that the odds ratios of 5 eQTLs were in line with the expression 
data in healthy volunteers. In contrast, the effects of only 3 of 7 eQTLs in patients were in line 
with the expression data, see Table 8.3. This is a pattern expected based on the physiological 
mechanism of aGvHD.
dIscussIon
This is the first study demonstrating an association between genetic polymorphisms and 
glucocorticoid responsiveness in aGvHD patients. Specifically, the genotype at two regulatory 
polymorphisms in allo-HSCT donors is associated with GC responsiveness. Based on TMEM71 
donor genotypes it was possible to predict response status with 65% accuracy. 
A recent study identified the biomarker suppression of tumorigenicity 2 (ST2) for treatment 
resistant GvHD and outcome after HSCT. ST2 level measurement can improve risk stratification 
of patients with treatment-resistant GvHD.19 In this study, we searched for genetic markers 
related to the GC-treatment effect. Several studies tried to identify genetic markers to explain 
GC non-responsiveness in a variety of diseases, mainly applying a candidate gene approach.13,14,20 
However, the pharmacological mechanism of GCs is complex, involving a multi-level signaling 
Figure 8.2 Allele frequencies in donor and patient genotypes for TMEM71 in responders and 
non-responders.
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pathway. Earlier attempts to move beyond the candidate gene approach identified cis-
regulatory polymorphisms associated with GC-response in asthma patients.21,22
The regulatory polymorphisms we tested in the pediatric patients were identified in healthy 
volunteers in which information from genome wide polymorphisms and in vitro transcriptional 
response toward GC treatment in lymphocytes was combined. This method of applying multiple 
levels of genotypic and phenotypic information allowed us to identify polymorphisms that 
interact with GC treatment to influence response and are therefore excellent candidates. 
Our study in healthy donors was performed in a relevant cell type for this clinical phenotype 
since lymphocyte GC sensitivity has been shown to be correlated with patient response across 
a wide range of diseases, including asthma,23,24 rheumatoid arthritis,25 and renal transplant 
rejection.26 In aGvHD alloreactive donor T lymphocytes interact with recipient immune cells 
and cause cytokine release and tissue damage. The healthy volunteers were from AA ancestry; 
the majority of the aGvHD patients and their donors are Caucasians. Response to GC treatment 
differs among ethnic groups, with African-Americans having a weaker response to GC treatment 
in comparison to Europeans.27 It is most likely that differences in response are due to allele 
frequency differences rather than a differential effect of polymorphisms in different ethnicities. 
This is also observed in our results; FAM117B was excluded from further analysis since the MAF 
was 0.1%; in the AA volunteers the MAF was 21%, which is in line with findings from the 1000 
genome project. When there is a big difference in allele frequencies in the two populations, 
potential interesting genetic markers in Caucasians, could have been not identified in the 
healthy volunteers with AA ethnicity, due to a low allele frequency in the AA population.  
The TMEM71 and DPYSL3 eQTLs were not associated with PHA induced T cell proliferation in 
the healthy volunteers. Furthermore, RBMS3 was strongly associated with PHA induced T cell 
proliferation and appeared to be a promising candidate eQTL. However, we did not find an 
association of RBMS3 with GC responsiveness in aGvHD patients. This is could be due to different 
immune response mechanisms in aGvHD and in PHA mediated T cell proliferation. 
In contrast to GvHD grade at start of the treatment, maximum aGvHD grade was higher in the 
non-responders. In all non-responders GvHD progressed to higher grades with liver or gastro-
intestinal involvement of their disease, due to inadequate treatment with GCs. Otherwise, the 
patient and donor characteristics of responders and non-responders were very comparable, 
except for gender and the source of donor cells. Patients receiving donor lymphocyte infusion 
or a stem cell boost were more likely to be non-responder. The clinical significance of prevention 
or early detection of GC non-responsiveness is demonstrated in this study by the significantly 
lower overall survival of GC non-responsive patients. 
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To more accurately estimate the predictive value of TMEM71 it is essential to replicate current 
findings. We performed simulations to calculate sample size for a replication cohort, using 
the same minor allele frequencies of TMEM71 and the same case-control ratio. A replication 
cohort should contain at least 110 patients in order to detect an odds ratio of 2.5, based on a 
statistical power of 0.8 at a significance threshold of p < 0.05. This replication of current findings 
is scheduled in the context of a multi-center study. 
We hypothesized that by analyzing genetic susceptibility factors, clinical responsiveness to GC 
can be predicted in individual patients before treatment is started. TMEM71 and DPYSL3 donor 
genotype are potential genetic markers in the prediction of GC responsiveness in patient with 
aGvHD. Furthermore, this knowledge should be implemented in prospective studies in which 
patients with a GC non-responsive genetic signature could be candidates for intensified GvHD 
prophylaxis and early switch to or direct initiation of alternative GvHD treatment modalities 
that could replace or complement GCs and, thereby, circumvent non-efficacious GC treatment.
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Chapter 9
Pharmacogenetics in transplant patients;
Mind the mix
Marloes H. ten Brink








Pharmacogenetics is aimed at individualizing drug treatment and increasing drug efficacy 
while reducing toxicity. Currently, pharmacogenetic information is accumulating rapidly 
and is beginning to show consistent reproducible results for a growing number of genetic 
markers for drug response. Several consortia have published guidelines to aid clinicians with 
the interpretation of pharmacogenetic test results1,2 and an increasing number of medical 
centers have acquired clinical genotyping facilities and centers are implementing prospective 
genotyping.3 Among these, there are many highly specialized care centers with complex patient 
populations. These patients may present unexpected challenges, as demonstrated by this case.
case descrIptIon
A 20-year-old woman was admitted for a living–related kidney transplant. A standard 
quadruple immunosuppressive regimen was prescribed (basiliximab induction, tacrolimus, 
mycophenolate, and prednisolone). Tacrolimus is metabolized by cytochrome P450 (CYP) 
3A4 and CYP3A5. To attain therapeutic concentrations, carriers of at least one copy of the 
CYP3A5*1 allele require a significantly increased tacrolimus dose.4 Therefore, all kidney 
transplant patients at our institution are preemptively genotyped for the CYP3A5*3 
(rs776746) and CYP3A5*6 (rs10264272) polymorphisms. Clinical genotyping is performed 
by two independent techniques: a commercially available TaqMan assay and a home-brew 
pyrosequencing method. For the case patient, results were conflicting. Pyrosequencing 
identified the patient as CYP3A5*1/*3, whereas TaqMan software called the patient as 
CYP3A5*3/*3 (Figure 9.1a and e). Repeated genotyping on a second blood sample showed 
identical results for pyrosequencing (data not shown), and TaqMan software identified the 
patient as CYP3A5*1/*3. Moreover, pyrosequencing results showed inconsistencies in peak 
proportions between the A and the G peak as compared with results obtained with plasmid 
controls,5 indicating that the genotyping result may be questionable (Figure 9.1a and b). 
Consultation with the attending nephrologist revealed a patient history including allogeneic 
hematopoietic stem cell transplantations (allo-HSCT). A first allo-HSCT in 1992 to treat 
β-thalassemia major was rejected. A second allo-HSCT in 2009, from a second donor, resulted 
in a mixed hematopoietic chimerism (28% autologous, 72% donor). Saliva samples from both 
the patient and the second stem cell donor were obtained and regenotyped. The donor was 
autocalled as CYP3A5*3/*3 and the patient was autocalled as CYP3A5*1/*3. Pyrosequencing 
and TaqMan results were in concordance (Figure 9.1c, d, and g), and the patient’s genotype 




Figure 9.1 Genotyping results of different samples based on pyrosequencing and the TaqMan 
assay. (a–d) Pyrosequencing results. Results for a) patient blood sample b) plasmid CYP3A5*1/*3 
control c) saliva sample of the patient and d) saliva sample of the donor. A peak indicates presence 
of the CYP3A5*1 allele; G peak indicates presence of the CYP3A5*3 allele. Pyrosequencing results 
from the patient’s blood sample (a) showed inconsistencies in peak proportion between the A and 
the G peaks as compared with the results obtained with (b) the plasmid control. As a result, the 
pyrosequencing software was not able to autocall the genotype of the patient. The saliva sample 
from the patient is autocalled as CYP3A5*1/*3, and the sample from the donor is autocalled as 
CYP3A5*3/*3. (e–g) TaqMan results. Blue dots indicate samples called as CYP3A5*3/*3; green dots 
indicate samples called as CYP3A5*1/*3; and red dots indicate samples called as CYP3A5*1/*1. 
Encircled dots are results obtained with DNA from the patient (triplos). Squared dots are results 
obtained with DNA from the donor. Conflicting results obtained with the e) first and f ) second 
blood samples. g) Saliva sample from the patient is called as CYP3A5*1/*3, and the sample from 
the donor is autocalled as CYP3A5*3/*3.
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level (5.5 µg/l) and area under the concentration-time curve (110 µg*h/l) achieved with a 
dose of 8 mg b.i.d. tacrolimus. It is essential to consider the source of the sample used to 
collect DNA for genotyping.
dIscussIon
This case description demonstrates the challenging aspect of pharmacogenetic testing in an 
allo-HSCT recipient and illustrates the importance of proper quality control mechanisms when 
performing pharmacogenetic testing. In our opinion these challenges are not limited to the 
allo-HSCT setting. Also pharmacogenetic testing in solid organ transplantation recipients should 
be handled with great care, taking the transplant type and the metabolic pathway, mechanism 
of action and toxicity of the applied drugs into consideration. Therefore, we now routinely 
request transplantation status on all our pharmacogenetic laboratory orders. 
In liver transplant recipients, the donor genotype will control enzyme expression patterns in the 
liver, while the recipient’s genotype can affect absorption of drugs through drug transporter 
expression patterns in the intestine. Indeed, several studies have reported that donor and 
recipient CYP3A5 genotype have a combined influence on the pharmacokinetics of tacrolimus 
following liver transplantation. This relation is time dependent and it appears that there is a 
shift in the major organ influencing tacrolimus disposition, from native intestine directly after 
the transplantation to donor liver due to recovery of the metabolic function of the liver.6
In renal transplant recipients, the hepatic metabolic capacity is not influenced by the 
transplantation and recipient genotyping would be sufficient in the case of drugs that are only 
subject to hepatic clearance. However, many drugs also undergo renal elimination and this 
can be influenced by drug transporters i.e. P-glycoprotein which are expressed in the kidney. 
Assuming that the donor kidney is the only functional kidney of the patient, both donor (locally 
in the kidney) and recipient (in the rest of the body) drug transporter genetic polymorphisms 
will affect elimination of these drugs. In addition the donor genotype potentially will also 
have influence on the development of toxicity in the donor graft. Hauser et al. demonstrated 
a higher incidence of cyclosporine nephrotoxicity when the donor, but not the recipient, had 
the ABCB1 3435TT genotype.7 
These examples demonstrate that it is challenging, yet of utmost importance to select the 
correct material for genotyping. In allo-HSCT recipients peripheral blood samples are not 
adequate for genotyping due to mixed chimerism or complete donor genotype. We collected 




with DNA derived from the patient’s saliva is more similar to that obtained with a plasmid control 
(CYP3A5*1/*3) than the pyrogram obtained from DNA derived from the patient’s blood sample. 
However, the saliva sample was still not identical to the plasmid control. This could be due to 
the fact that saliva samples obtained after allo-HSCT have been reported to display a chimeric 
or even complete donor genotype.8 A buccal swab is considered to be more informative about 
the germline genotype of a recipient of an allo-HSCT.
In our case, the use of two independent validated genotyping assays and standardized plasmid 
controls resulted in the discovery of the mixed chimerism of the patient. These findings show 
the importance of proper quality control protocols when performing pharmacogenetic testing 
in routine patient care. With the increasing number of medical centers acquiring clinical 
genotyping facilities, the need for external quality control programs for pharmacogenetic 
testing is rising. 
In conclusion, it is essential to consider the source of the sample used to collect DNA for 
genotyping in transplantation patients. In addition, quality control e.g. the use of validated 
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Although allogeneic hematopoietic stem cell transplantation (allo-HSCT) is basically a curative 
treatment in various hematologic malignancies and non-malignant diseases in both adult and 
pediatric patients, it may be accompanied by various complications, such as recurrence or 
persistence of the initial disease, severe infections, graft-versus-host disease (GvHD) and both 
acute and late toxicity related to the conditioning regimen. Pharmacotherapy is an essential 
part in the allo-HSCT procedure and therefore optimization of pharmacotherapy can help to 
reduce the risks of adverse events in allo-HSCT. Busulfan and treosulfan are both alkylating 
agents, which are widely used and play an important role in the conditioning regimen prior 
to allo-HSCT. Busulfan exposure has been related to allo-HSCT outcome and toxicity and 
therapeutic drug monitoring is often applied in clinical practice to target the exposure in 
the individual patient.1–3 In addition, several population pharmacokinetic (pop-PK) models 
have been developed to describe busulfan PK. However, significant interpatient variability 
remains, caused by unknown variables. In this thesis the role of genetic markers in busulfan 
PK is explored.
Treosulfan was only recently introduced as myeloablative agent in conditioning prior to allo-
HSCT. It is a promising drug with strong myeloablative and immunosuppressive capacity and a 
mild toxicity profile.4–6 It is currently unresolved whether treosulfan therapy could be optimized 
when targeting exposure, similar to busulfan therapy. Treosulfan PK in adults is linear, however, 
there are limited data in pediatric patients showing a wide interpatient variability.7 In this thesis 
further research on treosulfan PK in pediatric patients was performed, by development of a 
bioanalytical method and pop-PK model. 
A major risk after allo-HSCT is the occurrence of aGvHD, which is accompanied with significant 
morbidity and mortality.8 Despite improvements in donor matching and prophylaxis still 
approximately 25% of the patients will develop aGvHD requiring treatment with systemic high-
dose glucocorticoids (GCs) as the first line therapy.9,10 Unfortunately, about half of the patients 
do not respond to GCs and require alternative therapy.11,12 In other diseases non-responsiveness 
towards GCs has been observed too.13,14 Therefore it is suggested that GC-unresponsiveness is 
an intrinsic property of a subset of the population and differences in genetic make-up might 
contribute to this phenomenon.13,14 Further insight in biological factors causing GC resistant 
aGvHD will be instrumental in designing the most effective aGvHD treatment for the individual 
patient. 
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Busulfan
In this thesis it was investigated whether genetic markers could be identified to explain the 
interpatient variability in busulfan clearance. Genetic markers were studied in both an adult and 
a pediatric population. In adults, the absence of maturation effects and relative small variability 
in body weight makes the association of busulfan clearance and genetic markers probably 
more straight forward. In chapter 3 we studied the effect of SNPs in three genes encoding 
for glutathione-S-transferases (GSTA1, GSTM1, and GSTP1). These enzymes are involved in 
conjugation of busulfan with glutathione, with GSTA1 being the predominant enzyme.15 A 
SNP (rs3957357) in GSTA1 was associated with busulfan clearance and could explain 18% of 
the interpatient variability in this adult study population. No association between GSTM1, 
GSTP1 and busulfan exposure was observed, nor could any relation between GSTA1 genotype 
and clinical outcome be found in our study population. The latter is most probably due to the 
application of busulfan in a non-myeloablative regimen resulting in very low toxicity levels. 
The association of GSTA1 genotype with busulfan PK parameters has been observed in a few 
studies in adults as well.16,17 However, Krivoy et al.18 did not observe an association with GSTA1, 
but found an association with GSTP1 and two SNPs in ABCB1 in combination with GSTM1 and 
busulfan clearance. However, in this study the patients received busulfan orally and therefore 
other factors might contribute to this contradictious finding.  
In chapter 4 an exploratory pharmacoge netic approach was applied to investigate whether 
the remaining interpatient varia bility in busulfan clearance in adults could be explained. This 
analysis included a wide range of genes involved in drug ADME (absorption, distribution, 
metabolism and excretion). Two cohorts were composed; an exploratory and a validation 
cohort. Patients in the exploratory cohort were genotyped with the DMET array. This array 
contains 1936 SNPs in 225 genes involved in drug metabolism and transport. This array is a 
comprehensive platform to identify potential new genetic markers involved in busulfan PK. 
Again, the role of the GSTA1 in association with busulfan clearance was confirmed both in the 
exploratory and validation cohort and no additional genetic markers were identified explaining 
the remaining part of the variability in busulfan PK. This could have been due the relative 
small cohort sizes resulting in low statistical power to detect rare variants or variants with a 
small effect size. Although it has been suggested that transporters are involved in busulfan 
metabolism, we could not identify any genetic markers in a wide variety of transporters 
affecting busulfan metabolism. 
Clinical relevance of the GSTA1 genotype in busulfan-based allo-HSCT in adults is minor. The 
effect of GSTA1 genotype is potentially of more interest in pediatric patients, since in children 
Chapter 10
168
a high interpatient variability in exposure is observed, pediatric patients receive more often a 
myeloablative conditioning and a tighter control of exposure is aimed for in clinical practice.  
However, the effect of genetic markers on busulfan PK in pediatric patients seems to be 
more complicated to determine, which is illustrated by several studies in pediatric patients 
presenting conflicting results. Either no association between GSTA1 genotype and busulfan 
PK19,20 was observed or the association was found only in a subset of the study cohort receiving 
busulfan orally.21 However, there are also a number of positive studies,22–25 including chapter 5 
of this thesis.26 To our opinion, several factors might account for the discrepancies between 
the positive and negative studies towards the effect of genetic variation in GSTA1 on busulfan 
clearance in children, such as sample size,20 correction of busulfan clearance for body size19,20 
or administration route.21 
Interpatient variability of busulfan PK in children is higher in comparison with adults and 
several mechanisms from birth until adulthood will affect busulfan PK and with that the effect 
of genetic markers on busulfan PK. Young children have a higher clearance (expressed per 
unit of body weight) in comparison to adults, which is partially caused by an increased liver 
size to body weight ratio. To capture the effect of physiological growth and liver size, busulfan 
clearance should be expressed as function of allometric scaled body weight or body surface 
area.27,28 However, when clearance is expressed by body surface area there is still an increased 
clearance in younger children (< 4 years). This is most probably caused by an increased GST 
expression.29 Furthermore, in the earliest years after birth, maturation of enzyme function occurs 
as demonstrated by a 1.7 fold increase in busulfan clearance in the first 2 years after birth.28 
A genotype of each individual is set at conception. However, one’s phenotype is affected by 
environmental factors and can change over time. GSTA1 genotype affects GST activity and 
with that busulfan metabolism, however, the magnitude of effect of the genotype on busulfan 
metabolism is also determined by other contributing factors, such as administration route, co-
medication and age of the patient. Furthermore, the expression of the GSTA1 gene changes with 
age (as described above) and with that the relative contribution of this genotype to busulfan 
metabolism will change. A schematic overview of factors influencing busulfan PK is given in 
Figure 10.1. We hypothesize, that when there is abundant GST activity, which is the case at 
the age of 2–4 years, a less functional allele in GSTA1 gene will have limited effect on busulfan 
PK. This was demonstrated in chapter 5 of this thesis; a larger effect of GSTA1 genotype was 
observed in children under 2 years of age in comparison to the older children; explaining 20% 
versus 5% of interpatient variability, respectively. Therefore, genotyping of GSTA1 in pediatric 
patients seems only to be clinical relevant in a certain subpopulation based on age. 
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In chapter 5 also a novel genetic marker (CYP39A1) was associated with busulfan clearance 
in pediatric patients. The role of this genetic marker in general and in busulfan metabolism in 
particular is unclear yet and functional analysis should be performed. Furthermore, the effect 
of CYP39A1 in combination with GSTA1 needs to be replicated in a second cohort.  
In this thesis we searched for a genetic explanation of interpatient variability in busulfan PK 
in adults and in children. Investigating genetic markers in adults and children demonstrated 
that the effect of genetic variants is relative small to other patient related factors, such as age, 
maturation and body weight. Furthermore, not all the interpatient variability in busulfan PK 
cannot be explained by genetic markers involved in drug transport and metabolism. 
treosulfan
Treosulfan is an interesting alternative for busulfan in the conditioning prior to allo-HSCT. It has 
a mild toxicity profile and strong myeloablative capacity. It is most often applied in reduced 
toxicity or reduced intensity conditioning regimens. Data on PK of treosulfan in pediatric 
figure 10.1 Factors affecting busulfan pharmacokinetics in pediatric patients. Allo-HSCT: 




























patients is limited.7 To assess the PK profile of treosulfan in pediatric patients we developed and 
validated a bioanalytical method for determination of treosulfan in serum, a pop-PK model and 
a limited sampling strategy, described in chapter 6 of this thesis. Furthermore, in chapter 7 
we analyzed the PK profile of treosulfan in 21 pediatric allo-HSCT patients receiving treosulfan 
as part of their conditioning regimen. 
The presented population PK model performs adequately, which is mainly due to the predictive 
PK profile of treosulfan. We have demonstrated in chapter 6 and 7 that the interpatient 
variability in treosulfan exposure is relative small (14%) in pediatric patients above the age 
of 1 year. Furthermore, we could not relate early clinical outcome and toxicity to treosulfan 
exposure, This could be due to several reasons. First, such a relationship could be non-existent. 
Second, the interpatient variability may be too limited to observe such a relationship in this 
heterogeneous cohort of children. At first, a larger cohort and single-disease subgroups 
should be studied to more precisely assess the interpatient variability and the relationship of 
exposure with clinical outcome. Furthermore, it should be investigated whether treosulfan-
based conditioning is more effective when increasing the dose of treosulfan while keeping its 
beneficial toxicity profile. The optimal dose of treosulfan for the youngest and smallest patients 
remains to be established, since we were only able to study patients above the age of 1 year 
and with a body weight of more than 10 kg, when developing the limited sampling strategy. 
One patient was much younger (2 months and weighing 5 kg) and received a lower adjusted 
dose of 10 g/m2. Treosulfan exposure was assessed with the limited sampling strategy and 
the exposure of this young patient was similar to the mean exposure observed in the older 
patients. This suggests that younger patients may need a lower dose (based on body surface 
area). However, this is based on the finding in one patient and more data on the efficacy and 
toxicity profile in infants is required. 
All patients above 1 year of age received 14 g/m2 of treosulfan and a decrease of treosulfan 
exposure with age was observed. However, the higher exposure in the younger patients was 
not related to increased toxicity and this implicates that dose escalation in the older patients 
is possible. Treosulfan-based conditioning was relatively well tolerated and effective, as 
demonstrated by the mild toxicity profile in comparison to other conditioning regimens, a 
high overall survival (90%) and good disease free survival (74%). However, chimerism levels 
after 1 year and primary engraftment could be improved, especially in diseases where effective 
myeloablation and donor chimerism are mandatory, such as hematologic malignancies. It is 
therefore warranted to continue the research of treosulfan PK in relation to clinical outcome, 
in order to identify the optimal exposure and dosing regimen. 
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GlucortIcoId responsIveness In aGvHd
Acute GvHD is one of the major complications after allo-HSCT which occurs when donor cells 
engraft and mature donor T-cells react with recipient immune cells. In malignant diseases a 
beneficial effect of aGvHD has been demonstrated, since it may also be accompanied with graft-
versus-leukemia (GvL) effect. However, the right balance between the beneficial GvL effect and 
the adverse event of aGvHD is difficult to achieve. In patients diagnosed with aGvHD grade 2 or 
higher, first line treatment with high-dose glucocorticoids remains the gold standard. However, 
approximately only half of the patients responds adequately to this therapy. Non-responsiveness 
to GCs is associated with high morbidity and mortality. Furthermore, non-responsiveness will 
delay adequate treatment of the aGvHD, very often resulting in worsening of the disease. 
Overall, non-responsiveness towards GCs in aGvHD treatment is of major clinical concern. In 
chapter 8 of this thesis 7 expression quantitative trait loci (eQTLs) were identified in healthy 
volunteers and these 7 eQTLs and an eQTL of RBMS3 were investigated for association with 
GC non-responsiveness in pediatric patients with aGvHD. In this study it was demonstrated 
that genetic markers are involved in GC responsiveness and that donor genotype has a 
predominant effect on responsiveness. This finding is in line with the physiological process 
of aGvHD where alloreactive donor T-cells interact with immune cells of the recipient and GC 
therapy is considered to mainly target donor lymphocytes activity. 
The pharmacologic effect of GCs is complicated and is affecting multiple targets and gene 
expression. Several studies sought to indentify genetic markers for association with GC-
responsiveness and most of them were based on a candidate gene approach and mainly 
studied SNPs in genew encoding for the GC receptor and transcription factors. Combining 
genome wide genotyping data and multiple levels of phenotypic data provides the opportunity 
to identify polymorphisms that interact with GC treatment and influence response. These 
polymorphisms are therefore excellent candidates. The strength of the study in chapter 8 is 
that findings from genome wide information were combined into a candidate gene approach 
study on a retrospective patient cohort. 
pHarmacoGenetIc testInG In allo-Hsct recIpIents
In this thesis pharmacogenetic testing was applied in 2 widely used drugs in allo-HSCT. When 
pharmacogenetic testing is more broadly applied in allo-HSCT patients it is essential to choose 
the right biospecimen for collecting DNA as we described in chapter 9. Patient material should 
preferably be acquired before the allo-HSCT. When genotyping patients with malignant disease 
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it is important to obtain germline DNA, therefore a blood sample in remission is a good option. 
Furthermore, we have demonstrated in chapter 9 that after allo-HSCT, mixed chimerism in a 
patient could affect genotyping outcomes, emphasizing the need for proper quality control 
procedures.
future perspectIves
Busulfan conditioning can be optimized with therapeutic drug monitoring and evidence has 
been provided that tight control of exposure results in a better outcome.3,30 It is essential to 
identify the optimal target exposure giving the optimal balance between efficacy and toxicity 
for different conditioning regimens. Research on the optimal busulfan exposure should be 
performed in more homogenous cohorts; patients receiving the same conditioning regimen 
and having the same underlying disease. This may result in disease and regimen specific 
recommendations.
The same accounts for treosulfan-based conditioning, however, the experience with treosulfan-
based conditioning is limited and with that the knowledge on PK of treosulfan. First, the optimal 
dose and combination of drugs in treosulfan-based conditioning should be investigated. We 
hypothesize that the efficacy of treosulfan-based conditioning can be improved if a higher dose 
of treosulfan is administered and keeping its beneficial toxicity profile. At this point, busulfan 
is considered the most effective myeloablative conditioning regimen, whereas treosulfan 
appears to have a more favorable toxicity profile. Therefore, in pediatric patients, treosulfan is 
preferentially used in patients with co-morbidities or in non-malignant diseases. In malignant 
diseases a strong myeloablative conditioning is required. Treosulfan effectiveness might be 
improved at a higher dose. Therefore, it would be interesting to expand research on treosulfan 
PK and whether higher exposure translates into improved outcome. Ultimately, this may lead 
to a dose-escalation study in patients requiring a potent myeloablative conditioning regimen. 
Another advantage of treosulfan is the relative small interpatient variability in exposure. To further 
optimize the clinical use of both alkylating drugs, a direct comparison is warranted. Busulfan- 
and treosulfan-based conditioning should be compared prospectively in a large homogenous 
cohort in patients with the same underlying disease and disease status. A good example of such 
a prospective randomized study is the recently started ALL SCTPED 2012 FORUM study (EudraCT: 
2012-003032-22) in which busulfan- and treosulfan-based conditioning regimens are directly 
compared to a traditional total body irradiation-based regimen in pediatric patients with ALL. 
The finding that genetic markers are involved in non-responsiveness towards GCs in aGvHD is 
very promising. At first, the results should be replicated in a second and larger cohort. This will 
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lead to a more accurate measure of the predictive value of the two eQTLs, giving the possibility 
to study the effect of the eQTLs prospectively in pediatric patients with aGvHD. Furthermore, 
the physiological effect of the SNPs in TMEM71 and DPYSL3 should be further elucidated. At first, 
the SNPs should be studied in an in vitro model which resembles immune response in aGvHD 
accurately. When the SNPs remain to be associated with GC non-responsiveness in aGvHD, it 
could be of great interest to study them in other diseases such as asthma, inflammatory bowel 
disease and rheumatoid arthritis. For allo-HSCT patients ultimately, HSCT donors should be 
genotyped for the SNPs related to GC non-responsiveness and these biomarkers can be used 
to identify patients that will not benefit from GC therapy when encountering aGvHD. When 
aGvHD occurs in these patients, an alternative aGvHD therapy can be started directly and more 
stringent aGvHD prophylaxes can be applied in these patients. In addition, anti-thymocyte 
globuline (ATG) dose may be adapted based on the genotype of the donor, to reach the optimal 
balance between T-cell depletion to reduce the risk of aGvHD and rapid immune reconstitution. 
Furthermore, PK-models for estimation of ATG exposure are being developed and matching of 
ATG exposure to donor genotype could even be more beneficial. 
Pharmacologic research in the field of allo-HSCT is often focused on one agent and one 
mechanism to optimize the studied drug. However, during allo-HSCT multiple factors, such 
as drugs, patient and donor characteristics, have also an effect on outcome. For example, the 
conditioning regimen can affect the risk of aGvHD. Therefore, future pharmacological studies 
should emphasize on the effects of combination of drugs, together with specific patient 
conditions, in order to further improve allo-HSCT outcome. 
conclusIon
In this thesis, studies on three different pharmacological agents applied in pediatric and adult 
allo-HSCT have been performed. The goal of these studies was to elucidate mechanisms causing 
interpatient variability and thereby optimize current therapies for each individual patient. We 
demonstrated that GSTA1 is involved in busulfan PK in adults and pediatric patients and in 
children a novel genetic marker, CYP39A1, was demonstrated to affect busulfan PK. Interpatient 
variability in treosulfan PK in pediatric patients is not as large as observed with busulfan, which 
could be a beneficial aspect of treosulfan. We also demonstrated that pharmacogenetic markers 
in HSCT donors are involved in GC responsiveness of patients with aGvHD. The procedure 
of allo-HSCT is very complex and pharmacotherapy plays an important role. Studies on the 
optimization of current drug therapies and combining results on different agents could have 
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Pharmacotherapy plays an essential role in an allogeneic hematopoietic stem cell transplanta­
tion (allo­HSCT) procedure. Busulfan and treosulfan are two alkylating agents often applied 
in the conditioning regimen administered prior to the allo­HSCT. Finding the right balance 
between efficacious conditioning and toxicity remains the challenge for both agents. In 
chapter 2 of this thesis an overview of current strategies in optimization of busulfan and 
treosulfan therapy is given. Busulfan exposure has been related to clinical outcome and 
therapeutic drug monitoring is often applied in clinical practice to guide personalized 
dosing. Busulfan has a considerable unexplained interpatient variability in clearance. In 
chapter 3, 4 and 5 we sought to determine genetic markers that are related to interpatient 
variability in busulfan clearance. In chapter 3, three genes encoding for glutathione­S­
transferases (GSTA1, GSTM1, and GSTP1) were analyzed in relation to busulfan PK and clinical 
outcome in 66 adult patients. In this study an association of GSTA1 genotype (rs3957357) 
with busulfan clearance and exposure in adults patients was observed. However, only 18% 
of the interpatient variability could be explained by the GSTA1 genotype. In chapter 4, a 
comprehensive pharmacogenetic analysis was performed by genotyping adult patients with 
the DMET array. This array contains 1936 SNPs in 225 genes involved in drug metabolism 
and transport; patients in the exploratory cohort were genotyped with this array. Based on 
the results from the first cohort, seven top genetic markers were selected and validated in 
a second independent cohort. In this validation cohort only one SNP in GSTA5 (rs4715354) 
remained significantly associated with busulfan clearance and the GSTA5 genotype explained 
6.5% of variability of busulfan clearance. This SNP in GSTA5 is in linkage disequilibrium with 
GSTA1 genotype and was therefore a positive control for the association of GSTA1 with 
busulfan PK. No additional genetic markers involved in drug metabolism and transport were 
associated with busulfan PK. 
In chapter 5, the top 7 genetic markers from the exploratory adult cohort of chapter 4 were 
analyzed in pediatric patients. Since GSTA5 was in linkage with GSTA1, we analyzed GSTA1 
genotype (rs3957357) instead of GSTA5 in the pediatric cohort. In children, apart from GSTA1, 
also CYP39A1 was associated with busulfan clearance. When combined, the two haplotypes 
explained 17% of the variability in busulfan clearance. Furthermore, in younger children (<2 
years of age) a stronger effect of GSTA1 on busulfan clearance was observed. We hypothesized 
that maturation effects account for this difference and when there is abundant GST activity, 
which is the case at the age of 2–4 years, a less functional allele in GSTA1 gene would have 
limited effect on busulfan PK.
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Chapter 6 and 7 focus on treosulfan, also an alkylating agent, in pediatric conditioning 
regimens. The experience with treosulfan­based conditioning is limited and only a few studies 
investigated the PK profile of treosulfan in pediatric patients. In chapter 6 we developed 
and validated a bioanalytical method, population­PK model and limited sampling strategy. 
With the population­PK model and the limited sampling strategy treosulfan exposure can 
be determined based on two serum samples of an individual patient. These developments 
provide the opportunity to study treosulfan PK in a comprehensive manner in large pediatric 
cohorts, including infants. In chapter 7, a pilot study on treosulfan PK and clinical outcome 
was performed. It was demonstrated that treosulfan­based conditioning is very effective 
and toxicities are limited, in comparison to other conditioning regimens. Furthermore, 
there is potential of dose­escalation especially in older children, to increase the efficacy of 
treosulfan. This is of interest in diseases where a more myeloablative conditioning is required, 
such as malignant diseases. The interpatient variability of treosulfan clearance was 14% and 
intrapatient variability was 5%. Furthermore, no relationship between treosulfan exposure 
and clinical outcome was observed.
Acute graft­versus­host disease (aGvHD) is one of the major complications after allo­HSCT and 
is accompanied with significant morbidity and mortality. When patients are diagnosed with 
grade 2 or higher aGvHD, systemic treatment with high­dose glucocorticoids is started as first 
line treatment. However, only half of the patients respond adequately to this therapy and also 
in other diseases non­responsiveness to glucocorticoids has been observed. Therefore, it is 
assumed that non­responsiveness is an intrinsic factor of a subset of the population. In chapter 
8 of this thesis 7 expression quantitative trait loci (eQTLs) in healthy volunteers were identified. 
The cis­eQTLs affect the expression of the following genes: LPIN2, DPYSL3, TMEM71, GZMA, 
MOB3C, TTF2, FAM117B only in presence of glucocorticoids. Furthermore, the 7 eQTLs were not 
associated with glucocorticoids affected T­cell proliferation in vitro. We then analyzed the effect 
of the 7 eQTLs and an eQTL of RBMS3 on glucocorticoids responsiveness in pediatric patients 
with aGvHD (grade 2 or higher). Since T­cells of the donor play an important role in aGvHD, 
we genotyped the 8 eQTLs in patient and donor DNA. In this chapter, it was demonstrated 
that donor eQTL genotype is associated with response­status and patient genotype is not; 
TMEM71 and DPYSL3 donor genotype were associated with GC­responsiveness and TMEM71 
alone had a predictive value of 65%. 
In chapter 9, a case of pre­emptive genotyping of a patient receiving a kidney transplantation 
was described. To determine the adequate individual tacrolimus dose, CYP3A5 genotype 
is determined in these patients. However, based on two genotyping methods conflicting 
results were obtained. Consultation with the attending nephrologist revealed a patient 
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history including two allo­HSCTs. This patient had a mixed hematopoietic chimerism and 
when genotyping peripheral blood samples from the patient, also a mixed CYP3A5 genotype 
was obtained. This case shows the importance of proper quality control protocols when 
performing pharmacogenetic testing in routine patient care, especially in complex patients, 
such as allo­HSCT recipients. 
The goal of these studies was to elucidate mechanisms causing interpatient variability and 
thereby optimize current therapies for each individual patient. We demonstrated that GSTA1 is 
involved in busulfan PK in adults and pediatric patients and in children a novel genetic marker, 
CYP39A1, was demonstrated to affect busulfan PK. Interpatient variability in treosulfan PK in 
pediatric patients is not as wide as busulfan, which could be a beneficial aspect of treosulfan. 
We also demonstrated that pharmacogenetic markers in HSCT donors are involved in GC 
responsiveness of patients with aGvHD.
In the future, a direct comparison of busulfan­ and treosulfan­based conditioning in a large 
homogenous cohort is warranted. The effect of the donor eQTLs on glucocorticoid non­
responsiveness should be replicated in a second independent cohort and when current 








Bij een allogene hematopoietische stamceltransplantatie (allo-HSCT) worden stamcellen van 
een donor toegediend aan een patiënt met als doel het immuunsysteem of bloedvormend 
systeem van de patiënt te herstellen. Een allo-HSCT wordt toegepast bij bloedkanker 
(verschillende typen leukemie), bij ziekten waarbij het afweersysteem niet of onvoldoende werkt 
of ziekten waarbij er een tekort is aan goed functionerende bloedcellen. Deze aandoeningen 
kunnen aangeboren zijn of zijn verworven na de geboorte. Aangeboren ziektes kunnen vlak na 
de geboorte al aan het licht komen, daarnaast zijn er verschillende vormen van bloedkanker die 
vooral bij kinderen voorkomen en allo-HSCT wordt daarom veelvuldig bij kinderen toegepast. 
Wanneer lichaamsvreemde stoffen worden toegediend zal het lichaam er voor zorgen dat 
deze zo snel mogelijk worden opgeruimd. Dit is het geval bijvoorbeeld bij een infectie met een 
bacterie of een virus of bij toediening van cellen of organen in het geval van een transplantatie. 
Dus als een patiënt stamcellen van een donor ontvangt, is er het risico dat deze worden 
afgestoten door het lichaam. Er worden verschillende maatregelen genomen om de kans op 
afstoting zo klein mogelijk te houden. In de eerste plaats wordt er gezocht naar een donor 
die zo gelijk mogelijk is aan de patiënt. Dit gebeurt op basis van humaan leukocytenantigen 
(HLA) matching; antigenen van patiënt en donor moeten zo veel mogelijk overeenkomen, 
zodat het afweersysteem van de patiënt de cellen van de donor zo min mogelijk herkent als 
lichaamsvreemde cellen. HLA-antigenen van broers en zussen zijn soms identiek aan elkaar, of 
kunnen veel op elkaar lijken. Daarom is een broer of zus vaak een geschikte donor. Daarnaast zijn 
er mogelijkheden om stamcellen van niet-gerelateerde donoren toe te dienen waarbij vooraf 
is vastgesteld dat deze voldoende overeenkomsten vertonen met de cellen van de patiënt zelf. 
Allogene stAmceltrAnsplAntAtIe
De patiënt krijgt voorafgaand aan de allo-HSCT een chemokuur, ook wel conditioneringsfase 
genoemd, die bestaat uit een combinatie van geneesmiddelen. Deze conditionering heeft als 
doel het afweersysteem zo veel mogelijk te remmen (immuunsuppressie), zodat de donorcellen 
niet worden afgestoten. Verder wordt met de conditionering “myelosuppressie” beoogd, dit 
houdt in dat zo veel mogelijk stamcellen van de patiënt worden gedood, zodat er ruimte is voor 
de stamcellen van de donor om zich te nestelen en te gaan delen. In het geval van leukemie zal 
de chemokuur er ook voor zorgen dat kankercellen zo veel mogelijk worden gedood. De dosis 
van de verschillende geneesmiddelen is hoog in vergelijking met een “normale” chemokuur. Dit 
resulteert erin dat de hoeveelheid bloedcellen in de patiënt heel laag wordt, dit wordt aplasie 
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genoemd. Alleen wanneer een patiënt in aplasie is, is het mogelijk om de donor stamcellen 
toe te dienen. Echter, als een patiënt vrijwel geen witte bloedcellen meer heeft dan werkt het 
immuunsysteem niet meer en kan de patiënt gemakkelijk geïnfecteerd raken met een bacterie 
of een virus. Om deze reden krijgen alle patiënten preventief antibiotica en middelen tegen 
virusinfecties. Daarnaast worden ze verzorgd in een geïsoleerde ruimte met gefilterde, schone 
lucht om de patiënt zo veel mogelijk te beschermen tegen infecties.  
Nadat de stamcellen zijn toegediend is het doel dat deze zich nestelen en gaan expanderen, 
wat uiteindelijk moet leiden tot herstel van het immuun- en bloedsysteem. In deze fase na 
de allo-HSCT bestaat het risico dat de stamcellen van de donor worden afgestoten of de 
immuuncellen van de donor kunnen reageren tegen de cellen van de patiënt zelf en schade 
veroorzaken. Dit laatste fenomeen heet graft-versus-host ziekte. 
doel vAn de studIe
In de verschillende fasen van een allo-HSCT procedure krijgt een patiënt geneesmiddelen 
toegediend, in de conditioneringsfase, in de preventie en behandeling van infecties en bij 
complicaties die kunnen optreden tijdens de allo-HSCT. Deze middelen kunnen toxisch 
zijn en schade geven bij de patiënt of kunnen soms juist iets hoger worden gedoseerd om 
daarmee effectiever te zijn. Het doel van het onderzoek beschreven in dit proefschrift is de 
behandeling met bestaande geneesmiddelen rondom een allo-HSCT verder te optimaliseren. 
Het onderzoek is gericht op drie geneesmiddelen: busulfan en treosulfan, beide cytostatica die 
in de conditioneringsfase worden toegepast, en glucocorticosteroïden, die worden toegepast 
bij de behandeling van acute graft-versus-host ziekte. Onderzoek naar optimalisatie van deze 
geneesmiddelen wordt gedaan door relaties te zoeken tussen de concentratie of blootstelling 
(farmacokinetiek) van een geneesmiddel in het bloed en het effect van het geneesmiddel. Of 
door te kijken of er genetische kenmerken zijn in een patiënt die maken dat het geneesmiddel 
een afwijkend effect heeft in verschillende individuen (farmacogenetica).  
BusulfAn en treosulfAn
Busulfan en treosulfan zijn beide alkylerende cytostatica die worden toegepast in de 
conditioneringsfase bij allo-HSCT in volwassenen en kinderen. Met busulfan is al veel ervaring en 
in eerder onderzoek is aangetoond dat de concentratie (blootstelling) in het bloed gerelateerd 
is aan de effectiviteit en toxiciteit van busulfan. Als de concentratie in het bloed van busulfan 
te hoog is, dan bestaat er kans op toxiciteit; leverschade en mucositis (beschadiging van de 
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slijmvliezen). Wanneer de concentratie van busulfan te laag is, dan is er verhoogde kans op 
afstoting van het transplantaat. In de praktijk wordt daarom tijdens de vierdaagse kuur van 
busulfan de concentratie in het bloed gemeten en eventueel de dosis aangepast, zodat de 
juiste blootstelling wordt bereikt in een patiënt. 
De ervaring met treosulfan in allo-HSCT is nog beperkt en vooral in kinderen is er weinig 
onderzoek gedaan naar de concentratie van treosulfan in het bloed van verschillende patiënten. 
Het middel lijkt op busulfan, maar geeft minder toxiciteit en is mogelijk iets minder effectief. 
In hoofdstuk 2 van dit proefschrift is een overzicht gegeven van de eerdere onderzoeken die zijn 
gedaan om de huidige conditioneringen op basis van busulfan en treosulfan te optimaliseren. 
Busulfan wordt gedoseerd op basis van het lichaamsoppervlak of lichaamsgewicht van de 
patiënt, maar desondanks kan de blootstelling tussen individuen erg verschillen. Dit zou 
kunnen komen door verschil in genetische opmaak van patiënten. In hoofdstuk 3 is gekeken 
naar verschillen in het DNA (polymorfismen) van patiënten. Polymorfismen in 3 genen zijn 
onderzocht in 66 volwassen patiënten die busulfan kregen voorafgaand aan hun allo-HSCT. De 
drie genen coderen voor drie verschillende enzymen die betrokken zijn bij het omzetten van 
busulfan naar een inactieve stof (metabolisme); GSTA1, GSTM1 en GSTP1. De polymorfismen in 
deze genen werden gerelateerd aan de busulfanconcentratie in het bloed van de individuele 
patiënten. Eén polymorfisme in GSTA1 (rs3957357) was gerelateerd aan de blootstelling van 
busulfan in volwassenen; patiënten met twee C-allelen hebben gemiddeld de hoogste klaring, 
patiënten met het CT-genotype hebben een lagere klaring in vergelijking met patiënten met 
het CC-genotype en patiënten met het TT-genotype hebben gemiddeld de laagste klaring 
en daarmee de hoogste blootstelling van busulfan in het bloed. Echter slechts 18% van de 
variabiliteit in klaring in de studiegroep kon worden verklaard met dit polymorfisme in GSTA1. 
In hoofdstuk 4 hebben we daarom breder gezocht naar genetische polymorfismen die een 
effect zouden kunnen hebben op de farmacokinetiek van busulfan. Een eerste studiegroep van 
65 volwassenen is gegenotypeerd met behulp van de DMET array (Drug Metabolizing Enzymes 
and Transporters array). Met deze array kunnen 1936 genetische veranderingen in 225 genen, 
betrokken bij metabolisme en transport van geneesmiddelen, worden geanalyseerd. De zeven 
meest belovende polymorfismen uit de eerste studiegroep werden vervolgens geanalyseerd 
in een tweede studiegroep van 78 volwassen patiënten. In deze groep was één polymorfisme 
in GSTA5 (rs4715354) geassocieerd met busulfanklaring en deze kon 6.5% van de variabiliteit 
in klaring verklaren. Het polymorfisme in GSTA5 is gekoppeld aan het polymorfisme in GSTA1 
(rs3957357); wanneer een individu een afwijkend allel heeft in GSTA1 is de kans groot dat 
deze ook een afwijkend allel heeft in GSTA5. De bevinding dat GSTA5 geassocieerd is met 
busulfanklaring is daarom een positieve controle van het effect van GSTA1 op busulfanklaring. In 
187
Samenvatting
deze studie zijn geen andere polymorfismen, in genen betrokken bij geneesmiddelmetabolisme 
en -transport, gevonden die waren geassocieerd met de farmacokinetiek van busulfan. 
De zeven meest veelbelovende polymorfismen uit het volwassenencohort van hoofdstuk 4 
zijn ook geanalyseerd in een studiegroep van 84 kinderen, dit is beschreven in hoofdstuk 5. In 
dit hoofdstuk hebben we het polymorfisme in GSTA1 in plaats van het polymorfisme in GSTA5 
geanalyseerd. Hiervoor is gekozen, omdat deze twee polymorfismen gekoppeld zijn en GSTA1 
functioneel is en GSTA5 niet. In de kinderen die busulfan kregen toegediend voorafgaand aan 
hun allo-HSCT was wederom het polymorfisme in GSTA1 (rs3957357) en een polymorfisme in 
CYP39A1 (rs9381468 en rs953062) geassocieerd met busulfanklaring. Tezamen kunnen deze 
twee genetische varianten 17% van de variabiliteit in busulfanklaring in kinderen verklaren. 
Tevens is gebleken dat het effect van GSTA1 groter is in kinderen onder de twee jaar. Een 
verklaring zou kunnen zijn dat in jonge kinderen de GSTA1-activiteit nog niet maximaal is en 
daarom het effect van genetische variatie groter is. 
In hoofdstuk 6 en 7 is onderzoek gedaan naar de farmacokinetiek van treosulfan. Er zijn 
enkele studies die de farmacokinetiek van treosulfan in kinderen die een allo-HSCT ondergaan 
beschrijven, deze studies zijn uitgevoerd in kleine patiëntengroepen. In hoofdstuk 6 zijn 
ontwikkeling en validatie van een bioanalytische methode voor het bepalen van treosulfan in 
het bloed, een populatie-farmacokinetisch model en een “limited sampling model” beschreven. 
Met behulp van het populatie-farmacokinetisch model en het “limited sampling model” kan 
de farmacokinetiek van de populatie worden beschreven en kan met behulp van slechts twee 
bloedmonsters van een individuele patiënt de klaring en blootstelling worden berekend. 
Met behulp van deze methode kan de farmacokinetiek gemakkelijker worden bestudeerd, 
tevens bij baby’s, aangezien er slechts twee bloedmonsters hoeven worden afgenomen van 
maximaal 500 µl. 
In hoofdstuk 7 is een eerste verkennend onderzoek in 21 kinderen uitgevoerd waarin de 
farmacokinetiek van treosulfan is gerelateerd aan uitkomst van de HSCT en toxiciteit. De 
variabiliteit in blootstelling tussen patiënten was 14% en de van-dag-tot-dag-variatie is 5%. 
Treosulfanconditionering bleek effectief te zijn en de toxiciteit was relatief mild in vergelijking 
met andere conditioneringsschema’s. Hieruit volgt dat de effectiviteit van treosulfan mogelijk 
te verbeteren is, door de dosis te verhogen. Dit zou dan in eerste instantie vooral onderzocht 
kunnen worden in oudere kinderen en in kinderen waarbij een sterkere conditionering nodig 
is, bijvoorbeeld in het geval van verschillende typen leukemie. 
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glucocorticosteroïden en acute graft-versus-host ziekte
Nadat de stamcellen van de donor zijn toegediend en de donorcellen zich nestelen in het 
beenmerg van de patiënt is er een risico op het optreden van acute graft-versus-host ziekte 
(aGvHD). Bij aGvHD vallen de immuuncellen van de donor cellen van de patiënt aan en zorgen 
voor schade, vooral in het maag-darmstelsel, de lever en de huid. Deze ziekte heeft een hoge 
morbiditeit en mortaliteit. De eerstelijns therapie bij patiënten met graad 2 aGvHD of hoger 
bestaat uit hoge doses systemische glucocorticosteroïden (GC’s). Helaas reageert ongeveer 
slechts de helft van de patiënten voldoende op deze therapie. Het niet reageren op GC’s (GC-
resistentie) is ook bekend bij andere ziektes waarbij GC’s worden toegepast. Men denkt dat 
GC-resistentie een intrinsieke eigenschap is van een deel van de populatie, waarbij mogelijk 
de genetische opmaak van een patiënt een rol speelt. In hoofdstuk 8 hebben we nieuwe 
genetische markers ontdekt in gezonde vrijwilligers die een rol spelen bij GC-resistentie en 
deze vervolgens getest in kinderen met aGvHD na hun allo-HSCT. De genetische markers 
die onderzocht zijn hebben een effect op de expressie van genen in de aanwezigheid van 
GC’s. Deze markers worden ook wel “expression quantitative trait loci” (eQTLs) genoemd. In 
gezonde vrijwilligers zijn zeven eQTLs geïdentificeerd. De expressie van de volgende genen is 
geassocieerd met het genotype van de eQTLs: LPIN2, DPYSL3, TMEM71, GZMA, MOB3C, TTF2, 
FAM117B. Echter, het genotype van de eQTLs hadden geen effect op in vitro T-cel proliferatie. 
In de kinderen zijn deze 7 eQTLs en een eQTL van RBMS3 geanalyseerd. Aangezien in aGvHD 
de GC-behandeling vooral is gericht tegen de immuuncellen van de donor, hebben we de 
patiënt zelf en zijn of haar donor gegenotypeerd voor de 8 eQTLs. In hoofdstuk 8 hebben we 
aangetoond dat het genotype van de donor van belang is om de GC-respons van de individuele 
patiënt met aGvHD te kunnen voorspellen. Met name de eQTLs die een effect hebben op 
TMEM71 en DPYSL3 zijn geassocieerd met GC-respons en TMEM71 donorgenotype heeft een 
voorspellende waarde van 65%. 
genotyperen van allo-Hsct patiënten
In hoofdstuk 9 is een casus beschreven van een patiënt die een niertransplantatie zou 
ondergaan. Hiervoor worden immunosuppressieve geneesmiddelen gegeven en één van de 
geneesmiddelen is tacrolimus. Dit geneesmiddel wordt gemetaboliseerd door CYP3A5 en de 
activiteit van dit enzym is afhankelijk van de allelen die de patiënt van het CYP3A5-gen heeft. 
Om direct te starten met een goede dosis wordt voor start van tacrolimus het genotype van 
CYP3A5 bepaald. Dit wordt routinematig met behulp van twee onafhankelijke methoden 
gedaan, zodat er altijd een accurate uitslag wordt uitgegeven. Bij deze patiënt gaven de twee 
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methoden echter tegenstrijdige resultaten en toen de behandelend arts werd geconsulteerd 
bleek dat de patiënt in het verleden een allo-HSCT had ondergaan. Het bloedmonster dat 
was gebruikt voor de genotypering bevatte cellen van de donor en de patiënt zelf, wat vaak 
voorkomt na een allo-HSCT. Dit resulteerde in een gemengd genotype van CYP3A5 in het perifere 
bloed. Het genotype is vervolgens bepaald in speeksel van de patiënt. Dit materiaal gaf een 
eenduidiger resultaat van het genotype van de patiënt zelf, welke het meest van belang is bij 
het metabolisme van tacrolimus. Deze casus geeft het belang van goede kwaliteitscontroles 
en de keuze van patiëntmateriaal aan voor genotyperen in de klinische praktijk. 
conclusIe
In dit proefschrift is onderzoek gedaan naar drie geneesmiddelen die worden toegepast bij allo-
HSCT in kinderen en volwassenen, met als doel het optimaliseren van de huidige therapieën. 
We hebben aangetoond dat variaties in het GSTA1-genotype in volwassen en GSTA1- en 
CYP39A1-genotype in kinderen een effect hebben op de farmacokinetiek van busulfan. De 
variatie in treosulfanklaring tussen patiënten is relatief klein, dit zou één van de voordelen van 
treosulfan kunnen zijn. In aGvHD-patiënten blijkt dat het donorgenotype meer van belang is 
voor het voorspellen van de GC-respons dan het genotype van de patiënt zelf. In de toekomst 
moeten busulfan- en treosulfanconditionering in grote homogene studiegroepen direct met 
elkaar vergeleken worden, zodat een goede keuze voor één van de middelen kan worden 
gemaakt voor de individuele patiënt. De resultaten met betrekking tot de donorgenotypes 
van TMEM71 en DPYSL3 en GC-respons moet nog worden onderzocht en bevestigd in een 
tweede onafhankelijk cohort. Wanneer de huidige resultaten worden bevestigd dan zouden 
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